




FELINE FOAMY VIRUS IN DOMESTIC CATS: USE AS A VACCINE VECTOR, 







Submitted by  
Carmen Denise Ledesma-Feliciano  





In partial fulfillment of the requirements 
For the degree of Doctor of Philosophy  
Colorado State University 
Fort Collins, Colorado  































Copyright by Carmen Denise Ledesma-Feliciano 2019 
 







FELINE FOAMY VIRUS IN DOMESTIC CATS: USE AS A VACCINE VECTOR, 




Foamy viruses (FVs) are retroviruses from the Spumaretrovirinae subfamily. FVs are 
globally prevalent retroviruses with a unique molecular biology. FVs establish apparently 
apathogenic lifelong infections. Due to this, FVs are considered attractive vectors for vaccine 
and gene therapy development. Feline foamy virus (FFV) infects domestic cats and has 
widespread and high prevalence around the world. However, FFV has also been isolated from 
cats suffering from concurrent disease, including renal syndromes and other retroviral co-
infections such as feline immunodeficiency virus (FIV). Much remains unknown about FFV 
infection and in vivo experimental infections are rare in the literature. 
To test FFV’s use as a vaccine vector and understand the interaction between viral proteins 
and host antiviral restriction factors, we developed an infective chimeric vaccine containing 
lentiviral FIV vif replacing FFV bet. FFV Bet and FIV Vif counteract feline innate APOBEC3 
(feA3) restriction factors through different mechanisms. FeA3 action on retroviral genomes lead 
to hypermutation and degradation of viral DNA. In vitro, we show that vif can replace bet to yield 
replication-competent chimeric viruses. We experimentally inoculated 12 domestic cats (n=4 per 
group in naïve, wild-type, and chimera-inoculated groups) with the FFV-Vif chimera and wild-
type FFV in order to compare viral replication kinetics through PCR and specific antibody 
development through ELISA. Inoculation with the chimeric vector resulted in the development of 
a specific immune response against FFV Gag and Bet and FIV Vif proteins. In addition, we 
show that the domestic cat can be superinfected with different strains of FFV. The chimeric virus 
displayed attenuated infection in vivo, as provirus was not detected in PBMC for any chimera-
 iii 
only inoculated animals. Thus, Bet may have additional functions other than A3 antagonism 
required for successful in vivo infection. Our studies further exemplify how FV vaccine vectors 
are an attractive tool to counteract lentiviral infections and poses the possibility to induce 
immunity against other lentiviral antigens. 
In order to further characterize wild-type infection, we also collected blood, saliva, and urine 
over a 6-month time-period with a necropsy and tissue collection at the end of the study. 
Animals were monitored daily for clinical signs of disease and temperature and weight data 
were collected weekly. None of the cats showed clinical signs of infection and complete blood 
count and chemistry were unremarkable. However, we found significant differences in blood 
urea nitrogen, one of the markers used to assess renal function, when comparing infected 
versus control animals. All animals inoculated with wild-type virus showed a persistent 
proviremia (in PBMCs) and viral tissue tropism was primarily lymphoid with the exception of one 
cat that had an expanded tissue tropism to other lymphoid tissues and oral mucosa. This animal 
had altered viral kinetics compared to the rest of infected animals, in addition to a negative 
correlation between lymphocyte count and viral load. Histopathological analysis showed 
evidence of microscopic pathology in the kidneys, lung, and brain of infected animals. This 
same cat had an increase in urine protein at the time of highest PBMC proviremia. Additionally, 
transmission electron microscopy showed ultrastructural changes indicative of transient renal 
injury in the kidneys of infected animals. We additionally found electron dense structures in the 
cytoplasm of tubular epithelial of as of yet unknown origin. 
Due to the renal changes we saw in the experimental study and pathology reported in the 
literature, we conducted a survey of FFV in pet cats in the USA and Australia (AU) suffering 
from chronic kidney disease (CKD) and compared findings to age- and sex-matched controls 
without CKD. We found an association between CKD and FFV in males, and males in general 
are also at a significantly increased risk of FFV infection.  
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We then assessed through an FFV serosurvey whether FFV was associated with FIV and 
causing potentiation of FIV disease in two cohorts of naturally FIV-infected cats. One of the 
groups consisted of cats living in 1-2 cat households that did not experience much FIV-related 
morbidity and mortality, while the second group of cats housed in a large multicat household 
suffered from severe clinical symptoms and mortality. We hypothesized the reason for this 
discrepancy could be an increase in FFV/FIV co-infection rate in the group of cats with higher 
morbidity and mortality. We found that FFV is associated with FIV in these groups and that 
males are also at an increased risk for FFV infection. Finally, we conducted an in vitro co-
infection study to assess potentiated infection as determined by more rapid development of 
cytopathic effects (CPE) and higher viral titers in the supernatant. GFox cells were inoculated 
with FFV and FIV in single, and dual simultaneous and staggered inoculations. A p26 ELISA 
was used to determine amount of FIV reactivity in the cells, while a chemiluminescent β-
galactosidase assay was used to detect amount of β -gal produced in FeFAB FFV reporter cells. 
The in vitro assays showed increased permissivity of either virus following an initial infection of 
the other virus, showing these two retroviruses can accelerate and potentiate a secondary 
infection regardless of which virus infected initially. 
Overall, we have demonstrated the suitability of FFV as a vaccine vector candidate. 
Additionally, we have documented that FFV may cause subclinical alterations that in certain 
cohorts of domestic cats, may contribute to disease development in chronic cases. Finally, we 
showed that FFV interacts with another retrovirus and could potentially affect FIV-related 
disease. More studies should focus on the effects of FFV in chronic infections in addition to the 
effect of FFV on co-morbidities in a chronic timeline. 
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Feline foamy virus structure and replication 
Feline foamy virus is a complex retrovirus belonging to the Spumaretrovirinae subfamily. 
Spumaviruses are ancient viruses, with endogenous forms infecting vertebrates over 450 million 
years ago [1-5]. Foamy viruses (FVs) are unique within the Retroviridae, with differences in 
molecular biology and clinical consequence of infection compared to other feline retroviruses. 
Despite their ancient nature, much remains unknown about FVs in general in addition to their 
effect on other disease syndromes in their hosts [2, 6]. A hallmark of in vitro FV infection, and 
how they were originally incidentally discovered, is that they cause adherent epithelial or 
fibroblastoid-origin cells in culture to look “foamy” (the derivation of “spuma”) [2, 7-12]. FVs are 
retroviruses, and thus a defining part of their replication cycle is RNA reverse transcription (RT). 
In contrast to other retroviruses, the infective form of FVs is DNA rather than RNA, and some 
replication steps are more similar to hepadnaviruses, such as DNA being the infective genome 
with a late RT step, an intracellular recycling pathway, and temporal regulation of replication [2, 
3, 7, 13]. 
FV particles are spherical, about 100-140 nm in size, and feature prominent 10-15 nm 
spikes on their surface [2]. Proviral genomes range from 12-13 kilobases and contain the 
canonical retroviral gag, pol, and env structural genes and FV-specific accessory genes tas and 
bet downstream of env [3, 7]. Gag is a polyprotein with matrix, capsid, and nucleocapsid 
subunits [7, 8]. The pol gene encodes Pol, which is translated into a protein containing the 
domains for protease, reverse transcriptase, RNAse H, and integrase [7]. Env proteins includes 
transmembrane and surface subunits [7]. Tas is a trans-activator of FVs required for replication. 
Tas proteins bind both the unique spumaviral internal promoter (IP) found in FVs and upstream 
U3 LTR promoter for upregulated production of viral proteins [3, 5, 7, 8]. Bet is the second 
accessory protein expressed from terminal tas and bel2 open reading frames (ORF) and is 
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involved in countering host innate APOBEC3 antiviral restriction factors [5, 7, 14-19]. The 
genome is under initial regulation by the IP, which is basally active and leads to the production 
of Tas and Bet [2, 7, 20]. Tas bids both the IP and upstream LTR, leading to a positive feedback 
loop that produces more Tas, followed by structural Gag, Pol, and Env proteins under the 
control of the U3 LTR [7, 8]. Temporal regulation of gene expression is not typical in retroviruses 
[2, 3]. FVs are among the most conserved retroviruses, having one of the slowest rates of 
mutation for all RNA viruses [1, 4, 21, 22]. 
The life cycle of FVs begins when the DNA-containing viral particles attach to target cells 
(for full replication review and diagrams, see [7]). The specific attachment receptor for FV entry 
into target cells is currently unknown, but it is thought to be widely prevalent due to the wide 
tissue tropism these viruses display [6, 7, 23]. Heparan sulfate, a glucosaminoglycan present in 
extracellular matrix, has been shown to be a cellular attachment factor that enhances cellular 
permissivity for FV entry into target cells [23]. FV replication is characterized by an early phase 
of proviral integration, followed by a late phase production of progeny virus [7]. Following viral 
attachment to the (as of yet unknown) cellular receptor, viral entry occurs via pH-dependent 
Env-mediated endocytosis [6, 7, 24]. The capsids then migrate through the microtubular 
network to the centrosome and begin to accumulate [2, 6, 7, 25]. FVs require active cellular 
replication for their own replication cycle, thus if cells are in the G0 resting phase or arrested 
during the cell cycle, the capsids remain in the centrosome region [7, 26-28]. Once cells enter 
mitosis, the nuclear membrane breaks down and disassembled capsids yield DNA provirus that 
gains access to the chromosome [7, 27, 28]. Viral integrase mediates proviral integration into 
the host genome with no apparent preference of insertion sites [7]. FVs are less likely to 
integrate next to actively transcribed genes or into cellular promoters compared to other 
retroviruses [7, 29-32], a characteristic that makes them attractive candidates as viral vectors. 
The late phase begins as the integrated provirus usurps host machinery for transcription [5]. 
While Gag, Pol, Tas, and Bet are translated on free ribosomes in the cytoplasm, Env translation 
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takes place on endoplasmic reticulum ribosomes [7]. Capsid assembly takes place at the 
centrosome, and virion budding and release requires Env co-expression [2, 3, 8, 33]. FVs follow 
either exocytotic budding and/or budding at the plasma membrane, and in the case of FFV, both 
have been documented [3, 5, 7, 34, 35]. The exact time of reverse transcription into DNA is 
unknown, but capsids preassembled intracellularly contain reverse-transcribed DNA that is 
infective; this late RT step is more akin to hepadnavirus replication than other retroviruses [2, 3, 
7, 13, 36]. FVs can take one of two routes following infection: remain integrated as a latent 
provirus or result in productive infection [2, 7]. FV-infected cells contain many viral DNA copies, 
both integrated and un-integrated into the host genome, suggesting a recycling pathway [3]. 
 
APOBEC3 host innate anti-FFV restriction 
Various host innate antiviral restriction factors have been described as defenses against FV 
infection. Classes of restriction factors include tripartite interaction motif (TRIM5α, induces 
premature disassembly of viral capsids), apolipoprotein B mRNA editing enzyme (APOBEC3, 
edit complementary DNA – cDNA – during RT), tetherin (block particle release through 
cytoskeleton interference), and interferon (induces the previous three restriction factors) [5, 7, 
37-39]. In the case of APOBEC3 (A3), studies have shown that A3 become incorporated into 
nascent viral particles and edit viral cDNA intermediates by deaminating C-to-U, which in turn 
leads to a lethal mutagenesis that renders the viruses non-infectious [5, 7, 19, 40]. Retroviruses 
have in turn evolved ways to counter these host restriction factors [41]. FFV and feline 
immunodeficiency virus (FIV) produce accessory proteins that inactivate feline A3 (feA3) 
proteins, either by binding and inactivation (in the case of FFV) or degradation (as is the case 





FV infection in the domestic cat (Felis catus) and other animal species 
FVs are species-specific and have been reported in cows, horses, non-human primates 
(NHP), domestic and wild felids, and endogenous forms have been found in vertebrates as early 
as the Paleozoic era [1, 5, 7, 44-46]. Zoonotic transmission to humans is not reported, with the 
exception of a dead-end simian foamy virus (SFV) infection in humans occupationally exposed 
to NHP or involved in bush meat trade, where virus establishes latency in the face of a specific 
anti-SFV immune response [5, 47-54]. FFV (and FVs in general) establishes a persistent and 
lifelong infection in domestic cats that has historically been considered apathogenic [5, 7, 55-
58]. This infection persistence is established even in the presence of a specific immune 
response, which is usually detectable 2-3 weeks post-infection [7, 56, 57, 59]. It is theorized that 
FVs are apathogenic due to the long period of co-evolution with their hosts, resulting in 
attenuated infection [1, 4, 5, 7, 60]. Following initial infection, replicating virus is shed in the 
saliva while proviral latency is established mainly in circulating white blood cells and lymphoid 
tissues, but can be detected in most tissues in the body (Chapter 2 and [55, 58, 59, 61]).  
Transmission of FVs is primarily horizontal between animals through exposure to infectious 
saliva, and in the case of FFV, both biting during aggressive encounters as well as amicable 
grooming have been suggested as routes of transmission [58, 62-65]. The amount of virus shed 
in the saliva varies greatly between cats (Chapter 2 and [9, 56, 58, 59, 66]). Different species of 
NHP also shed virus in the saliva at varying levels. In one naturally FV-infected rhesus macaque 
study conducted in animals bred in a primate center, virus was shed in large quantities but in 
variable amounts between animals [67]. Another study assessing free-ranging macaque 
populations throughout Bangladesh found widely variable levels of replicating virus in buccal 
swabs [68]. Another study examining wild-source and naturally infected African green monkeys 
detected low levels of replicating virus sporadically in only one animal [69]. Replicating virus has 
been found in both stroma underlying basal epithelium of oral mucosa in African green monkeys 
and in surface epithelial cells from pharynx, tongue, and tonsil in rhesus macaques [60, 69]. 
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FFV in utero transmission has been reported but it is not thought to be a main route of 
transmission [58]. In cows, transmission through milk has also been suggested [70]. FFV is 
widespread globally, with prevalence rates around the world between 8-80% [62, 71-80]. 
Variation is related to geography, the specific cat population sampled (feral versus domestic, 
young vs old, etc), and the specific assay used for detection which have varying rates of 
specificity and sensitivity. Risk factors for developing infection include aging and sex status 
(male) (Chapter 2 and [62, 81]). 
In contrast to reports in the literature that FFV is apathogenic, there are studies 
documenting pathology in infected cats. In one report, experimentally FFV-infected cats 
developed histopathological changes in the kidneys and lungs almost 6 months after infection 
[59]. We have also found microscopic evidence of injury in the kidneys, lung, and brain of 
experimentally infected cats (Chapter 2). FFV has been isolated from cats suffering from renal 
and urinary syndromes [82-84], polyarthritis [85, 86], neoplasia [11, 12, 78, 87], and other viral 
infections including FIV [62, 63, 71], feline leukemia virus (FeLV) [88, 89], feline coronavirus 
(FCoV) [78, 90], feline calicivirus (FCV) and feline herspesvirus [9]. While SFV is also 
considered to be apathogenic in NHP, humans zoonotically infected with SFV show significant 
alterations in biochemical, hematological and leukocytic parameters [49]. 
 
Experimental FFV Infections 
Experimental infection studies of specific-pathogen-free (SPF) cats with FFV are rare. Initial 
studies up to the mid 1980’s focused on clinical monitoring and histology. Kasza and others 
reported non-SPF FFV-inoculated (subcutaneously, intramuscularly, and intraperitoneally) 2-4 
week old cats were free of disease 3-5 months post-inoculation (p.i.) and displayed 
lymphocytosis and an enlarged mesenteric lymph node and thymus but this could not be tied to 
disease as the cats were also heavily parasite-infested [11]. Pedersen and others intra-
articularly inoculated 4 month to 3 year old SPF and conventionally reared cats in order to 
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reproduce polyarthritic disease but failed to see evidence of disease following clinical and 
synovial fluid examination [85]. Pedersen has additionally experimentally inoculated cats but 
only generally described transmission taking place after co-housing cats over 2 years, the 
appearance of FFV antibodies in the blood 3 weeks p.i., lifelong infection, absence of clinical 
signs p.i., and a “normal” hemogram for up to 3 years p.i. [58]. Attention to experimental FFV 
infection again took place in the early 2000’s in the context of FV use as vaccine and gene 
delivery vectors. Alke and others experimentally inoculated FFV-negative 3-4 month old female 
cats with 106 FFV focus forming units (FFU), given intramuscularly. Cats were monitored for up 
to 86 days p.i. and blood, peripheral blood leukocytes, and saliva was collected to detect 
antibodies and re-isolate virus. Humoral kinetics over time, as shown by band intensity on 
immunoblots, was shown for Gag for only one animal but could not be determined for Bet. After 
utilizing radioimmunoprecipitation (RIPA) assays, Bet bands could be detected with increasing 
intensity over time and shown in 2 animals. Virus was re-isolated from saliva and peripheral 
blood lymphocytes (PBL) through co-cultivation with permissive and reporter cell lines. The 
authors also determined that FFV established a persistent infection even in the presence of 
neutralizing antibodies [56]. Schwantes and others developed and tested replication competent 
FFV-based vectors and compared to wild-type FFV infection in FFV-negative cats. The animals 
were monitored, and sera collected for 85 days p.i. to detect immunoglobulin G (IgG) by 
immunoblotting, and the authors found comparable immune response between vector and wild-
type inoculated cats, although the detection of the Bet humoral response was again 
troublesome. Virus derived from the cloned plasmid was similarly re-isolated from saliva and 
peripheral PBL [91]. Weikel and others experimentally inoculated SPF cats in order to develop 
an FFV immunohistochemistry (IHC) assay and demonstrated Bet proteins in the cytoplasm of 
macrophages and fibrocytes of interstitial connective tissue of lymphoid tissues collected after 
euthanasia on 65 days p.i., and did not see evidence of pathology through histological 
examination of tissues [55]. In 2008, German and others experimentally inoculated 8 SPF cats 
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and monitored them for 168 days. Blood and saliva were collected for hematology and 
biochemistry, anti FFV-IgG response was measured by indirect ELISA, FFV viral load through a 
qPCR based on the polymerase gene, and euthanasia, necropsy, and tissue collection was 
performed at the end of the study. The authors reported that the animals remained healthy, 
showed no alterations in hematological and biochemical parameters, had a bi-phasic rise and 
decrease of virus in blood, and a bi-phasic trend in IgG response. Virus load was highest in 
lymphoid tissues, lung and salivary gland, and animals also showed a mild glomerulonephritis 
and interstitial pneumonia determined through histology. This study however, did not have 
negative control animals to compare findings to [59].  
 
FFV use as a vaccine and gene therapy vector 
Retroviruses have been used in the fields of vaccine and gene therapy vector development 
in part due to their ability to incorporate as proviruses into the host genome, resulting in 
transmission of viral genes to cell progeny. Lentiviruses (LV), gammaretroviruses (GV) and FVs 
have all been used as vectors for gene therapy with varying success [31, 92, 93]. Lentiviral 
vectors have an advantage over FV vectors in that they do not require active cell division to 
integrate into the host DNA [28]. However, GV and LV have the potential to cause gene 
dysregulation and oncogenicity depending on where in the host genome they integrate. For 
example, human patients undergoing stem cell therapy for SCID-X1, a genetic severe combined 
immunodeficient disease, developed leukemia following GV vector use [94]. Safety studies have 
also showed the potential for oncogenicity and enhancer activity in GV and read-through 
transcription in GV and LV [30, 32]. GVs also show a high frequency of insertions near 
transcription start sites (TSS) in and near proto-oncogenes [31] and LV have also been found to 
integrate near TSS and units of active transcription [95]. In comparison, FVs were found to have 
a safer integration profile compared to GV and LV [29, 31, 32, 96]. Additionally, FVs have been 
found to have similar stem cell transduction efficiencies as LV [96]. FVs packaging capacity is 
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ideal, due to relatively small genome size, and self-inactivating properties which can be 
engineered into the vectors for enhanced safety and less capacity for recombination [97-101]. 
Taken in combination with the fact that FVs establish apparently apathogenic infections with 
wide tissue tropism, and in the case of FFV pose no zoonotic risk, it is not surprising FVs are an 
attractive option for developing vectors. Research into use of FV vectors can yield opportunities 
for therapeutic technologies in both humans and animals [102]. Some documented examples of 
FV use in this capacity include anti-HIV therapeutics in humans, canine leukocyte adhesion 
deficiency, canine SCID, FCV vaccinology, and stem cell technologies [96, 97, 103-107].  
 
FFV and chronic kidney disease in domestic cats 
As mentioned earlier, experimentally FFV-infected cats show evidence of renal 
histopathological changes and FFV has been isolated from cats suffering renal and urinary 
diseases. Chronic kidney disease (CKD) is the renal disease most commonly affecting pet cats, 
and its incidence increases as animals age, reaching up to 81% prevalence rates in cats over 
the age of 15 [108-111]. CKD develops following either acute or chronic insults to the kidneys, 
leading to functional and structural loss of kidney tissue [112-116]]. The renal lesions most 
commonly associated with CKD in cats are tubular degeneration and atrophy, interstitial fibrosis, 
mononuclear cell infiltration, and Bowman’s capsule and tubular membrane mineralization [114, 
115, 117, 118]. Glomerulopathies are much less common than tubulointerstitial disease and, if 
present, focal segmental glomerulosclerosis is usually the predominant manifestation [115]. 
Cats affected by CKD present with varying degrees of azotemia (increased blood urea nitrogen 
and creatinine), improperly concentrated urine, proteinuria, and increased urine:protein 
creatinine (UPC) ratio [112, 113]. CKD severity is classified in stages by the International Renal 
Interest Society (IRIS) based on severity of azotemia, proteinuria, and hypertension [113, 119]. 
Clinically, cats present with non-specific signs such as lethargy and anorexia, later progressing 
to polyuria (frequent urination), polydipsia (frequent water drinking), vomiting, uremic syndrome, 
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retinal detachment, anemia, hypertension, hyperparathyroidism and others as severity of 
disease progresses [113, 116, 118, 120]. 
While the specific etiology of CKD is unknown, both congenital or acquired syndromes can 
lead to the development of CKD [112, 114]. Primary or congenital causes for CKD, such as 
polycystic kidney disease and renal dysplasia, are considered much less common than acquired 
causes which include nutritional, toxic, neoplastic, immune-mediated, bacterial, and viral 
etiologies [112, 114]. Risk factors for development of CKD include aging, breed, gender (some 
male populations), hypertension, cardiovascular disease, endocrine disease, and urinary tract 
infections [112, 114]. FIV and FeLV infections have been linked to CKD. FIV infection causes 
renal amyloidosis, immune complex glomerulopathy, glomerulosclerosis and proteinuria, leading 
to the development of CKD [121-123]. Immune complex glomerulonephritis has been reported 
in cats suffering from FeLV and myeloproliferative neoplasms [82].  
Domestic cats experimentally infected with FFV developed a glomerulonephritis 
characterized by increased cellularity in the glomerular tufts and adhesions between Bowman’s 
capsules and glomerular tufts in addition to showing mitoses, sloughed material into tubular 
medullary tubules, and syncytia formation [59]. In addition, cats suffering from urinary disease 
have been positive for FFV [9, 59, 78, 83, 84, 124-126].  
 
FIV infection in domestic cats and co-infection with FIV 
FIV is a complex retrovirus belonging to the lentivirus subfamily with a global distribution 
[127]. Like FFV, its genome contains the canonical gag, pol, and env genes, but with different 
accessory genes vif, rev, and orfA [128, 129]. The gene vif, or viral infectivity factor, is involved 
in countering host innate viral restriction factors (like A3) through proteasomal degradation as 
described earlier [43]. As opposed to FFV, FIV reverse transcription occurs early, before proviral 
integration into the host genome (Table 1) [127, 130]. FIV infects T lymphocytes early in 
infection and macrophages in chronic stages [131-133]. FIV leads to an immunodeficient state 
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in some cats which predisposes them to secondary infections and neoplasia through a 
progression of three clinically distinct phases [63, 131, 134-139]. 
While not as highly prevalent as FFV, FIV can be detected in up to 30% of at-risk cats [63, 
136, 138, 140]. Similarly to FFV, the main transmission route for FIV is through saliva via biting 
during aggressive encounters [63, 127, 139]. In addition to the risk factors seen in FFV of aging 
and male sex, outdoor access and increased exposure to other cats and fighting is also 
associated with FIV infection (Table 1) [62, 63, 136, 138, 140].  
Co-infection between FFV and FIV is very common, with up to 90% of FIV-infected cats 
testing positive for FFV [62, 63, 71]. FFV/FIV co-infection experimental studies are rare and 
have not documented viral kinetics over time during infection or assessed chronic timelines of 
disease progression [141]. Studies assessing potentiation of infection and disease in NHP co-
infected with simian foamy virus (SFV) and simian immunodeficiency virus (SIV) have found 
increased SIV-related morbidity and mortality, and expanded SFV tissue tropism [67, 142]. In a 
recent report, FFV was found to be associated with FeLV progression and FCoV infection [88]. 
Cats co-infected with FFV and either FIV or FeLV might therefore suffer more serious disease 
consequences than cats with single infection, which could impact the health of cats and could 
also be factor for at-risk cats for developing CKD.   
 
Table 1. Comparison of FFV and FIV. 
 FFV FIV 
Subfamily Spumaretrovirinae Orthoretrovirinae 
Genus Spumavirus Lentivirus 
Infective form DNA RNA 
RT Step Late Early 
Anti-A3 gene/Protein bet/Bet vif/Vif 
Latency Lymphocytes, others? Lymphocytes 
Duration of infection Lifelong Lifelong 
Clinical disease Contested but considered apathogenic +/- Immunosuppression, death 
Risk factors Age, male sex Age, male sex, outdoor access 
Transmission (main) Saliva, friendly grooming? Saliva, biting 
Prevalence Up to 80% Around 30% in at-risk cats 
Zoonotic No No 
Viral vector use Yes Yes 
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Dissertation research 
My dissertation research is composed of three aims investigating FFV biology, use as a 
vaccine vector, and interaction with other feline disease syndromes. The first aim (Chapter 1) 
was to investigate the use of FFV as a vaccine vector as part of an FFV-FIV chimeric vaccine 
vector that contained the full FIV vif gene replacing a truncated FFV bet gene. My collaborators 
generated the infective FFV-Vif chimeras that I tested in SPF cats. I compared viral replication 
kinetics and specific immune response against FFV Gag and Bet and FIV Vif and found that 
replication of the FFV-Vif chimera was attenuated in vivo, yet the cats mounted a persistent 
antibody response towards all FFV and FIV proteins, indicating functional replication of viruses 
after experimental inoculation. We also noted the capacity of FFV to superinfect the same host 
after an already established FFV infection, providing an opportunity for vaccine development in 
pet cat populations that may have already been exposed to FFV.  
For the second aim (Chapter 2), I further characterized wild-type FFV infection due to its 
high prevalence around the world, and to validate reports associating FFV with other diseases 
in domestic cats. We specifically searched for evidence of pathology and sought to characterize 
infection to expand what is already reported in the literature. Since FVs are being used to 
develop vaccines and gene therapy, we felt it necessary to further determine if these viruses are 
truly apathogenic. I found mildly altered hematological and biochemical parameters potentially 
associated with renal injury, microscopic changes in the lung and brain, and ultrastructural 
changes in the kidney. Due to these results, I conducted a survey of FFV in pet cats suffering 
from CKD and found an association in male cats. 
For the third (Chapter 3), we hypothesized that FFV and FIV are associated, and that viral 
kinetics and/or FIV-associated disease is potentiated during co-infection. I conducted a 
serosurvey of naturally FIV-infected cats that suffered different outcomes of disease and 
determined FFV prevalence in these animals. We also found associations between FFV and 
FIV and in male cats. Based on these results I conducted in vitro assays to determine if the 
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viruses were potentiating each other as measured by increasing presence of virus and 
cytopathic effects. My in vitro experiments show that after initial infection with either FFV or FIV, 
the secondary virus’ kinetics are accelerated and enhanced, while kinetics of the initial virus is 
sometimes slightly dampened by the secondary virus. These results indicate further research 
regarding interactions of FFV and other viruses is needed. 
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Background: Hosts are able to restrict viral replication to contain virus spread before 
adaptive immunity is fully initiated. Many viruses have acquired genes directly counteracting 
intrinsic restriction mechanisms. This phenomenon has led to a co-evolutionary signature for 
both the virus and host which often provides a barrier against interspecies transmission events. 
Through different mechanisms of action, but with similar consequences, spumaviral feline foamy 
virus (FFV) Bet and lentiviral feline immunodeficiency virus (FIV) Vif counteract feline APOBEC3 
(feA3) restriction factors that lead to hypermutation and degradation of retroviral DNA genomes. 
Here we examine the capacity of vif to substitute for bet function in a chimeric FFV to assess 
the transferability of anti-feA3 factors to allow viral replication. 
Results: We show that vif can replace bet to yield replication-competent chimeric foamy 
viruses. An in vitro selection screen revealed that an engineered Bet-Vif fusion protein yields 
suboptimal protection against feA3. After multiple passages through feA3-expressing cells, 
however, variants with optimized replication competence emerged. In these variants, Vif was 
expressed independently from an N-terminal Bet moiety and was stably maintained. 
Experimental infection of immunocompetent domestic cats with one of the functional chimeras 
resulted in seroconversion against the FFV backbone and the heterologous FIV Vif protein, but 
virus could not be detected unambiguously by PCR. Inoculation with chimeric virus followed by 
wild-type FFV revealed that repeated administration of FVs allowed superinfections with 
enhanced antiviral antibody production and detection of low level viral genomes, indicating that 
chimeric virus did not induce protective immunity against wild-type FFV. 
                                               
1Chapter published as: Ledesma-Feliciano C, Hagen S, Troyer R, Zheng X, Musselman E, Slavkovic Lukic D, Franke 
AM, Maeda D, Zielonka J, Münk C, Wei, G, VandeWoude S, Löchelt, M: Replacement of feline foamy virus bet 
by feline immunodeficiency virus vif yields replicative virus with novel vaccine candidate potential. 
Retrovirology 2018, 15:38. 
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Conclusions: Unrelated viral antagonists of feA3 cellular restriction factors can be 
exchanged in FFV, resulting in replication competence in vitro that was attenuated in vivo. Bet 
therefore may have additional functions other than A3 antagonism that are essential for 
successful in vivo replication. Immune reactivity was mounted against the heterologous Vif 
protein. We conclude that Vif-expressing FV vaccine vectors may be an attractive tool to 
prevent or modulate lentivirus infections with the potential option to induce immunity against 
additional lentivirus antigens. 
 
Background 
Foamy viruses (FVs) are ancient retroviruses comprising the only genus of the subfamily 
Spumaretrovirinae, which are different in many aspects from the Orthoretrovirinae that comprise 
all other known retroviruses including lentiviruses (LVs) [2, 3, 7]. Despite having a wide tissue 
tropism in infected animals, FVs have historically been regarded as apathogenic and are 
endemic in primates, bovids, felids, and other hosts. Clusters of highly related viruses have 
been documented in closely related hosts [5, 55, 59, 143]. While humans do not have endemic 
FVs, they are susceptible to zoonotic infections from non-human primates [51, 144]. FVs and 
LVs such as feline immunodeficiency virus (FIV) have been used to develop vectors for vaccine 
antigen delivery and gene therapy in a variety of mammals [96, 97, 102, 105, 145-148]. In 
domestic cats (Felis catus), feline foamy virus (FFV) and FIV establish lifelong infections despite 
specific host antiviral immune responses [56, 63, 139, 149]. In contrast to FFV infection, FIV 
infection leads to the development of an immunosuppressive AIDS-like syndrome in some cats 
[63, 134, 136, 138, 149]. Thus, FVs are an attractive alternative to LV vectors due to their 
apathogenicity, wide tissue tropism, and establishment of a persistent infection with ongoing 
virus gene expression and replication [55, 56, 58, 59, 91, 145, 146]. Another advantageous 
feature of FV-based vectors is a safer integration profile than gammaretroviral and LV vectors 
[29, 96], a large packaging capacity, and the ability to introduce self-inactivating properties [97-
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101]. Investigating FV vector candidates could thus yield potential new therapies to benefit both 
humans and animals [102]. 
Both LVs and FVs are complex retroviruses encoding the canonical Gag, Pol, and Env 
proteins, regulatory proteins essential for replication in all cells, and accessory proteins required 
only in certain cells. For instance, LV Tat and FV Tas (also designated Bel1) proteins are both 
transactivators for virus gene expression, however, their mode of action is completely different 
(for review [20]). Regardless, both regulatory genes induce a positive feedback loop to generate 
more transactivator protein in addition to transcription of structural genes required for infectivity 
[20]. FVs additionally encode Bet that is generated via splicing, consisting of N-terminal Tas 
sequences while the majority of the protein is encoded by another reading frame, the bel2 gene 
[20]. Bet is the functional homologue of the LV Vif protein, both of which are involved in 
countering the host intrinsic antiviral restriction factors of the APOBEC3 (A3) family [14-19]. 
Like all other viruses, LVs and FVs are restricted by intrinsic cell mechanisms that impair or 
even suppress the different phases of virus replication, progeny production, and establishment 
of infection in the new host (for review see [41, 42]). Nonspecific innate immunity and cell-based 
intrinsic immunity employing antiviral restriction factors are both absolutely required to control 
pathogen replication before adaptive immunity matures for long-term suppression of viral 
replication [150, 151]. Therefore, a fine-tuned crosstalk between innate, intrinsic, and adaptive 
immunity is needed to control and eliminate the pathogen as well as to build up immunological 
memory [150-152]. Pathogens have evolved a plethora of counteracting strategies in order to 
evade this control, often by the acquisition of counteracting proteins [41, 42]. The idea and 
concept of host-encoded restriction factors and the viral counter-defense have been in part 
established in human immunodeficiency virus (HIV) research. These initial studies analyzed the 
interplay between host-encoded A3 cytidine deaminases that result mainly in lethal mutagenesis 
(C to U/T exchanges) of the retroviral HIV genome during reverse transcription, and the counter-
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defense by LV Vif (or Bet in FVs) which result in A3 degradation (via Vif) or sequestration (via 
Bet) [14, 15, 17, 42, 43].  
Analogous to human A3 function, feline A3 (feA3) proteins are produced in many cell types 
and introduce missense and stop mutations into nascent viral genomes, ultimately restricting 
viral replication through hypermutation and degradation [14, 15, 41]. Several studies on the 
function of FIV Vif and FFV Bet, which are of very different size and share no obvious sequence 
or structural homology [17, 19, 153], have revealed that they employ completely different modes 
of action to achieve the same end goal: preventing the packaging of feA3 proteins into the 
particle to avoid subsequent viral lethal mutagenesis. The FIV Vif protein (25 kDa) functions as 
an adapter molecule, binding to cognate or highly-related feA3 proteins and recruiting the 
ubiquitin proteasome degradation machinery, resulting in the removal of feA3 proteins from the 
virus-producing cell [43, 154-157]. This is the critical prerequisite to prevent cytidine 
deamination during or after reverse transcription of the genome. In contrast, FV Bet proteins (of 
43 to 56 kDa) tightly bind A3 proteins of their cognate host species without leading to 
degradation, likely acting via sequestration or blocking of essential binding and multimerization 
sites [14, 17, 18, 153]. Therefore, vif and bet are essential viral genes required to allow 
productive replication in cells with active A3 expression [34, 41, 158].  
Domestic cats produce multiple A3 proteins in one and two-domain forms. One-domain feA3 
proteins include the A3Z2 (present as A3Z2a, A3Z2b, and A3Z2c) and A3Z3 isoforms, while 
read-through transcription leads to the production of two-domain feA3Z2-Z3 proteins (in A3Z2b-
Z3 and A3Z2c-Z3 isoforms) [159]. These feA3 proteins have differential effects on FFV and FIV: 
A3Z2s markedly reduce titers of FFV lacking bet, while the A3Z3 and A3Z2-Z3 proteins inhibit 
FIV virions lacking vif with intermediate and high efficiency, respectively. Interestingly, both Bet 
and Vif counteract all feA3 regardless of whether the specific A3 isoforms efficiently restrict FFV 
or FIV [14, 15, 43, 154, 155, 159], suggesting a more complex relationship between these 
accessory genes and host restriction factor regulation than has yet been described. 
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Here we describe the generation and in vitro selection of FFV-Vif chimeras in which FIV vif 
partially or almost fully restored the replication capacity of bet-deficient FFV constructs in vitro. 
An in vitro-selected FFV-Vif variant that drives expression of the heterologous lentivirus Vif 
independent from any FFV protein and which is highly dependent on Vif expression in A3-
producing cells, was used for infection of domestic cats to test the chimera’s replication 
competence and immunogenicity. Replication of the FFV-Vif chimera was attenuated in cats 
compared to wild-type FFV. Cats infected with the FFV-Vif chimera developed persistent 
antibody responses towards FFV proteins and FIV Vif but proviral FFV-Vif chimeric genomes 
were at or below the limit of detection in peripheral blood mononuclear cells (PBMC) of infected 
cats. In contrast, proviral genomes were consistently detected in wild-type FFV-infected cats. 
Inoculation of cats in the FFV-Vif chimera cohort with wild-type FFV or re-inoculation with FFV-
Vif chimeric virus boosted anti-FFV Gag antibody titer following re-infection. These results 
suggest that compensatory changes arising in vitro seemingly allowed FIV-Vif to substitute for 
FFV-Bet function but were incapable of fully supporting FFV-Vif chimeric replication competence 
in vivo. These findings additionally suggest the capacity of spumaviruses to superinfect cats 
following prior attenuated FFV replication, indicating the potential suitability of chimeric FFV as a 
vaccine vector in the face of a pre-existing infection and immunity.  
 
Results 
FIV Vif and FFV Bet confer protection from feA3 restriction in vitro 
Previous studies have shown that the FIV Vif accessory protein has the capacity to direct 
proteasomal degradation of all known feA3 cytidine deaminase restriction factors irrespective of 
whether they strongly or moderately restrict FIV replication [43, 154, 155, 159]. Similarly, FFV 
Bet binds to all feA3 isoforms and inactivates their restriction potential by a degradation-
independent, different mechanism not comparable to FIV Vif [14, 15]. In addition, FIV Vif can 
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protect the replication capacity of bet-deficient FFV while FFV Bet correspondingly counteracts 
feA3-mediated restriction of vif-deficient FIV [41, 43].  
To confirm here that the viral defense proteins of FFV and FIV are functionally 
interchangeable to protect infectivity against feA3 restriction [14, 15, 43, 154, 155, 159], 
transient transfection studies were conducted, and representative data are shown here. First, 
we analyzed the susceptibility of FIV!vif-luc, a vif-deficient FIV luciferase (luc) expression 
vector (“Methods”, [43]) towards one-domain feA3Z3, and two-domain feA3Z2-Z3 isoforms 
(Appendix File 1A). The efficacy of luc marker gene transduction was determined in the 
presence of co-transfection with FFV bet, FIV vif, or an empty control vector. Both FIV Vif and 
FFV Bet restored the FIV vector titer almost fully while different levels of feA3-mediated 
restriction were detectable only in the absence of any viral defense protein. Similarly, the 
replication competence of the bet-deleted and feA3-sensitive pCF7-BBtr FFV mutant (Table 1, 
[91]) was rescued by Bet and Vif. In the absence of Vif and Bet proteins, the expression of the 
feA3Z2b isoform strongly suppressed the titers of bet-deficient pCF7-BBtr (Appendix File 1B). 
This antiviral restriction by feA3Z2b was partially or fully abrogated by co-expression of either 
FFV Bet or FIV Vif, respectively.  
 
Substitution of FFV Bet by functional Vif confers FFV replication competence in feA3 expressing 
cells 
To initially assess whether FFV Bet could be functionally replaced by FIV Vif, resulting in 
feA3-resistant FFV variants, bet sequences downstream of the essential tas transactivator gene 
(at Bet amino acid 117) in the full-length FFV clone pCF7-BetMCS (Table 1) [34, 91] were 
replaced by a codon-optimized FIV vif gene [43, 159] shown schematically and in detail in Fig. 




+FFV-Vif variants collectively referred to as “FFV Vif chimeras” 
‡Viral stocks used in domestic cat infection experiments 
 
Similar to other Bet fusion proteins engineered in the FFV proviral context [91, 145], an FFV 
protease (PR) cleavage site was introduced between the truncated N-terminus of Bet and the 
intact FIV vif gene start codon. Gene swapping did not affect FFV tas, and we have previously 
demonstrated that the N-terminal Bet sequence retained in the pCF7-Vif clones does not 
counteract feA3-mediated restriction of FFV replication [153]. Sequencing of resultant clones 
was conducted to confirm the genetic identity and correctness of the newly created clone pCF7-
Table 1. Viral clones and stocks used in this study. 
Clones Viral Stock Name+ Major mutation 
Effect on Replication 
(CrFK) 
pCF-7 [91] ‡wild-type FFV - - 
pCF7-BBtr FFV-BBtr 
Truncation at Bet amino 
acid 117 
Fully susceptible towards 
feA3-mediated restriction in 
vitro 
pCF7-BetMCS [34] FFV-BetMCS 
Insertion and replacement 
of Bet residues at amino 
acid 117 by insertion of a 
multiple cloning site 
Fully susceptible towards 
feA3-mediated restriction in 
vitro 
pCF7-Vif-4 FFV-Vif-4 




restriction in vitro 
pCF7-Vif-39 FFV-Vif-39 Spontaneous frameshift 
Fully susceptible towards 
feA3-mediated restriction in 
vitro 
pCF7-Vif W/*1 ‡FFV-Vif W/*1 
Trp to Stop mutation (TGG 
to TGA), unlinked vif gene  
Enhanced, compared to 
pCF7-Vif-4 
pCF7-Vif W/*2 FFV-Vif W/*2 
Trp to Stop mutation 
(TGGG to TAGA), 
unlinked vif gene 
Enhanced, compared to 
pCF7-Vif-4 
pCF7-Vif W/*1 M+ - 
Optimized upstream Met 
codon in pCF7-Vif W/*1 
Similar to pCF7-Vif W/*1 
pCF7-Vif W/*2 M+ - 
Optimized upstream Met 
codon in pCF7-Vif W/*2 
Similar to pCF7-Vif W/*2 
pCF7-Vif W/*1 M/T - 
Upstream Met codon 
mutated to Thr in pCF7-Vif 
W/*1 
Similar to pCF7-Vif W/*1 
pCF7-Vif W/*2 M/T - 
Upstream Met codon 
mutated to Thr in pCF7-Vif 
W/*2 
Similar to pCF7-Vif W/*2 
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Vif-4 (Table 1). A spontaneous frame shift mutation arose in subclone pCF7-Vif-39 (Table 1), 
abrogating BettrVif fusion protein expression completely, making this clone suitable for use as a 
negative control.  
Plasmids pCF7-Vif-4, pCF7-Vif-39, and parental wild-type FFV full-length pCF-7 genome 
(Table 1) were transfected into human embryonic kidney (HEK) 293T cells. Supernatants were 
passaged twice on Crandell feline kidney (CrFK) cells (known to express feA3 [159]) to assess 
the ability of the chimeras to replicate in feline-origin cells. The full-length BettrVif fusion protein 
and the mature Vif processing products were stably expressed by clone pCF7-Vif-4 which was, 
as expected, not the case for the frame shift mutant pCF7-Vif-39 (Fig. 1B, top panel). FFV Bet 
was only expressed by the wild-type pCF-7 genome upon transfection and serial passages (Fig. 
1B, middle panel). Similar amounts of full-length FFV p52Gag and the processed p48Gag were 
synthesized by pCF7-Vif-4 and wild-type pCF-7 in transfected HEK 293T and infected CrFK 
cells while in clone pCF7-Vif-39, Gag expression was almost lost at the second CrFK cell 
passage (Fig. 1B, bottom panel). The loss of Gag expression of clone pCF7-Vif-39 was 
paralleled by a very rapid decline of infectivity (Fig. 2A). In contrast, titers of pCF-7 were higher 
than those of pCF7-Vif-4 and none of them showed a sharp decline of viral infectivity. These 
data indicate that intact FIV vif-chimeric pCF7-Vif-4 is replication-competent in feA3-positive 
CrFK cells, albeit at lower efficiency than wild-type FFV (Fig. 2A). 
 
Passage through CrFK enhances FFV-Vif chimera replication efficiency   
We continued passaging progeny of wild-type pCF-7 and chimeric pCF7-Vif-4 (see above, 
Fig. 2A) for 20 passages in order to use in vitro selection and evolution to obtain FFV-Vif 
variants with higher replication capacity in the presence of the feA3 proteins endogenously 
expressed in CrFK cells [14]. During the first seven passages, wild-type pCF-7 displayed titers 
between 106 and 107 focus-forming units per ml (FFU/ml) (Fig. 2A). During this phase, infectivity 
of the chimeric clone pCF7-Vif-4 was approximately one to two logs lower (104-106 FFU/ml). 
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Starting at passage eight, however, titers of pCF7-Vif-4 progeny approached that of wild-type 
pCF-7, indicating emergence of pCF7-Vif variants with enhanced replicative ability in vitro (Fig. 
2A). Selected samples harvested during CrFK passaging were analyzed for FFV Gag and Vif 
expression (Fig. 2B). FFV Gag expression was consistently detectable in all cell lysates using 
FFV reference serum from cat 8014 (Fig. 2B, middle panel). Early, during viral passages 2 and 
5, the BettrVif fusion protein and its proteolytic cleavage products were the primary Vif-reactive 
proteins detectable. At passage 10, BettrVif became undetectable and the Vif protein of 
approximately 25 kDa was detected, along with additional Vif-reactive bands of higher molecular 
mass. At passage 15, mostly Vif proteins in the 25 kDa size range were identified (Fig 2B, top 
panel). 
To detect potential adaptive genetic changes in the FFV genome, DNA was prepared from 
FFV-Vif-4-infected CrFK cells at passage 18 and used as template for PCR to amplify and clone 
the complete bettrvif region. In seven of nine amplicons, a tryptophan codon (TGG, Trp) located 
in the bet sequence 50 codons upstream of the vif ORF had mutated to become TAG and TGA 
stop codons (Fig. 2C and Appendix File 2). These changes were transitions of either the first or 
second G residue to an A (Fig. 2C, top panel) yielding two different stop codons, indicated by an 
asterisk (*), as either a TGA (five out of seven sequences, designated W/*1) or a TAG stop 
codon (two out of seven sequences, designated W/*2). In the five clones that had incorporated 
the TGA stop codon in the bet sequence, a G172R mutation in the overlapping Tas-coding 
sequence occurred. In the two TGG to TAG mutants, a G residue following the TGG codon was 
also changed to A (i.e. TGGG was altered to TAGA). This resulted in a G172L exchange in Tas 
and a D/N change directly downstream of the new bet stop codon. All nucleotide exchanges 
correspond to C/T exchanges of the antisense strand in a sequence context PyPyC (Fig. 2C; 
Py=pyrimidine residue), corresponding to the canonical A3 mutation context in retroviral 





Figure 1. Schematic presentation of the construction of FFV-Vif chimeras and their molecular 
features. a Schematic presentation of the FFV genome with its genes and protein domains as well as the 
LTR and internal promoters (red bent arrows, top) and presentation of the engineered BettrVif fusion 
protein (bottom). The non-functional N-terminus of bet (purple) was fused in-frame to the codon-optimized 
FIV vif gene including the vif ATG start codon. A short linker encompassing the FFV PR cleavage site 
(vertical red arrow, bottom) was inserted between the N-terminus of Bet and Vif. Primer pairs used to 
insert the vif gene into the FFV genome are shown in blue and violet and with numbering in the bottom 
panel. b HEK 293T cells were transfected with wild-type pCF-7, functional clone pCF7-Vif-4, non-
functional clone pCF7- Vif-39, and pcDNA3.1 control DNA. Two days after transfection, cell culture 
supernatants and cells were harvested as described in the “Methods” section. Cleared supernatants were 
used for serial passaging in feA3-expressing CrFK cells and FFV titer determination (Fig. 2A). At 3 days 
p.i., infected CrFK cells and supernatants were harvested and used as above. Cell lysates from 
transfected HEK 293T cells and CrFK cells after the first and second passage were subjected to 
immunoblotting against FIV Vif and co-transfected GFP, FFV Bet, and FFV Gag (cat serum 8014). The 




Figure 2. In vitro selection and molecular characterization of pCF7-Vif-4 variants with increased 
replication competence. Plasmid pCF7-Vif-4, -39, and pCF-7 were transfected into HEK 293T cells. 
Two days after transfection, cell-free supernatants were inoculated on CrFK cells and serially passaged 
twice a week on CrFK cells (every 3 or 4 days) as described above for Fig. 1B. a FFV titers were 
determined in duplicate using FeFAB reporter cells and are shown as bar diagram for selected passages 
over time. Error bars represent the standard deviation. b Selected cell extracts from the CrFK passages 
were subjected to immunoblotting. The immune-detection with a Vif-specific antiserum initially showed 
mainly the engineered BettrVif and the proteolytically released Vif, then various unidentified Vif variants, 
and finally (passages 10 and 15) predominantly the authentic Vif protein. FFV Gag proteins were 
detected in all samples as expected using cat antiserum 8014 while in the bottom panel the β-actin 
loading control is shown. c Sequence context of the in vitro-selected W/* mutations (light blue original Trp 
to the stop codon in red) suggests feA3 editing of the minus strand of FF7-Vif-4-derived reverse 
transcription intermediates in the PyPyC sequence context (top panel, Py=pyrimidine residue). Below, 
mutagenesis of the in-frame ATG 14 codons upstream of the vif gene is shown only for the sense strand 
(bottom panel). The ATG start codon is shown in light blue and the engineered residues and changes 
amino acids are in red.  
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Unlinking vif from bet by Trp/stop mutagenesis is essential for increased infectivity  
The importance of the identified Trp/stop (W/*) mutations upstream of the vif sequence was 
analyzed using reverse genetics. Both W/* mutations in the bel2 linker sequence upstream of vif 
were inserted into the original pCF7-Vif-4 to determine whether they represent adaptive 
mutations increasing the titer of the corresponding FFV-Vif chimera. These clones were named 
pCF7-Vif W/*1 (TGG/TGA) and pCF7-Vif W/*2 (TGG/TAG, Table 1).  
An additional outcome of the W/* mutations was the “emergence” of an in-frame ATG codon 
between the new W/* stop codon and the authentic vif start codon (Appendix File 2). To test 
whether this ATG codon could serve as an alternative translational initiation codon for the 
inserted vif gene, this Met ATG was replaced in the engineered pCF7-Vif W/*1 and –W/*2 
clones and the parental pCF7-Vif-4 clone by a threonine (Thr) codon (suffix M/T, see Fig. 2C 
lower panel and Table 1). In addition, and as a complementing strategy, the surrounding 
nucleotide sequence of this ATG codon was converted to an optimal Kozak translational 
initiation context sequence (GCCA/GCCATGG, start codon underlined, [160]) as shown in Fig. 
2C, lower panels. The corresponding clones are labeled by the suffix M+ (Table 1). The M/T 
mutation resulted in a silent mutation at the tas C-terminus while the change to a Kozak 
sequence resulted in two amino acid exchanges in tas at the C-terminus, i.e. D206H and 
A208G, and, in addition, a leucine to phenylalanine (L/F) exchange upstream, and a leucine to 
valine (L/V) exchange directly downstream of the potential Met start codon in the linker 
sequence (see Fig. 2C). 
Transient co-transfection studies using a luc FFV LTR reporter construct together with either 
a CMV-IE promoter-driven Tas expression clone and a CMV-IE-driven b-gal plasmid or the FFV 
genomes pCF-7, pCF7-Vif-4, pCF7-Vif W/*1, and the different M/T and M+ derivatives thereof 
were conducted. While the CMV-IE promoter-driven Tas expression clone yielded very high luc 
activities, the genomic wild-type and chimeric proviral FFV clones described above did not show 
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significant differences in Tas transactivation, indicating that the mutations introduced do not 
significantly influence overall transactivation and gene expression (Appendix File 3). 
Clones pCF7-Vif W/*1 and -W/*2 and the different M/T and M+ derivatives were transfected 
into HEK 293T cells and supernatants were tested for the replication competence of the FFV-Vif 
chimera in feA3-positive CrFK cells by serial CrFK cell passaging as described above. Serial 
passaging after either 60 h or 84 h (Appendix File 4A and 4B) showed similar outcomes: the 
pCF-7-encoded wild-type FFV had slightly higher titers (about 5-fold) than mutants pCF7-Vif 
W/*1 and –W/*2 and their derivatives. For these clones and the corresponding M/T and M+ 
clones, titers were stable during serial passages. This was not the case for the original pCF7-
Vif-4 clone encoding the BettrVif fusion protein, where titers steadily and reproducibly declined 
upon serial passages in several independent experiments. The data show that both W/* 
mutations in the FFV bet sequence upstream of the vif gene cause in feA3-expressing CrFK 
cells a clear increase of replication competence compared to the pCF-Vif-4 encoding the BettrVif 
fusion protein. However, the replication competence of the pCF7-Vif W/*1 and –W/*2 clones 
was slightly lower than that of the wild-type FFV genome pCF-7. In addition, the FFV-encoded, 
in-frame ATG codon located 14 codons upstream of vif is probably not used as a start codon for 
Vif protein expression since its replacement by a Thr codon, or the optimization of the 
surrounding residues towards more efficient translational initiation, did not significantly affect 
viral titers. 
 
Reduced steady state levels of feA3Z2b by FFV-Vif chimeric clones pCF-Vif-4 and pCF7-Vif 
W/*1 and –W/*2 
Co-transfection experiments were conducted to study whether the steady state levels of 
feA3Z2b are decreased by BettrVif fusion protein or the authentic Vif encoded by FFV-Vif 
chimeric clones pCF-Vif-4 or pCF7-Vif W/*1 and –W/*2, respectively (Table 1). As indicated in 
Fig. 3 (bottom panel), parental wild-type FFV full-length pCF-7 genome and FFV-Vif chimeric 
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clones pCF-Vif-4, pCF7-Vif W/*1, and –W/*2 were transfected into HEK 293T cells together with 
a plasmid encoding HA-tagged feA3Z2b (the major feA3 restriction factor of Bet-deficient FFV) 
[14, 15]. Cells transfected with the plasmid encoding feA3Z2b and pcDNA as well as pcDNA-
only-transfected HEK 293T cells served as controls. Cellular antigens were harvested two d 
after transfection and subjected to immunoblotting (Fig. 3). The control blots conducted confirm 
proper loading of samples (anti b-actin, bottom panel) and comparable expression of FFV 
proteins in wild-type and chimeric FFV provirus-transfected samples and BettrVif fusion proteins 
and FIV Vif by FFV-Vif chimeric clones pCF-Vif-4 and pCF7-Vif W/*1 and –W/*2, resp. (anti FFV 
Gag and anti FIV Vif, middle panels). As expected and previously shown [14, 15], the steady-
state levels of HA-tagged feA3Z2b were not significantly affected by co-expression of wild-type 
FFV expressing Bet (anti HA, top panel, compare lanes 2 to 3 and 8 to 9). In stark contrast, 
levels of HA-tagged feA3Z2b were reproducibly and strongly reduced in cells expressing either 
BettrVif and/or authentic FIV Vif (compare lane 2 to 4, 5, and 6 and lane 8 to 10, 11, and 12 in 
Fig. 3, top panel). In another and independent experiment with a highly similar outcome, only 
co-transfection of CMV-IE promoter-based and codon-optimized FIV Vif expression plasmids 
reduced feA3Z2b to undetectable levels (data not shown). In summary, the data clearly support 
the conclusion that the Vif protein in the FFV-Vif chimeric clones leads to decreased steady 
state levels of feA3Z2b, most probably via proteasomal degradation [15, 43, 154, 155, 159].  
 
Experimental infection of cats with chimeric virus FFV-Vif W/*1  
To investigate whether the FFV-Vif chimera with the Bet-independent expression of Vif is 
replication-competent and immunogenic in cats, we performed inoculation experiments with 
FFV-Vif W/*1 (Table 1). This clone was selected for in vivo infection studies since it is the major 
variant detected in our in vitro experiments and is caused by only a single nucleotide exchange 
from the original engineered pCF7-Vif-4 chimera. Cats were separated into naïve (N), wild-type 
(WT), or chimeric (CH) groups based on inoculum type. The timeline of inoculations, sample 
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collections, and final necropsy are shown in Fig. 4. None of the cats displayed signs of clinical 





Figure 3. Reduced steady state levels of feA3Z2b in FIV Vif- and Bet Vif-expressing cells.  
Parental wild-type FFV full-length pCF-7 genome and FFV-Vif chimeric clones pCF-Vif-4, pCF7- Vif W/*1, 
and –W/*2 were transfected into HEK 293T cells together with 0.5 (Fig. 3, lanes 2 to 6) or 1.0 µg (lanes 8 
to 12) of a plasmid encoding HA-tagged feA3Z2b as indicated below the blots. Cells transfected with the 
plasmid encoding feA3Z2b and pcDNA, as well as pcDNA-transfected cells served as controls (lanes 2 
and 8, and 1 and 13, respectively). Cells were lysed 2 d after transfection and 20 µg total of each protein 
lysate was subjected to immunoblotting against HA (detecting HA-tagged feA3Z2b), FIV Vif, FFV Gag 
and β-actin (from top to bottom and indicated at the left). Lane 7 was loaded with a pre-stained protein 
marker. The bands corresponding to apparent molecular masses of 40 and about 55 kDa are seen below 
and above the B-actin of 42 kDa (bottom panel developed in an Intas ECL Chemocam Imaging device). 
All other blots were exposed to autoradiography films and thus, pre-stained protein markers are not 
visible in lane 7. The names of proteins specifically detected by immunoblotting are given at the right-





Figure 4. Experimental infection of cats with wild-type FFV and the FFV-Vif W/*1 chimera. Twelve 
SPF cats were separated into groups (n = 4 each) based on the inoculum type administered at day 0: 
naïve (N), wild-type FFV (WT), and chimeric FFV-Vif W/*1 (CH). Cats received 105 TCID50 of either wild-
type or chimera. Animals were monitored daily for clinical signs of infection and blood samples were 
collected on days specified on the timeline above to characterize infection and immune responses. 
Samples were collected for baseline data on day -21. On day 53, cats in the CH group were re-inoculated 
with either undiluted wild-type FFV of 2.78 × 105 TCID50/ml (n = 2, referred to as CH1WT and CH2WT) or 
undiluted FFV-Vif W/*1 of 5.56 × 104 TCID50/ml (n = 2, referred to as CH3CH and CH4CH). Inoculation 
time points are marked by green stars. Animals were humanely euthanized and necropsied on day 176 
p.i. (black X). 
 
Wild-type inoculated cats exhibited persistent FFV DNA proviral loads in PBMC in contrast to 
chimera-inoculated cats 
To compare viral load and kinetics between inoculation groups, we evaluated the presence 
of FFV proviral DNA in PBMC over time (Fig. 4 and 5). Naïve control cats remained absolutely 
PCR-negative at all time points tested (Appendix File 5). Cats in the WT group developed a 
persistent PBMC proviral load as early as 21 days post-infection (p.i.) (Fig. 5A and 6), while 
indeterminate PCR reactions were detected earlier (Fig. 5A and Appendix File 5). By day 42 p.i., 
all WT cats were PCR positive and positivity was consistently detected throughout the rest of 
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the study (Fig. 5A). Cat WT3 (subsequently also referred to as “outlier”) had a PBMC FFV DNA 
pattern that differed from the rest of the WT cohort (Fig. 6). This animal was not PCR-positive 
until day 42 (versus day 21 as in its cohort-mates). Throughout the rest of the study, the outlier 
cat’s overall viral load was however much higher (highest at 5,920 viral copies/106 cells on day 
142 p.i.) than the other WT cats (WT2 had the highest viral load at 1,230 viral copies/106 cells 
on day 28 p.i.) (Fig. 6).  
Three out of four cats inoculated with only FFV-Vif chimeric virus (CH group) showed 
indeterminate results for FFV PBMC provirus DNA by qPCR analysis at some of the time points 
tested prior to re-inoculation on day 53 p.i. (Fig. 5B and Appendix File 5). One of the chimera-
inoculated cats re-inoculated on day 53 with wild-type virus (cat CH2WT) demonstrated FFV 
proviral DNA in PBMC 24 d post re-inoculation, while the other cat in this cohort remained 
indeterminate or negative throughout the study (Fig. 5C). The highest viral load recorded for cat 
CH2WT was 656 viral copies/106 cells 24 days post re-inoculation (Fig. 6). Both cats re-exposed 
to the FFV-Vif chimera displayed repeated indeterminate PCR results in blood before and after 
superinfection (Fig. 5B and D).  
 
Gag-specific immune reactivity in infected animals confirms replication competence of wild-type 
FFV and FFV-Vif chimera 
All FFV-infected cats strongly seroconverted against Gag while all naïve control animals were 
negative (Appendix File 6, reactivity at 1:50 dilution). In order to determine the kinetics and 
strength of anti-Gag reactivity, selected serum samples from wild-type FFV and FFV-Vif-infected 
animals were analyzed before and after superinfection (only cats in the CH group received a 
second inoculation, Fig. 7A and B). Wild-type FFV-infected cats had detectable specific anti-Gag 
antibody responses as early as 21 or 28 days p.i. (Fig. 5A and Appendix File 5). 
Antibody levels for these cats continued to increase to final titers between 500 and 2,500 
(Fig. 7A). FFV Gag antibodies of FFV-Vif-infected animals were first detected by day 15 p.i. 
 30 
(Fig. 5B and Appendix File 5) and increased gradually until superinfection, after which Gag-
specific titers were attained that were equivalent to wild-type-infected cats (Fig. 7A and B). Anti-
Gag reactivity was detected in all four CH group cats at approximately the same seroconversion 
rate as wild-type FFV-infected cats, though titers tended to be lower prior to re-exposure in the 




Figure 5. Results of PCR and ELISA assays over the entire study period. Summary of real time 
quantitative and nested PCR (qPCR and nPCR, respectively) on PBMCs and ELISAs for FFV Gag and 
Bet and FIV Vif performed before and following inoculation as given in the panels. The same symbols 
were used for cats 1–4 in WT and CH groups. Only the cats for which symbols are present (see inserted 
legend) were tested at the corresponding time point. Gray boxes represent time points where animals 
were not tested. CH-group cats were re-inoculated on day 53 (not shown) as described in 
“Methods”. a WT group results (days -21 to 168 p.i.). b CH group results (days -21 to 42 p.i.). c CH×WT 





Figure 6. Wild-type FFV inoculated cats developed persistent infection of PBMCs. Real time 
quantitative PCRs (qPCR) were performed on PBMCs following inoculation on day 0 (left green star). The 
solid red line illustrates the proviral load mean of three WT-inoculated cats with similar viral kinetics. 
These cats had detectable PBMC FFV DNA on day 21 p.i. by both qPCR and nested PCR and developed 
persistent proviral loads between 100 and nearly 1500 copies per million PBMC. The dotted red line 
displays a different PBMC FFV DNA pattern observed in cat WT3 (“outlier”) which was not PCR-positive 
until 42 days p.i. (nPCR, see Fig. 5a). This individual had a mean proviral load 1–2 logs higher than the 
other WT cats and almost 6000 viral copies per million PMBC at peak viremia. The blue line represents 
cat CH2WT, which was re-inoculated with wild-type virus on day 53 p.i. (right green star). This was the 
only re-inoculated cat to test unambiguously positive on day 63 p.i. (qPCR). The other cat in this cohort 
(CH1WT) and the two cats in the CH×CH group are not represented in the graph due to indeterminate 
qPCR and negative nPCR results (see “Methods” and Fig. 5c and d). Naïve cats were completely PCR-




Figure 7. Cats infected with wild-type FFV and FFV-Vif W/*1 developed FFV Gag-specific 
immunoreactivity. A GST-capture ELISA was performed to evaluate antibody response to FFV 
infection. a Anti-Gag antibody titers in WT cats on days 28, 42, 70, and 168 p.i. The dotted red line 
represents WT3, the outlier cat. Animals displayed rising levels of antibody by day 42 which either 
continued to increase over time or plateau. b Anti-Gag antibody titers in CH cats that were re-inoculated 
with wild-type (CH×WT, dotted lines) or FFV-Vif W/*1 chimera (CH×CH, solid lines). These cats similarly 
had increasing anti-Gag antibodies around day 42 that continued to increase or plateau following re-
inoculation. In order to detect low-level reactivity, sera were assayed at a 1:50 dilution leading to some 
reactivities which were out of the linear range of the assay. 

































Infected cats seroconverted against accessory FFV Bet and FIV Vif proteins 
All cats infected with wild-type FFV only (WT 1-4) or FFV-Vif plus wild-type FFV (CH1WT 
and CH2WT) demonstrated substantial FFV Bet sero-reactivity by day 168 p.i. (Fig. 5A and C, 
Fig. 8A, and Appendix File 5). As observed in previous studies [56, 145], Bet-specific antibodies 
appeared slightly later than Gag sero-reactivity (Fig. 5 and Appendix File 5). Naïve controls and 
cats CH3CH and CH4CH were Bet-antibody negative as expected. Most importantly, Vif 
reactivity in three out of four FFV-Vif-infected animals was clearly positive at day 42 p.i., prior to 
superinfection on day 53 p.i. (Fig. 8B). Surprisingly, Vif-specific reactivity in these animals was 
detectable by day 15 p.i. despite the fact that qPCR did not detect provirus (Fig. 5B and 
Appendix File 5). Re-inoculation of these cats with either wild-type FFV (animals CH1WT, 
CH2WT) or FFV-Vif chimera (CH3CH) resulted in a boost in Vif sero-reactivity at day 63 p.i. 
Animal CH4CH, which showed no Vif reactivity prior to superinfection, exhibited only transient 
FIV Vif reactivity after re-exposure (Fig. 8B). 
 
Discussion 
This study describes the generation of replication-competent variants of FFV that express 
FIV Vif in lieu of FFV Bet. An engineered FFV genome expressing a fusion protein of a non-
functional N-terminal Bet domain fused to the full-length Vif was clearly attenuated in vitro. 
Second-generation FFV-Vif chimeras expressing the authentic codon-optimized vif gene 
showed much higher vif-dependent replication competence in feA3-expressing cells, only 
slightly decreased in vitro compared to wild-type FFV. In experimentally infected cats, 
replication of the chimeric FFV-Vif variant was attenuated but led to the induction of FFV Gag-
specific antibodies together with those directed against the engineered heterologous FIV Vif 
protein. Importantly, cats infected with the FFV-Vif chimera could be superinfected with wild-
type FFV or the chimera, in both cases resulting in a strong immunological boost of sero-




Figure 8. Animals inoculated with wild-type FFV or FFV-Vif chimera seroconverted to FFV Bet or 
FIV Vif. Antibody response against FFV Bet and FIV Vif antigens were measured by antibody capture 
ELISAs as described in the “Methods” section. a Anti-Bet antigen reactivity for each animal at final time 
points unless specified. WT cats (red bars), and cats that received chimera and then wild-type FFV 
(CH×WT, black and blue striped bars) seroconverted against Bet. Animals exposed to only FFV-Vif W/*1 
(cats CH1 and CH2 prior to day 53, and CH3CH and CH4CH, solid blue bars) were negative for anti-Bet 
antibodies as expected. Black bars show naïve cats, and positive and negative control samples. b Three 
out of 4 animals inoculated with chimeric virus developed a detectable anti-Vif immune response as early 
as 15 days p.i. Antibody response increased following re-inoculation for all animals, causing a detectable 
response in the fourth animal (CH4CH), though sero-reactivity was low compared to other animals for this 
individual, and only rose above positive cutoff absorbance on days 63 and 168. Filled shapes indicate 
positive ELISA absorbance values compared to negative controls (> 2 standard deviation above the mean 
of duplicate negative samples), whereas open triangles for CH4CH indicate ELISA absorbance values 




The successful replacement of FFV bet by FIV vif in the context of the FFV genome may 
have been aided by two mechanisms. First, a codon-optimized and thus Rev-independent FIV 
vif gene was inserted, allowing for efficient translation of the Vif protein [20]. Second, LV Vif 
proteins function as catalytic regulators of proteasomal feA3 degradation; therefore, much lower 
amounts of fully functional Vif may be required to inactivate A3 activity compared to FV Bet, 
which acts stoichiometrically via direct binding to the feA3 protein [15]. Thus, the attenuated 
replication of the initially constructed pCF7-Vif-4 chimera was likely due to high expression 
levels of the functionally impaired BettrVif fusion protein.  
In support of the hypothesis that Bet and Vif are differentially expressed in vivo, Bet sero-
reactivity is high and has diagnostic value in infected cats and bovines [70, 80]. In contrast, 
while anti-Vif antibodies have been described in HIV patients [161, 162], Vif has not been shown 
to be a major humoral immune target of FIV infection, and seroconversion against Vif has not 
been well studied in FIV infection (personal communication, Dr. Chris Grant).  
Apparently, inhibitory effects of either the complete N-terminal part of Bet plus the linker 
sequence, or the N-terminal residues of the linker residues present downstream of the 
engineered FFV PR cleavage site (see Fig. 1A) favored the emergence of Trp/stop (W/*) 
variants. This is strongly suggested by the fact that two independent, yet highly related 
mutational events led to the W/* mutation in the linker sequence upstream of vif. The reverse 
genetic experiments conducted do not support translational initiation at the upstream Met 
residue located in the linker sequence as important for Vif protein expression. We thus assume 
that in the in vitro-selected clones, fully functional Vif is expressed from its authentic start codon, 
though the exact mechanism by which FIV Vif protein is expressed from pCF7-Vif W/*1 and 
pCF7-Vif W/*2 is unknown. We assume that internal re-initiation of protein biosynthesis may be 
involved, but other mechanisms cannot be excluded. While the mechanism of Vif expression of 
clones pCF7-Vif W/*1 and pCF7-Vif W/*2 is unknown, all FIV Vif proteins engineered into the 
FFV genome including the first-generation clone pCF7-Vif-4 encoding the BettrVif fusion protein 
 35 
lead to dramatically reduced steady state levels of feA3 proteins as shown for the major 
restriction factor of FFV, feA3Z2b (see Fig. 3).  
In line with the assumption that the original BettrVif fusion protein conferred suboptimal 
protection against feA3 restriction, both mutations leading to the adaptive W/* mutations 
occurred in a sequence context of the negative strand that is indicative of feA3 editing, 
suggesting the chimeric viruses did not confer robust protection against feA3. Both mutated C 
residues of the negative strand are preceded by C residues in the sequence 5’-TCCC-3’ 
(deaminated C residues in bold face letters, see also Fig. 2C), and therefore should function as 
optimal feA3 substrates, however, alternative mutational pathways might have also played a 
role. The fact that suboptimal feA3 inhibition leads to adaptive changes induced by feA3 DNA 
deamination supports our proposed concept that the heterologous and functionally relevant 
transgene FIV vif is essential for efficient propagation of the replicating virus, and thus confers a 
strong selective advantage by protecting against feA3 restriction. Consequently, the transgene 
vif has to be stably maintained in the absence of bet during serial passages, as demonstrated in 
Fig. 2B. The importance of the vif transgene for FFV-Vif replication is further underscored by the 
fact that additional adaptive changes, such as unlinking from N-terminal Bet sequences, were 
required to restore full biological activity as an inhibitor of feA3 restriction.  
The advantage of adapting this replication-competent FV vector system as a vaccine 
delivery vehicle is that the immunogen Vif is essential for replication and should be thus stably 
maintained by the engineered vector. Further, LV Vif has been shown to elicit T and B cell 
reactivity in HIV-infected individuals [163-167]. A corresponding PFV-based replicating vector 
system carrying the HIV vif gene may therefore be an interesting vector for the development of 
anti-HIV immunotherapies. 
The in vivo wild-type FFV inoculations confirm that experimental infection of outbred, 
immunocompetent cats with clone pCF-7-derived wild-type FFV leads to a persistent infection 
with consistent detection of FFV proviral DNA in PBMC and a strong sero-reactivity against Gag 
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and Bet proteins, similar to other reports [56, 145]. In contrast, animals inoculated with FFV-Vif 
W/*1 remained either proviral DNA negative or indeterminate throughout the study based on 
nested and qPCR analysis of PBMC DNA (Fig. 5B and D). Surprisingly, despite the inability to 
unambiguously detect FFV provirus in cats exposed to FFV-Vif W/*1, clear sero-reactivity 
against FFV Gag and heterologous Vif protein were detected after primary inoculation (Fig. 5 
and 7). This observation is consistent with previous studies in different FVs that serology is 
much more sensitive for the identification of exposed animals than PCR-based studies using 
PBMC [56, 62, 80, 168].  
FFV in vivo infection experiments were conducted with wild-type FFV or chimeric FFV-Vif 
W/*1. This resulted in detectable, but low, proviral load in wild-type-infected animals and either 
undetectable or indeterminate proviral loads in cats infected with the FFV-Vif chimera. It is 
feasible that the exchange of Bet for Vif altered tissue tropism and site of viral replication in 
FFV-Vif W/*1 exposed cats, and this contributed to the inability of tracking viral infection via 
peripheral blood PCR. While initially either negative or indeterminate based on PCR results, cat 
CH2WT was superinfected with wild-type FFV on day 53 p.i. and showed a productive PBMC 
FFV infection on a similar timeline after inoculation as the wild-type-infected animals. 
The animals in the chimeric cohort did not seroconvert against Bet as anticipated but they 
displayed clear anti-Vif antibody responses starting at day 15 p.i., demonstrating that 
substituting Bet by Vif elicited specific immune responses. Given that anti-Vif antibodies have 
not been widely reported during FIV infection, our findings may indicate replication is occurring 
in cells or cell compartments where it is more easily recognized as a foreign antigen. Antibody 
production against Vif was initially not robust but following re-inoculation with both wild-type and 
FFV-Vif chimeric virus, anti-Vif antibody response markedly increased (Fig. 8B). Following re-
inoculation of the FFV-Vif-infected animals with wild-type FFV virus, both cats initially infected 
with FFV-Vif W/*1 also produced anti-Bet antibodies, demonstrating that infection with the 
chimera did not protect against subsequent infection with wild-type FFV (Fig. 5C and 8A).   
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The data document that, despite a lack of consistent detection of FFV provirus DNA, FFV-Vif 
W/*1 is able to induce persistent antibody responses in domestic cats that were boosted by re-
inoculation. As noted above, we were able to document superinfection with two highly related 
FFV variants. Clinical evaluations following exposure to wild-type FFV or chimera suggests that 
FFV produces an apathogenic infection during the study period. Further studies should be 
conducted to understand chronic FFV infection and potential associated pathologic changes as 
well as the possibility of worsened pathology following superinfection with other FFV serotypes 
or other viral infections [74]. It would also be important to challenge wild-type FFV-infected cats 
with chimeric virus to determine whether infection with wild-type FFV may induce neutralizing 
immunity thus preventing superinfection with an attenuated FFV vaccine construct. 
It cannot be ruled out that the antibody response detected in FFV chimera-infected animals 
was related to exposure to viral inoculum versus actively replicating virus, since PCR results 
were indeterminate. However, anti-Vif antibody production in three out of four FFV-Vif chimera-
inoculated cats detected throughout the monitoring period, and an anti-Gag response equivalent 
to wild-type antibody titers is supportive of the conclusion that low-level viral replication occurred 
[56, 62, 80, 168]. Whether or not FFV-Vif W/*1 replicated poorly or not at all, the fact that pCF7-
Vif W/*1 was highly replication-competent in CrFK cells but strongly attenuated in vivo suggests 
that Bet may play a currently unknown critical role in viral replication competence in vivo in 
addition to antagonizing A3-mediated restriction. Here, inactivation of other components of the 
host’s innate or intrinsic immunity as well as an essential co-factorial role for the replication in 
specific cell types in vivo are plausible reasons for the attenuated phenotype. Alternatively, 
other aspects of the manipulated pCF7-Vif W/*1 genome may impede replication in the native 
host. Further studies may elucidate additional complex host-virus restriction pathways that are 
relevant in vivo but are functionally masked or not relevant during in vitro infections. 
Findings presented here illustrate a role for pCF7-Vif W/*1 to be used as a novel anti-LV 
vaccine delivery scaffold. This system would exploit a non-pathogenic vector that has to stably 
 38 
retain the Vif vaccine antigen and may be a therapeutic option to boost immunity towards an 
existing HIV infection in order to eliminate infected cells. The option to insert additional B and T 
cell epitopes at the terminus of the truncated Bet may be a means to extend and direct the host 
immune response towards additional epitopes (Slavkovic Lukic and Löchelt, unpublished 
observations). The ability to administer repeatedly or simultaneously the FV-based vaccine 
vector, directing expression of additional or newly acquired antigens, is an additional strength of 
our system as low level or absence of replication would hinder use of pCF7-Vif W/*1 as a vector 
delivery system that requires greater viral replication. Our results suggest that prior infection 
with wild-type FFV might not impair response to FFV-Vif, though superinfection studies will need 
to be conducted before this vector could be commercially developed. Experiments determining 
the viability of FV-LV Vif chimeric variants would also have to include assays to determine 
stability and functionality of inserted heterologous epitopes. Since we have documented that 
seroconversion occurs against Vif and Gag during FFV-Vif W/*1 exposure in the absence of 
intentional adjuvation, the attenuated replication does not impair its use as an antigen 
expression platform for eliciting antibodies against foreign antigens and could even improve its 
biological safety.  
  
Conclusions 
Our in vitro and in vivo studies show the feasibility of constructing a replicative FFV-Vif 
vector that incorporates FIV Vif and replaces FFV Bet protein expression to counteract intrinsic 
feline A3 restriction factors. The FFV-Vif chimera inoculation of domestic cats induced a specific 
immune response against the heterologous Vif protein which under superinfection boosted 
antibody production against both FFV Gag and FIV Vif. Superinfection was also possible using 
wild-type FFV as evidenced by seroconversion against FFV Bet in animals initially inoculated 
with the chimeric construct, which provides plausibility of using this vector in domestic cat 
populations which may already be infected with wild-type virus. These findings demonstrate that 
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this and additional FV vector systems may be further studied to develop potential therapeutic or 
preventive avenues against lentiviral infections including HIV. 
 
Methods 
Cells, culture conditions, and DNA transfection 
Crandell feline kidney (CrFK) cells were used for FFV infection and propagation [14, 74, 79]. 
Human embryonic kidney (HEK) 293T cells used for plasmid transfection were propagated as 
described [169]. FeFAB cells (CrFK-derived cells that carry a β-galactosidase gene under the 
control of the FFV LTR promoter that is activated via FFV infection and subsequent Tas 
expression) were used to determine viral titer as described previously [169]. PBMC were 
purified from feline blood using Histopaque gradients (Sigma Aldrich, St. Louis, MO). HEK 293T 
cells were transfected or co-transfected by using a modified calcium phosphate method 
described previously [169]. In serial passage experiments, wild-type pCF-7 and Vif-chimera 
pCF-Vif-4 were transfected into HEK 293T cells [146]. Supernatants were harvested 2 days post 
transfection and used to infect feA3-positive CrFK cells. Supernatants from these infections 
were serially passaged twice a week (every third or fourth day p.i.) to new, uninfected CrFK 
cells. A total of 20 serial passages were conducted. 
 
FFV propagation and titration 
For viral propagation of wild-type FFV and chimera (generated by transfection of HEK 293T 
cells), 106 CrFK cells/ml were seeded and infected at a multiplicity of infection (MOI) of 0.1. 
Supernatants were harvested and used for viral titer estimation and further viral propagation. 
FFV titers were determined using 5 x 104 FeFAB cells/well grown in 24-well plates and infected 
with serial 1:5 dilutions as described [146]. Titers were calculated by determining the highest 
dilution that contained blue-colored infected cells through light microscopy. 
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Wild-type and FFV-Vif chimera viral propagation and titration for cat infections 
2 µg of FFV pCF-7 [91] or pCF7-Vif W/*1 plasmid were transfected into CrFK cells using 
Lipofectamine and supernatants were harvested for amplification in CrFK cells. Microscopic 
observation of cells was conducted daily and considered to be infected if they displayed 
cytopathic effects (CPE) of vacuolization, cytomegaly, and multinucleation [10-12]. 
Supernatants of infected cells were harvested and frozen on 2, 6, 9, and 13 days p.i. CPE end-
point dilution titration was conducted on CrFK cells to determine TCID50/ml. CrFK (3 x 10
4 
cells/well) were incubated with 25 µl of virus-containing supernatants in five-fold dilutions from 
the aforementioned days and observed for CPE up to 17 days p.i. The number of CPE-positive 
wells was used to determine TCID50/ml using the method of Reed and Muench [170]. 
Supernatants that yielded the highest titers were selected for animal inoculations. 
 
FIV titration system and FFV LTR luc reporter assay 
Production of FIV luc reporter viruses, normalization according to reverse transcriptase 
activity, and target cell infection and reporter readout were done as previously described [43]. 
FFV reporter assays using co-transfection of HEK 293T cells with the full-length FFV LTR luc 
reporter plasmid pFeFV-LTR-luc and the different FFV chimeras generated in this study or the 
FFV Tas expression construct pFeFV-Bel1 were conducted as described previously [171].  
 
Molecular cloning 
Replacement of FFV bet coding sequences by a codon-optimized FIV vif gene in the FFV 
provirus vector pCF7-BetMCS, which carries a multiple cloning site directly downstream of bet 
without affecting tas [34], was done via fusion PCR cloning using the proof-reading Pfu 
polymerase as specified by the supplier (New England Biolabs, Frankfurt Germany) [146]. For 
PCR primer sequences, see Table 2. In brief, the codon-optimized vif gene was first amplified 
using a sense primer with upstream sequences encompassing a terminal NheI site, followed by 
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a SacII site and the sequence encoding the FFV protease (PR) cleavage sequence AAVHTVKA 
(see Fig. 1A, and Appendix File 2) directly fused in-frame to the start codon of vif while the 
antisense primer was complementary to the terminal vif sequence followed by an AgeI 
restriction site (Fig. 1A, bottom panel, pair of blue primers, # 1 and 2). The other amplicon was 
generated with a sense primer also containing an AgeI site and annealed to FFV sequences 
about 120 nt upstream of the essential FFV poly-purine tract while the antisense primer was 
downstream of a unique SphI site in the U3 region of the FFV LTR (Fig. 1A, bottom panel, pair 
of violet primers, # 3 and 4). The amplicons generated were fused in a third PCR using only the 
sense primer of the first and the antisense primer of the second reaction (primers # 1 and 4). 
The amplicon was digested with NheI and SphI and inserted into pCF7-BetMCS [34] digested 
with NheI and SphI. The resulting clone pCF7-Vif was analyzed by DNA restriction analysis and 
DNA sequencing. Similarly, site-directed W/* mutagenesis in pCF7-Vif-4 and mutagenesis of the 
methionine codon and its flanking sequences in pCF7-Vif W/*1 and –W/*2, were done using 
PCR primers shown in Table 2. The resulting fragments were inserted into the clones pCF7-Vif 
W/*1 and pCF7-Vif W/*2 via three component ligations using unique BspEI, NheI and XhoI 
restriction sites.  
 
Cloning and sequencing of in vitro selected FFV-Vif variants 
DNA from CrFK cells infected with in vitro selected variants of pCF7-Vif-4 was harvested at 
passage 18 using the DNeasy extraction kit as specified by the supplier (Qiagen, Hilden, 
Germany). Sense primer FFV 9366 and antisense primer 10288 (Table 2) were used to amplify 
a 923 nt fragment of the bel1–vif region. Amplicons were cloned into pCR-TOPO TA vectors 





 Table 2. Primers used for cloning and PCR detection. 
Primer Name Sequence (5’ – 3’) 
pCF7-Vif cloning 
FFV-Vif #1 GCGGGCTAGCGCCGCGGTACACACCGTCAAAGCCATGAGCGAGGGGACTGGCAG 
FFV-Vif #2 GTGCTCTCCAAAGACCGGTTATCACAGCTCGCCGCTCCACAGCAGATTCC 
FFV-Vif #3 GGCGAGCTGTGATAACCGGTCTTTGGAGAGCACAAGCTGATG 
FFV-Vif #4 CGCTCTGTTGCATGCCG 
Mutagenesis of the upstream start codon 
FFV 9233-F GCGGTCCGGAACACCCAAGACGGATCCTACTCG 
M/T-R CGGCGCTAGCTCTAGTTAGCGTAGTCAAATCCCTCTCCCCAC 
M+-R CGGCGCTAGCTCTAGTTACCATAGTGAAATCCCTCTCCCCAC 
PCR amplification of in vitro-selected FFV-Vif variants 
FFV 9366-F CCACTTCTGTTTGGACCTTACC 
FFV-10288-R CAGCTTGTGCTCTCCAAAGC 





Real-time quantitative PCR 




Animals and experimental design 
Twelve specific-pathogen-free (SPF) cats, aged 6-8 months and negative for common feline 
pathogens including FFV and FIV, were obtained from the Colorado State University (CSU) SPF 
Colony and housed in an Association for Assessment and Accreditation of Laboratory Animal 
Care International-accredited animal facility at CSU. All procedures were approved by the CSU 
Institutional Animal Care and Use Committee prior to initiation of the study. Cats were separated 
into three groups (n=4 per group) based on inoculation type: FFV-negative CrFK culture media 
(naïve, N), wild-type FFV (WT), or chimeric FFV-Vif W/*1 (CH) (Fig. 4). Virus-inoculated animals 
received 105 TCID50 in 2 ml under ketamine anesthesia, split into 1 ml intramuscularly (i.m.) and 
1 ml intravenously (i.v.). Cats were monitored daily for clinical signs of disease, and body 
temperature and weight were measured weekly. Peripheral blood was collected via cephalic or 
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jugular venipuncture and processed to obtain serum and PBMC. On day 53 p.i., all cats in the 
CH cohort were re-inoculated each with 5 ml of undiluted virus (wild-type virus 2.78 x 105 
TCID50/ml or chimeric virus 5.56 x 10
4 TCID50/ml, split into 1 ml i.m., 2 ml i.v., and 2 ml 
subcutaneously). Two of these cats were re-inoculated with wild-type FFV virus (henceforth 
referred to as CH1WT and CH2WT) and the other two cats with FFV-Vif W/*1 (now referred to 
as CH3CH and CH4CH). Animals were humanely euthanized for necropsy on day 176 p.i. (Fig. 
4). 
 
Nested and real-time quantitative PCR assays 
Nested FFV PCR (nPCR) was performed on PBMC DNA to screen for initial infection status. 
Proviral DNA was purified and amplified using 0.5 µM gag-specific forward and reverse primers 
listed in Table 2 under the following cycling conditions for the first round of nPCR: 94ºC for 2 
min, 35 cycles of 94ºC for 30 s, 57ºC for 30 s, 72ºC for 1 min, and a final elongation step at 
72ºC for 5 min. For the second round, 2 µl of first-round product was added to the reaction and 
amplified in these conditions: 94ºC for 2 min, 35 cycles of 94ºC for 30 s, 57ºC for 30 s, 72ºC for 
30 s, and 72ºC for 5 min. Products were electrophoresed in 1.5% agarose gel in Tris-acetate 
buffer and stained with GelRed™ Nucleic Acid Gel Stain (Biotium, Hayward, CA) then visualized 
to look for the 333 base-pair PCR product. Real-time quantitative PCR (qPCR) was performed 
in triplicate on viral DNA as previously described [168] using 0.5 µM forward and reverse Gag-
based primers and 0.1 µM probe (Table 2) with the following modified conditions: 95°C for 3 
min, 45 cycles of 95°C for 10 s, and 60°C for 40 s. Viral copy number quantification was based 
on a plasmid standard curve prepared from plasmid pCF-7. FFV-Gag real time PCR assay 
sensitivity is 1-10 viral copies per reaction [168]. Infection status was divided into 3 categories: 
positive, negative, and indeterminate. Animals considered unequivocally “positive” had qPCR 
results with Cq values less than or equal to 37 in 2-3 out of the three reactions, consistent with 
viral load greater than 10 copies/reaction. Animals considered “negative” were negative for all 
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triplicate tests (this included all naïve cats and “no template” controls at all defined times). 
Animals classified as “indeterminate” had qPCR replicates with Cq values > 37, equivalent to 0-
10 copies per well. Indeterminate copy number calculations were not used in Fig. 6 since values 
obtained were below the assay’s lower limit of quantitation. 
 
Gag, Bet and Vif immunoblotting  
Cell lysate from FFV-infected CrFK cells or transfected HEK 293T cells were subjected to 
immunoblot analyses as described [56, 146]. Identical amounts of proteins were separated by 
SDS-PAGE, blotted, and reacted against different anti-FFV sera. FFV Gag and Bet proteins 
were detected by rabbit anti-Gag polyclonal serum (1:3,000 dilution) and rabbit anti-Bet 
polyclonal serum (1:2,500 dilution) [146]. FIV Vif was detected by a mouse anti-FIV-Vif antibody 
(NIH AIDS repository, Maryland, USA) at a 1:500 dilution. Membranes were incubated with 
secondary anti-rabbit polyclonal antibodies or anti-mouse IgG (Sigma, Munich, Germany) 
conjugated to horseradish peroxidase (1:5,000 to 1:2,000 dilution) and visualized by 
chemiluminescence (ECL Western Blot Kit, Amersham Buchler, Braunschweig, Germany). Blots 
were then probed against actin using mouse anti-actin antibody (1:8,000 dilution, Sigma). 
 
GST-capture ELISA for detection of Gag and Bet seroconversion 
GST-capture ELISA was performed to detect anti-FFV Gag and anti-FFV Bet antibodies as 
previously described [80, 172]. Glutathione casein was used to coat 96-well plates (Thermo 
Fisher Scientific, Waltham, MA) overnight at 4°C then plates were blocked with casein blocking 
buffer (0.2 % (w/v) casein in PBS and Tween20, Thermo Fisher Scientific). Plates were 
incubated with BL21 E. coli-produced lysates containing GST-tag, GST-Gag-tag, or GST-Bet-
tag recombinant proteins (0.25 µg/µl in casein blocking buffer). Cat sera were pre-adsorbed with 
GST-tag lysate (2 µg/µl) in a 1:50 dilution and then incubated in duplicate (Fig. 7A and B) or 
triplicate (Appendix File 6) with each GST conjugate. The plates were incubated with anti-cat-
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IgG Protein A peroxidase (1:50,000 dilution, Sigma Aldrich). For the substrate reaction, plates 
were incubated with TMB substrate before stopping the reaction with sulfuric acid. Absorption 
(optical density, OD) at 450 nm was measured and the mean reactivity for each was used. 
Detection cutoff values were determined from negative sera as 2 x (mean + 3 standard 
deviations). A significant number of reactions at the serum dilution used were out of the linear 
range of the assay. For anti-Gag antibody titrations, sera from days 28, 42, 70, and 168 p.i. 
were diluted at 1:100, 1:250, 1:500, 1:1,000, 1:2,500, and 1:5,000. Titer was determined as the 
highest dilution the cat tested positive for anti-Gag antibodies, using the cutoff formula 
mentioned above. 
 
FIV Vif antibody capture ELISA 
Sera were subjected to an FIV Vif antibody capture ELISA to detect corresponding 
antibodies in chimeric FFV-Vif-inoculated cats. 96-well plates were coated with 2 ng/µl Vif 
antigen and incubated overnight at 4°C. Mouse Vif monoclonal antibody (obtained from Dr. 
Chris Grant, Custom Monoclonals International, Sacramento, CA) was used as a positive 
control. After blocking, cat sera (1:100 dilution) or Vif monoclonal antibody (10 ng/µL) were 
applied in duplicates, then goat anti-cat (or anti-mouse) IgG-HRP (MP Biomedicals, Santa Ana, 
CA) was used as secondary antibody (1:1,000 dilution). TMB reagent was used for the 
substrate reaction then stopped with sulfuric acid before measuring absorption (450 nm). For 
detection cutoff, the mean negative sera absorbance readout was used in the following formula: 
mean + (2 x SD). A number of reactions at the serum dilution used were out of the linear range 









Foamy viruses (FVs) are globally prevalent retroviruses with a unique molecular biology that 
establish apparently apathogenic lifelong infections. Feline foamy virus (FFV) has been isolated 
from domestic cats with concurrent diseases, including renal syndromes. We experimentally 
infected five cats with a well-characterized FFV strain to further describe viral kinetics and 
tropism, immune phenotype, renal parameters, and presence of pathology. A persistent 
infection of primarily lymphoid tropism was detected. One cat with a significant negative 
correlation between lymphocytes and PBMC proviral load displayed an expanded tissue 
tropism. Significantly increased blood urea nitrogen, increased urine protein-to-creatinine ratio, 
and ultrastructural kidney changes were noted in infected cats. Histopathological changes were 
observed in the brain, large intestine, and other tissues with increased severity in infected 
animals. We performed an FFV prevalence survey of pet cats with chronic kidney disease 
(CKD) and age- and sex- matched controls in the United States of America (USA) and Australia. 
We identified an association between CKD and FFV infection in male USA cats. While FFV did 
not cause clinical signs during acute experimental infection, findings in experimentally infected 
cats and pet cats with CKD support subclinical impacts of FFV infection potentially contributing 
to renal dysfunction, a common syndrome of unknown etiology in domestic cats. 
 
Introduction 
Feline foamy virus (FFV) is a retrovirus belonging to the ancient Spumaretrovirinae 
subfamily that infects domestic cats (Felis catus) and was originally incidentally discovered 
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following development of cytopathic effects (CPE) in feline cell lines. Foamy viruses (FVs) 
cause multiple CPE in vitro including multinucleation, giant cell formation, and vacuolization, 
leading to cells looking “foamy” (and where the “spuma” originates) [1, 9, 11, 12, 173]. In 
naturally-occurring infections of the domestic cat, however, FFV infection does not cause 
obvious disease, and has not been definitively associated with pathology despite establishing a 
persistent, life-long infection with a wide tissue tropism [11, 55-59, 61]. It is believed the 
apathogenicity of FVs in general is due to long periods of co-evolution within their hosts that has 
led to a disease-free or highly attenuated infection [1, 9, 56]. FV transmission is thought to 
primarily occur via salivary shedding and ongoing contact between animals, though alternate 
routes such as vertical transmission through lactating dams have been reported [58, 70]. In 
cats, biting and amicable prolonged contact, such as grooming, have been suggested as 
possible routes of transmission [58, 62, 139]. Global FFV prevalence in pet and feral domestic 
cats can be high and varies from 8 to 80% based on geographic location, population sampled, 
and assay type [62, 71-80]. FFV prevalence studies of cats in the USA have documented 
infection rates of 10 to 75%, with age and male sex identified as risk factors in some cohorts 
[58, 62, 81].  
FVs are generally host-specific with the exception of non-human primates (NHP) where 
simian foamy virus (SFV) virus may be transmitted to related species and zoonotically to 
humans [48, 49, 52-54, 66, 174, 175]. Zoonotic transmission of FFV to humans has not been 
detected thus far [5, 47, 73]. Because of the apparent apathogenicity, wide tissue tropism, and 
large genome size, FVs have been used to develop vaccine and gene therapy vectors in 
multiple species including cats and as a model for future human therapies [29, 57, 91, 97, 102, 
104-106, 146]. Many aspects about FV biology, including target cells, latency reservoirs, the 
specific receptor used for cell entry, viral kinetics over time following infection, and peripheral 
blood mononuclear cell (PBMC) phenotype changes during infection have been poorly 
documented [5, 6, 23, 59]. Experimental FFV infection studies in disease-free SPF domestic 
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cats with age- and sex-matched negative controls using modern and specific assays are rare 
[11, 55, 56, 58, 59, 85, 91, 106].   
While FFV has been detected in apparently disease-free and healthy animals and has 
historically been considered apathogenic, it has been detected in animals suffering from renal 
and urinary tract disease [9, 59, 78, 83, 84, 124-126], polyarthritis [85, 86], neoplasia [11, 12, 
78, 87], upper respiratory illness [59, 78], and myeloproliferative diseases [58]. FFV has also 
been associated with other pathogens, such as during co-infections with feline 
immunodeficiency virus (FIV) [62, 63, 71, 86], feline leukemia virus (FeLV) [85, 88, 89], feline 
coronavirus [78, 90], and Bartonella henselae [72]. German et al. have reported kidney and lung 
histopathological changes following experimental FFV inoculation [59]. A recent study of 
zoonotic infections of SFV to African hunters found significantly decreased amounts of 
hemoglobin and basophils and alterations of renal parameters including blood urea nitrogen 
(BUN) and serum creatinine, among other hematological changes [49]. The findings in both cats 
and humans thus may call into question whether chronic infections with FVs are truly 
apathogenic. 
Chronic kidney disease (CKD) is the most commonly diagnosed renal disease syndrome in 
cats. CKD prevalence rates can reach up to 50% in cat populations and up to 85% as cats 
become geriatric [108-110]. CKD is characterized by functional and structural loss of kidney 
tissue likely resulting from prolonged or repeated insults to kidneys [112-115]. Cats affected by 
CKD can present with increased BUN and serum creatinine, improperly concentrated urine, and 
increased urine protein:creatinine (UPC) ratio. While the etiologies of CKD are often unknown, a 
list of comorbidities have been associated with the development of CKD, including retroviral 
infections [82, 121-123]. 
Due to the widespread and prevalent presence of FFV in domestic cat populations and the 
knowledge gaps that remain about FFV pathogenicity, especially considering its use in vaccine 
and gene therapy development, the data of a previous in vivo FFV experimental infection in 
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healthy SPF domestic cats [57] were further analyzed in detail to specifically assess clinical, 
immunological, and pathological characteristics and changes during early infection, and 
compared findings to age- and sex-matched negative controls. We identified altered 
hematological and biochemical parameters potentially associated with renal damage, 
histopathological changes in the lung, brain, and other tissues, and ultrastructural changes in 
the kidney. Based on these findings, and reports in the literature mentioned above regarding 
FFV’s potential effect on renal tissue, we conducted an FFV survey of pet cats suffering from 
CKD in the USA and Australia (AU) and compared to age- and sex-matched cats without CKD 
to more fully elucidate potential links between the two conditions. We found that in males, there 
is an association between FFV and CKD, in addition to an association between male sex and 
FFV infection overall. 
 
Materials and Methods 
Cells and virus generation 
Plasmid pCF-7 encoding an FFV genome that is replication-competent in vitro and in vivo 
was used as virus source [91]. Virus production has been described in more detail previously 
[57]. Crandell feline kidney (CrFK) cells [14, 74, 79] were used for transfection, viral 
propagation, and titer determination as described [57]. A CPE end-point dilution assay was used 
to determine viral titer (50% tissue culture infectious dose, TCID50/mL) for cat inoculations [57, 
170]. CPE consistent with FFV infection include cytomegaly, vacuolization, and syncytia 
formation [10-12]. 
 
Animals and study design for experimental FFV inoculation 
Cats were infected with pCF-7-derived FFV as a control group for a previous study testing 
an experimental molecularly modified FFV vector [57]. This present report provides further 
detailed analyses about FFV-associated hematologic and microscopic pathologies to identify 
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any FFV-induced changes during experimental infection. Briefly, nine cats (male castrated and 
intact females, aged 6-8 months) from the Colorado State University (CSU, Fort Collins, CO) 
specific-pathogen-free (SPF) colony, which is free of FFV, were housed in an animal facility at 
CSU accredited by the Association for Assessment and Accreditation of Laboratory Animal Care 
International. All animal procedures were approved by the CSU Institutional Animal Care and 
Use Committee (IACUC, Protocol #: 13-4104A, approved December 05, 2013). Cats were 
separated into naïve (N) and FFV groups based on inoculum (Fig. 1, modified with permission 
from [57]): cats N1-4 received FFV-negative CrFK culture media and FFV1-4 cats were 
inoculated with 105 FFV particles (based on a 2.78 x 105 TCID50/ml determined by end-point 
dilution titration in CrFK cells) in CrFK culture supernatant [57]. Each cat was inoculated with 2 
ml, divided into 1 ml intravenously (i.v.) through the cephalic vein and 1 ml intramuscularly (i.m.) 
into hindlimb musculature. A fifth cat was inoculated at the start of the study with 105 viral 
particles (5.56 x 105 TCID50/ml, also determined through end-point dilution titration in CrFK cells) 
of the afore-mentioned chimeric FFV but remained PCR negative. This cat was subsequently 
inoculated with 1.4 x 106 TCID50/ml of the pCF-7-derived FFV on day 53 of the study and 
became FFV PCR positive [57]. This animal, referred to as FFV5, was included in our analyses 
to increase the statistical power of this study. The study timeline and sample collection schedule 
(blood, saliva, urine, and tissues) are shown in Fig 1. 
Cats were monitored daily for clinical signs of infectious disease, and body temperature and 
weight measurements were taken on a weekly basis. Peripheral blood obtained through 
venipuncture (cephalic or jugular veins) was used for flow cytometric PBMC phenotype analysis 
or processed to collect serum and plasma shortly after collection. Whole blood and sera were 
submitted to the CSU Veterinary Diagnostic Laboratory (VDL) for complete blood count (CBC) 
and chemistry analyses. Saliva was collected by swabbing oral mucosa with a sterile cotton-tip 





Figure 1. Experimental timeline of FFV (strain pCF-7) inoculation and sample collection in 
domestic cats. Cats were separated into groups based on inoculum type: negative CrFK culture media 
(naïve control cats N1-4) or 105 TCID50 FFV in CrFK cell culture supernatant (cats FFV1-5). Blood, saliva, 
urine, and tissues were collected on dates specified. Sample collection for cat FFV5 was on a different 
schedule than the rest of the cohort. Samples for baseline data were collected on day -21. On day 176 
post-inoculation, cats were euthanized to perform necropsy and tissue collection (black X). Figure 
modified with permission from [57]. 
 
Urine was collected through cystocentesis and submitted to the CSU VDL for urinalysis, 
urine sediment, and urine protein:creatinine (UPC) ratio determination. Urine was considered 
properly concentrated if it had a urine specific gravity (USG) over (>) 1.035. UPC ratio was 
considered normal if below 0.2 and borderline proteinuric if between 0.2 and 0.4 [119]. On day 
176 post-inoculation (p.i.), cats were euthanized and necropsied to assess gross pathology and 
harvest tissues for virus detection, histopathology, and renal-specific assays at the International 
Veterinary Renal Pathology Service (IVRPS) in The Ohio State University (OSU, Columbus, 
OH). 
Sample selection for client-owned cats with CKD and age-matched controls without CKD is 
described below (section 2.7). 
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Nested and real-time quantitative PCR for virus detection and quantification 
Nested PCR (nPCR) and real-time quantitative PCR (qPCR) for FFV provirus DNA detection 
and quantification were performed as described [57, 168]. DNA was purified from whole blood, 
saliva, and plasma using the DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany) and 
amplified using 0.5 µM forward and reverse primers under conditions described [57, 168]. nPCR 
products were electrophoresed in agarose gel and stained to identify the desired PCR product. 
qPCR was performed in up to triplicate on purified FFV DNA as described [57, 168]. Tissue 
DNA was purified with the DNeasy Blood and Tissue Kit after homogenizing in Buffer ATL and 
Proteinase K using the FastPrep-24 Instrument (MP Biomedicals, Santa Ana, CA). Saliva and 
plasma RNA was purified using the QIAamp Viral RNA Mini Kit (QIAGEN). RNA was reverse 
transcribed to cDNA using Superscript II and random hexamer primers (Invitrogen, Carlsbad, 
CA) and resulting cDNA was used for qPCR as described above.  
 
Hematological and flow cytometric analyses for PBMC phenotyping 
White blood cell (WBC) populations (lymphocytes, neutrophils, and monocytes), red blood 
cells, and hematocrit (HCT) were measured over the study period. For flow cytometric PBMC 
phenotype analysis, EDTA-anticoagulated blood was incubated with fluorescent-labelled 
antibodies (Appendix File 7) diluted in cold flow buffer (PBS with 5% bovine fetal serum and 
0.1% sodium azide) and processed by the IMMUNOPREP whole blood lysis method on a Q-
Prep EPICS Immunology Workstation (Beckman Coulter, Fort Collins, CO) to lyse red blood 
cells. Samples were analyzed with a Gallios Flow Cytometer (Beckman Coulter). Output data 
were analyzed using FlowJo software (FlowJo, Ashland, OR). Data from the CBC were used to 
determine absolute neutrophil, lymphocyte, and monocyte cell numbers by multiplying the 
number of nucleated cells by percentages of each cell population. These absolute population 
numbers were then multiplied by percentages of each cell subpopulation obtained through flow 
cytometry for each cat per timepoint. PMBC phenotype analyses were divided into two panels. 
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Panel A assayed T lymphocyte populations while Panel B determined number of B cells, natural 
killer (NK) cells, and monocytes. Markers for activation (CD134+, CD125+, MHCII+) and 
apoptosis (Fas+) were also assayed. In total, 24 populations were measured for each cat per 
timepoint (Table 1). General WBC activation and apoptosis were determined by multiplying 
WBC counts by MHCII+ and Fas+ percentages.  
Table 1. White blood cell populations assayed for PBMC phenotype analysis. 
















Double positive T cells CD4+CD8+ 
Flow Cytometry 
(Panel B) 
B cells CD21+ 
Activation CD21+MHCII+ 
Apoptosis CD21+Fas+ 






WBC activation MHCII+ 
WBC apoptosis Fas+ 
1T helper, 2T cytotoxic 
 
Renal pathology assays on FFV-inoculated and naïve control cats 
Renal tissues collected from cats FFV1-5 and N4 during necropsy were submitted to the 
IVRPS for comprehensive analysis with light microscopy (LM), transmission electron 
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microscopy (TEM) and immunofluorescence (IF). Samples were submitted in 10% buffered 
formalin for LM, 3% glutaraldehyde for TEM, and Michel’s transport media for IF, and were 
processed as previously described [176]. Briefly, formalin-fixed paraffin embedded samples 
were sectioned at 3 µm thickness and stained with HE, Periodic Acid Schiff (PAS), Masson’s 
Trichrome (MT), and Jones Methenamine silver method (JMS). Samples for TEM were 
processed routinely and examined with a JEOL JEM-1400 TEM microscope (JEOL USA, Inc., 
Peabody, MA) and representative electron micrographs were taken with an Olympus SIS Veleta 
2K camera (Olympus Soft Imaging Solutions GmbH, Münster, Germany). For IF, samples were 
washed to remove residual plasma constituents, embedded in Optimal Cutting Temperature 
(OCT, Sakura Finetek USA INC, Torrance, CA), and frozen until sectioning. The OCT blocks 
were sectioned at 5 µm thickness and direct IF performed with FlTC-labeled goat anti-feline 
Immunoglobulin (Ig)G, IgM, and IgA antibodies (Bethyl Laboratories, Montgomery, TX) as well 
as FITC-labeled rabbit anti-human lambda light chain (LLC), kappa light chain (KLC), and C1q 
antibodies (Dako-Agilent, Santa Clara, CA). Stained sections were examined using an Olympus 
BX51 epifluorescence microscope and representative images were taken with a Nikon Digital 
Sight DS-U2 camera (Nikon, Tokyo, Japan). TEM assessment was not performed on control cat 
N4. 
 
Gross necropsy and histologic characterization of tissues 
To evaluate pathologic changes associated with FFV infection, necropsy was performed on 
cats FFV1-5 and control cat N4 on day 176 p.i. The following tissues were collected and stored 
either frozen in -80°C for viral tropism determination (qPCR) or in 10% buffered formalin for 
histopathological evaluation by light microscopy: lymph nodes (submandibular, mesenteric, pre-
scapular, retropharyngeal, and ileocecocolic), thyroid, tongue, tonsil, oral mucosa, salivary 
glands, thymus, heart, lung, spleen, liver, kidney, ovary, testis, mammary tissue, brain 
(cerebrum, cerebellum, brainstem), small intestine (jejunum, ileum), colon, bone marrow, and 
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hindlimb skeletal muscle. For histopathological assessment, formalin-fixed tissue samples were 
embedded into paraffin and 5 μm sections were collected onto charged slides (Superfrost; CSU 
CDL, Fort Collins, CO). One slide of each tissue was stained with hematoxylin and eosin (HE) 
for microscopic examination. Tissues were scored using the following scale: 0 = no apparent 
pathology/change, 1 = minimal change (minimally increased numbers of small lymphocytes, 
plasma cells, macrophages, and/or mast cells), 2 = mild change (mild inflammation, edema, 
and/or parafollicular expansion, secondary follicle formation, and presence of tingible body 
macrophages within lymph nodes), 3 = moderate change (as previously described, but more 
moderately extensive), 4 = marked changes (as previously described, but with severe 
inflammation, edema, and/or lymphoid reactivity). 
 
CKD sample collection and classification criteria  
In order to determine associations between FFV infection and chronic renal lesions, we 
opportunistically collected blood samples from pet domestic cats following routine clinical care in 
the USA and AU. Samples in the USA group were obtained from the CSU Veterinary Teaching 
Hospital (VTH) and AU samples were obtained from the University of Sydney VTH (Sydney, 
Australia). Pet cats were considered to be CKD-positive (+) based on presence of clinical signs 
on presentation, history, serum creatinine > 1.6 mg/dl, and improperly concentrated urine when 
normally hydrated, signified by USG less than (<) 1.035 [119]. Severity of CKD was staged from 
I to IV based on International Renal Interest Society algorithms [119]. For comparison of FFV 
infection and CKD incidence, we selected samples from age- and sex-matched CKD-negative 
cats (-) that did not display clinical and biological changes indicative of CKD. Urine specific 
gravity for CKD-negative cats was not validated.  
An overall total of 223 samples were analyzed for FFV infection by either nPCR (whole 
blood) or an FFV Gag ELISA (sera/plasma) as described previously [57]. There were 53 
sera/plasma samples in the CKD+ USA group, 45 sera/plasma samples in the CKD- USA 
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group, 59 whole blood and 28 sera/plasma samples in the CKD+ AU group, and 38 whole blood 
samples in the CKD- AU group. Normal reference values varied for BUN and creatinine based 
on equipment used at each location. In the USA group, the normal range for BUN was 18 – 35 
mg/dl and serum creatinine 0.8 – 2.4 mg/dl. Four different laboratories were used for testing 
cats from AU and serum creatinine and BUN were classified as abnormal based upon the 
references established for each laboratory (BUN: 7.2 – 10.7 mmol/L, 5.7 – 12.9 mmol/L, 5 – 15 
mmol/L, or 3 – 10 mmol/L; serum creatinine: 91 – 180 µmol/L, 71 – 212 µmol/L, 40 – 190 
µmol/L, or 0.08 – 0.2 mmol/L). CBC, blood chemistry, USG, UPC ratio, and sex were recorded 
when available. Cats for which sex data were not known (n=7) were omitted in sex-specific data 
analyses. USG data was not available for the CKD- US cohort. 
 
Statistical analyses 
Data are presented as mean of duplicate or triplicate values and standard deviations 
displayed as error bars in corresponding graphs. For the experimentally FFV-inoculated cats, 
two-tailed Student’s t test were performed on hematology, flow cytometry, BUN, serum 
creatinine, and USG data sets. A P-value less than (<) 0.05 was considered statistically 
significant. For cat FFV5, the timeline following re-inoculation on day 53 with FFV was adjusted 
so that day 53 equaled day 0 p.i. Timepoints from there on were grouped with either the 
equivalent day or the nearest date post-inoculation to adjust FFV5’s timeline to be consistent 
with FFV 1-4. A Pearson’s correlation coefficient was calculated to determine presence of a 
correlation and its significance between lymphocyte population numbers and FFV proviral load 
over time. To assess distributions of viral load to lymphocyte counts, we ran a generalized linear 
mixed model (GLMM) with the individual cat as a random factor and lymphocyte count as a 
fixed factor. Data was only run through the GLMM if viral load was at detectable levels and the 
data fit a negative binomial distribution.  
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For the CKD analyses, Student’s t tests were performed on BUN, serum creatinine, and 
USG data as described above. Risk ratios (RR) and chi-square tests were performed to assess 
the independence of three pairs of categorical variables: 1) sex and FFV infection, 2) sex and 
CKD, and 3) FFV infection and CKD. For each pair of variables, cats were stratified by location 
(USA or AU), sex (M or F), FFV status (+ or -), and CKD status (+ or -). If a chi-square test 
produced a P-value < 0.05, RRs and 95% confidence intervals (95% CI) were calculated as an 
additional post-hoc test. RRs describe the probability of a health outcome occurring in an 
exposed group to the probability of the event occurring in a comparison, non-exposed group. A 
RR > 1 suggests an increased risk of that outcome in the exposed group, and a RR < 1 
suggests a reduced risk in the exposed group.  
Excel (Microsoft Corporation, Redmond, WA) and Prism (GraphPad, La Jolla, CA) were 
used to conduct the Student’s t tests, calculate the lymphocyte and proviral load Pearson’s 
correlation coefficient, and produce graphs. GLMM and CKD analyses were run using the 
statistical program R version 3.4.2 [177]. The “fitdistrplus” package [178] was used to determine 
error distributions of the viral load data and the “glmmTMB” package [179] was used to run the 
GLMM. Chi-square tests and RRs for CKD were calculated using the ‘epitools’ package [180]. 
 
Results 
FFV-infected cats did not show clinical signs of infection despite a persistent FFV proviral load 
and specific humoral response 
As previously reported, all FFV group cats became PBMC FFV DNA positive (PCR), starting 
at 21 d p.i. (Fig. 2) [57]. One cat (FFV3) was not PCR positive until day 42 but maintained a 
much higher proviral load than the rest of the cohort from that point on (Fig. 6 in [57]). Cat FFV5 
was FFV PCR positive by 10 days p.i. with FFV pCF-7 (Fig. 2 and 3). FFV DNA was 
consistently detected in PBMC once the animals showed positivity [57]. Out of 80 FFV saliva 
samples tested, FFV RNA was detected only once (cat FFV4 on day 133 p.i.). All plasma 
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samples tested were FFV-negative (Table 2). Cats in the naïve group remained negative at all 
times. Additional proviral kinetics and anti-FFV antibody responses have been reported 
previously [57].  
Despite evidence of productive infection and specific immune response [57], none of the 
cats developed a fever, had changes in body weight, or displayed signs of clinical illness related 
to infection (such as anorexia or lethargy). CBC and chemistry values did not change 
significantly from baseline or indicate disease (data not shown).  
 
 
Figure 2. FFV proviral load in PBMC of cats FFV1-5 with summary of significant findings. FFV-
infected cats began showing PBMC provirus 21 days p.i. Cat FFV5 was re-inoculated and its timeline 
adjusted to match the rest of the cohort; this cat showed FFV positivity on day 10 post-reinoculation (*) 
[57]. BUN was significantly increased in infected cats compared to naïve on days 15, 21, and 28. Cat 
FFV3 had decreased lymphocytes compared to the rest of its cohort, which was negatively correlated to 
proviral PBMC load (see “Results”). FFV3 also had borderline proteinuria on days 122 and 142 p.i. 
Histopathological changes found after necropsy on day 176 are shown at the right-hand margin. Graph 
shows mean of FFV group cats’ FFV proviral load with bars denoting standard deviation. Numbers in 
parenthesis indicate number of cats out of the FFV cohort showing findings, with an asterisk (*) indicating 
findings also observed in the control cat to a lesser severity. 
 
FFV provirus tissue tropism is primarily lymphoid in nature 
FFV DNA was detected in the tissues of four out of the five FFV-inoculated cats primarily in 
lymphoid tissue including lymph nodes (submandibular, retropharyngeal, and prescapular, 
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which are involved in draining lymph from head, neck, and forelimbs), tonsil, and spleen (Table 
3). 
Table 2. Summary of findings for diagnostic assays used in this study. Bold font indicates that at 
least one cat was positive for the measured value, or differences in values between naïve and FFV-
infected animals were significant. Cat FFV5 was on a different inoculation and sample collection schedule 
following re-inoculation on day 53 p.i. (see Fig. 1). 
Assay Days Tested Summary of Findings 
Saliva qPCR (RNA) 
36, 42, 49, 56, 63, 86, 112, 119, 126, 
1331, 142, 147, 154, 161, 168, 176 
Only cat FFV4 was RNA-positive at 
133 d p.i. 
Plasma qPCR 
(DNA) 
42, 86, 142, 176 








Virus shows primarily lymphoid tissue 
tropism. Cat FFV3 had expanded 
tropism to other lymphoid and non-
lymphoid tissues compared to cohort 
(see Table 3). FFV not detected in cat 
FFV4’s tissues. 
CBC, Chemistry 
-21, 0, 3, 7, 10, 15, 21, 28, 42, 56, 63, 
70, 77, 86, 98, 112, 126, 142, 154, 
168, 176 
Not indicative of disease for infected 
cats. 
PBMC Phenotype 
-21, 0, 3, 7, 10, 15, 21, 28, 42, 56, 70, 
86, 112, 142, 168 
Significantly increased populations in 
FFV cats included monocytes and 
CD21+MHCII+, while CD8+CD25+, 
CD8+CD134+, CD8+FAS+, CD56+, 
and CD56+MHCII+ cells were 
decreased. 
BUN, Creatinine 
-21, 0, 7, 15, 21, 28, 42, 56, 63, 70, 
77, 86, 98, 112, 126, 142, 154, 168, 
176 
While BUN remained within normal 
limits for all cats, values were 
significantly increased in FFV group 
cats compared to naïve on bolded 
days. Creatinine values were within 
normal ranges and did not rise above 
1.8 mg/dl. 
Urinalysis 
-21, 3, 7, 10, 42, 56, 63, 70, 86, 91, 
98, 112, 122, 142, 156, 171, 176 
USG was >1.035 for all cats 
throughout study. Urinalysis and urine 
sediment were unremarkable. 
UPC Ratio 
36, 70, 86, 91, 98, 122, 142, 156, 171, 
176 
UPC ratio was 0.1 (normal) for all 
cats, except for cat FFV3 where it 
increased to 0.2 (borderline 
proteinuric) on 122 and 142 d p.i., 
coincidentally the time of highest 
PBMC viral load [57]. 




Table 3. FFV provirus has a primarily lymphoid tissue tropism. Viral load was determined through 
DNA qPCR and is presented as viral copies per million cells. Cat FFV3 had altered PBMC FFV DNA 
kinetics and expanded tissue tropism compared to the other FFV cats. Cat FFV5 was on a different 
inoculation schedule than the rest of the FFV cats (see Fig. 1, “Materials and Methods”). Bold text 
indicates difference in either proviral load or presence compared to other cats in the group. 
Tissue N4 FFV1 FFV2 FFV3 FFV4 FFV5 Total 
Salivary gland - - - - - - 0 
Tongue - - - - - - 0 
Oral Mucosa - - - 2.10 x 102 - - 1 
Tonsil - 2.41 x 102 4.03 x 102 - - 5.10 x 102 3 
Prescapular LN - 5.89 x 103 - - - 4.96 x 102 2 
Submandibular LN - 3.35 x 102 2.26 x 102 - - 5.78 x 102 3 
Retropharyngeal LN - 1.86 x 102 1.19 x 102 1.49 x 102 - 2.35 x 102 4 
Mesenteric LN - - - - - - 0 
Thymus - - - 3.48 x 102 - - 1 
Spleen - 5.93 x 102 3.11 x 102 2.10 x 102 - 3.35 x 102 4 
Ileum - - - - - - 0 
Bone marrow - - - 6.10 x 102 - - 1 
Kidney - - - - - - 0 
Muscle - - - - - - 0 
 
 
Cat FFV3 showed an expanded tissue tropism to central lymphoid tissues (thymus and bone 
marrow) in addition to non-lymphoid tissue (oral mucosa). The prescapular lymph node was the 
tissue with highest viral load (cat FFV1). Cat FFV5 showed an FFV tissue tropism similar to the 
rest of the FFV group, with the submandibular lymph node having the highest viral load (Table 
3). Control cat N4 and cat FFV4 did not have detectable provirus in any of the tissues 
examined.  
 
Significant PBMC phenotypic changes were rare though a negative correlation was found 
between lymphocytes and FFV proviral load in cat FFV3 
Out of the 24 cell populations and activation or apoptosis markers assayed for each cat per 
timepoint (Table 1), there were only 9 instances where significant differences (P < 0.05) were 
found between infected and control animals (Table 2). Significantly increased populations were 
found between FFV (1-5) and N (1-4) groups in the following instances: (1) absolute monocyte 
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numbers on days 15 (P = 0.036) and 42 (P = 0.025) p.i. and (2) CD21+MHCII+ cells on d 86 p.i. 
(P = 0.0076). FFV-group cats had decreased populations in the following instances: (1) 
CD8+CD25+ cells on d 112 p.i. (P = 0.044), (2) CD8+CD134+ cells on d 10 p.i. (P = 0.031), (3) 
CD8+FAS+ on d 10 p.i. (P = 0.015), (4) CD56+ cells on d 112 p.i. (P = 0.00038), and (5) 
CD56+MHCII+ cells on days 15 (P = 0.049) and 112 p.i. (P = 0.00070).  
We further evaluated WBC populations in cat FFV3 due to the altered PBMC FFV provirus 
pattern observed [57]. This cat appeared to have lower lymphocytes and a trend for decreasing 
lymphocyte count over time compared to the rest of the infected and naïve cats (Fig. 3A, blue 
line) as PBMC proviral load increased over time (Fig. 3B, black line). A Pearson’s correlation 
coefficient test for this cat showed a significant negative correlation between lymphocyte cell 
number and viral load over time (r = -0.653, P = 0.006). There was no correlation found in the 
rest of the infected cats (data not shown) and there was no significant relationship between viral 




A       B 
 
Figure 3. High viral load correlates with decline in circulating lymphocytes in cat FFV3. A Absolute 
lymphocyte population numbers determined through complete blood count for cat FFV3 (blue line) 
appeared to decrease over time compared to all other cats in the study. Naïve cats are grouped on the 
black line and the rest of the FFV-group cats are displayed in the red line. B A significant negative 
correlation (r = -0.653, P = 0.006) was found between lymphocytes and FFV proviral load [57] in cat FFV3 
as lymphocyte population numbers (blue line) decreased and proviral load (determined by qPCR, black 
line) increased over time. Bars denote standard deviation. 
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Significant differences in renal parameters were detected in experimentally infected compared 
to control cats  
UPC ratios were 0.1 (normal) for all cats throughout the study, with the exception of two 
timepoints in cat FFV3 (d 122 and 142 p.i.) where its UPC ratio increased from 0.1 to 0.2 
(borderline proteinuric), before decreasing back to normal (0.1) on day 176 p.i. (Fig. 2) [181]. 
This mild transient increase in UPC coincided with the timepoint when this cat’s PBMC FFV 
proviral load was highest (d 142 p.i.) (Fig. 3B, black line) [57]. BUN concentration remained 
within normal ranges (18-35 mg/dl) for all cats throughout the study, however values tended to 
be higher in infected cats compared to naïve controls (Fig. 4). BUN was also significantly 
increased in FFV cats compared to naïve controls on three consecutive timepoints: days 15 (P 
= 0.012), 21 (P = 0.039), and 28 (P = 0.025) (Fig. 2 and 4). All cats had properly concentrated 
urine (USG > 1.035) and urinalyses and urine sediment were unremarkable throughout the 
study. Serum creatinine concentrations were below 1.8 mg/dl at all timepoints, and there were 




Figure 4. Blood urea nitrogen (BUN) levels are higher in FFV infected cats compared with naïve 
control cats. While BUN, one of the biomarkers used to assess renal health, remained within normal 
range (18-35 mg/dl) for all cats, concentrations tended to be higher in infected cats (red line) compared to 
naïve cats (black line) on days 15, 21, and 28 p.i. (red asterisks, P < 0.05). Lines represent mean of BUN 
measurements for the cats in each group. Vertical lines denote the standard deviation for each grouped 
measurement.  
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Ultrastructural changes were noted in kidneys of FFV infected cats 
Histopathology of the kidneys from cats FFV1-5 and N4 (Table 4) demonstrated a few small 
foci of tubular degeneration encompassing fewer than 15 tubular cross-sections per focus in 
cats FFV1 and FFV2; cat FFV1 also had associated atrophy of the tubules. Glomeruli from the 
remaining cats in this cohort and the control cat were within normal limits.  
 
Table 4. Summary of pathological findings in glomeruli of FFV-infected cats. Kidney tissue was 
collected during necropsy on day 176 and submitted to the International Veterinary Renal Pathology 
Service for analysis. 
Analysis Finding FFV1 FFV2 FFV3 FFV4 FFV5 
Cats 
Affected 
Histology Tubular degeneration (+/- atrophy) + + - - - 2 
TEM 
Podocyte effacement +/+ ++ ++ + +++ 5 
Cytoplasmic electron dense figures - + + + + 4 
Cytoplasmic myelin figures + + - + - 3 
Cytoplasmic vacuolization - + + - - 2 
Wrinkled glomerular capillary walls - - - - + 1 
+ = minimal, +/+ = minimal to mild, ++ = mild, +++ = moderate 
 
 
TEM evaluation of glomeruli from cats FFV1-5 (Fig. 5) demonstrated minimal to moderate 
segmental effacement of podocyte foot processes in all infected cats (Fig. 5 top left panel, and 
Table 4). There were a few small segments of wrinkled glomerular capillary walls in cat FFV5 
(Table 4). Electron-dense whorls resembling myelin figures appeared free in the cytoplasm or 
within cytoplasmic vacuoles in tubular epithelial cells of three of the infected cats (Table 4). 
Cytoplasmic vacuolization of parietal or tubular epithelial cells was present in two cats (Table 4). 
Within the cytoplasm of the proximal tubular epithelial cells of four of these cats, there were 
small electron-dense spirals and linear structures of 10-15 nm in length arranged in pairs, 
stacks, polygonal shapes, or spirals, and of variable length (Fig. 5, top right and bottom panels). 
Sometimes the linearly shaped ones had a beaded appearance or formed structures resembling 
a zipper. Mitochondria occasionally wrapped around the structures. In cat FFV5, the structures 
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were similar to the ones found in the other FFV cats but appeared significantly more organized. 




Figure 5. Transmission electron microscopy (TEM) documents podocyte foot process effacement 
and structures in the cytoplasm of epithelial cells. Podocyte foot process effacement (top left panel). 
Examples of organized linear structures in tubular epithelial cell cytoplasm are depicted in top right and 
bottom panels. These structures ranged from polygonal (top and bottom right panels) to ovoid (bottom left 
panel). Some structures were composed of a single electron dense line (top right panel), whereas others 
were composed of numerous parallel electron dense lines separated by regularly spaced electron lucent 
lines (bottom panels). 
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Immunofluorescence did not demonstrate definitively positive (granular) labeling for any of 
the antibodies (IgG, IgM, IgA, LLC, KLC, and C1q). Cat FFV3 had weak blush to linear staining 
with IgM of the glomerular mesangium and some capillary walls but based on the pattern of 
staining, it was considered non-specific. Naive control cat N4’s immunofluorescence was 
negative.  
 
Mild lymphoplasmacytic infiltrates and lymphoid hyperplasia of multiple tissues were associated 
with FFV exposure 
No significant clinical or pathological findings were grossly observed in control (N4) or FFV-
infected cats (FFV1-5) during necropsy. Microscopic evaluation of tissues from FFV-infected 
cats revealed mild (n=3) to moderate (n=2) lymphoid hyperplasia in retropharyngeal, 
submandibular, mesenteric, and prescapular lymph nodes, characterized by numerous 
secondary follicles that contain abundant tingible-body macrophages. The tonsils of infected 
animals exhibited minimal (n=1), mild (n=3), and moderate (n=1) lymphoid hyperplasia with 
multifocal infiltration of small numbers of lymphocytes beyond the capsule in one mildly affected 
animal. Two infected cats exhibited mild thyroiditis characterized by multifocal infiltrates of small 
lymphocytes, plasma cells, and macrophages within the interstitium and surrounding colloid-
filled follicles of varying size. Within the ileum, Peyer’s patches were minimally (n=1) to mildly 
(n=4) hyperplastic, and one animal exhibited multifocal lymphoplasmacytic infiltrates extending 
deep into the submucosa. Additionally, minimal (n=3) to mild (n=1) lymphoplasmacytic colitis 
was observed in FFV-infected cats, with lymphoplasmacytic infiltration into the submucosa that 
caused disruption of the submucosal architecture (n=3), as well as small numbers of 
degenerate neutrophils scattered within the submucosa (n=1). In the cerebrum of FFV-infected 
cats, there were minimally (n=2) to mildly (n=3) increased numbers of glial cells (gliosis) and 
paired astrocytes (astrocytosis) surrounding scattered neurons within the gray matter 
(satellitosis), a feature that was most prominently noted within the frontal lobe and thalamus 
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(Fig. 6B). Cat FFV5 also had small numbers of small lymphocytes within the meninges 
(lymphocytic meningitis) (Fig. 6C). Scattered neurons within these regions were multifocally 
swollen, rounded, and demonstrated mild central dispersion of Nissl substance (chromatolysis), 
as well as rare, scattered neurons that exhibited hypereosinophilic and/or fragmented cytoplasm 
(potentially indicative of neuronal necrosis) (n=2) (Fig. 6D). One cat had mild multifocal 
lymphohistiocytic mastitis.  
 
 
Figure 6. FFV-infected cats exhibit early neurodegenerative changes in the central nervous 
system. A Neurons in the CNS of naïve, uninfected cats contain uniform, round nuclei, abundant 
basophilic Nissl substance, and flanked by few glial cells (black arrow). Frontal lobe, Hematoxylin-eosin 
(HE) 400x. Scale bar = 100µm. B Neurons in the CNS of an FFV-infected cat (FFV3) exhibit moderate 
satellitosis, characterized by increased numbers of glial cells (black arrows). Thalamus, HE 400x. Scale 
bar = 100µm. C The meninges of an FFV-infected cat (FFV5) are expanded by minimal numbers of 
mature small lymphocytes (red arrows) and plasma cells (red arrowheads). Cerebellum, HE 400x. Scale 
bar = 100µm. Neurons in the frontal lobe of this animal (inset) are shrunken, with hypereosinophilic 
cytoplasm, and exhibit moderate satellitosis (black arrows). Frontal lobe, HE 400x. D Neurons in the CNS 
of an FFV-infected cat are swollen and rounded, with an indistinct nucleus and a dispersed Nissl 
substance (chromatolysis). Thalamus, HE 400x. Scale bar = 100µm. 
 67 
Histologic changes in cat FFV5 were more pronounced when compared to the other infected 
animals and included moderate lymphoid hyperplasia in the tonsil with moderate numbers of 
lymphocytes and macrophages within the tonsil medullary sinus, and enlarged germinal centers 
in the Peyer’s patches. Within the lung of this cat, the parabronchial interstitium and alveolar 
septa were multifocally expanded by small numbers of small lymphocytes, intact neutrophils, 
and macrophages (interpreted as mild interstitial pneumonia). Alveoli were occasionally filled 
with small numbers of alveolar macrophages and frequently lined by plump, cuboidal epithelial 
cells, indicating type 2 pneumocyte hyperplasia, with occasional clubbing of alveolar walls due 
to mild smooth muscle hypertrophy.  
Non-specific histologic findings in control cat N4 included mild lymphoid hyperplasia in the 
mesenteric lymph node, tonsil, and thymus, minimal to mild inflammatory infiltrate in the tongue, 
and mammary tissue, and minimal chromatolysis in the cerebrum. Findings in this control cat 
ranged from very subtle to mild and were less severe than in infected animals. 
 
FFV is prevalent in domestic pet cats and there is an association between FFV and CKD in 
males 
Overall FFV prevalence was 57%, with AU prevalence (67%) being higher than in the USA 
(44%) (Appendix File 8). Prevalence rates were slightly higher in CKD+ compared to CKD- 
cohorts for the AU, USA, and Overall (Fig. 7). Males tended to have higher FFV prevalence in 
CKD+ versus CKD- groups (Fig. 7). Cats in all groups had an average IRIS stage between II 
and III with the majority of cats in stage II (data not shown). Results show there is no significant 
association between CKD and FFV infection when all cats from all locations are included. 
To measure the strength of association between sex, FFV infection, and CKD, we 
additionally calculated relative risk ratios among groups. Amongst all CKD+ cats, there was a 
significant association between sex (male) and FFV infection status (P = 0.037). Male CKD+ 
cats across all sites had a RR of 1.37 with a 95% CI of (1.04, 1.81) and female CKD+ cats 
 68 
across all sites had a RR of 0.73 with a 95% CI of (0.55, 0.96). Amongst the USA cats there 
was a significant association between sex and FFV infection status (P = 0.023), and male USA 
cats had a RR of 1.77 with a 95% CI of (1.13, 2.78). Female USA cats had a RR of 0.57 with a 
95% CI of (0.36, 0.89). Finally, amongst USA CKD+ cats there was a significant association 
between sex and FFV infection status (P = 0.010). Male USA CKD+ cats had a RR of 2.42 with 
a 95% CI of (1.26, 4.65) and female USA CKD+ cats had a RR of 0.41 with a 95% CI of (0.22, 
0.80). No significant differences were found in the BUN and blood creatinine concentrations 




Figure 7. Male cats with CKD are more likely to have FFV infection. We found a significant 
association between CKD and FFV infection in male cats. Males with CKD have higher FFV prevalence 
rates than females in Australia (AU) and United States (USA). Australia had increased FFV prevalence 
rates compared to the USA. M=male; F=female. Asterisks denote significant associations between sex, 
CKD, and FFV status (P-value < 0.05) as analyzed by Chi-square test. Additional statistical details in 
“Results” section Statistical analyses. Chi-square test statistics and P-values are reported in Appendix 






One of the aims of this study was to further characterize FFV infection and host immune 
response in healthy SPF domestic cats through experimental FFV inoculation over the acute 
phase of infection. In addition to clinical monitoring, assessing viral kinetics and tropism, 
determining specific antibody response, and a histopathological assessment of different tissues, 
we conducted assays to expand infection characterization. This included flow cytometric 
assessment of specific white blood cell subsets suggested to be involved in FFV infection and 
renal-specific assays to determine the extent of FFV involvement in renal health or disease. 
Experimentally infected cat samples used in this study were obtained from cats reported in a 
previous study in which an FFV-based vaccine candidate was tested and PBMC FFV proviral 
load and antibody response compared to wild-type FFV infection [57]. Based on microscopic 
findings from the wild-type FFV-infected cohort indicating that renal displayed evidence of injury 
during early FFV infection, we next investigated the potential association of FFV with CKD in 
client-owned cats following natural FFV infection. 
FFV established a detectable, persistent, and clinically apathogenic infection during the 
relatively acute 6-month time period of our study [56, 57, 59, 91]. Provirus was primarily isolated 
from lymphoid tissues, mainly PBMC, the retropharyngeal lymph node, and spleen, 
demonstrating lymphoid tropism as previously reported [55, 59, 81]. The expanded tissue 
tropism found in cat FFV3 with 10-fold higher proviral load than other cats also included the oral 
mucosa. Surprisingly, we were unable to detect virus in the tissues of one cat (FFV4) which also 
tended to have lower PBMC proviral loads [57]. Viral RNA was detected once in the saliva (also 
in cat FFV4), indicating that in our acute time period, limited amounts of virus were being shed, 
and salivary excretion may not correlate with widespread tissue distribution. A recently 
published report on FFV-infected cats in Brazil detected FFV DNA in buccal swabs via nested 
and quantitative PCR and found over 46% FFV positivity in buccal swabs through both methods 
[66]. Animals in this study were more likely to be FFV positive in PBMC than in buccal swabs, 
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as can be seen in primates due to a delay in salivary positivity of virus compared to blood [182]. 
A wide variability of FV positivity has been reported in different nonhuman primate species and 
even within the same species [68, 69, 183]. Samples from cats in the Brazilian study were also 
sourced from pet and feral cats with unknown time periods of FFV infection. It is possible that 
due to the acute time period in our study, infection had not yet reached high enough levels in 
the oral cavity in order to show positivity in the saliva. Nevertheless, the Brazilian study and this 
one suggest individual variability in salivary FFV shedding. 
A significant negative correlation between lymphocytes and proviral load was notable in cat 
FFV3, despite the fact that PBMC phenotype analysis did not indicate increased cell death or 
lymphocyte subset contraction in any of the FFV-infected cats, thus PBMC phenotyping appears 
to not be useful as an indicator of FFV infection. These findings may indicate that a subset of 
FFV-infected cats experience higher viral loads that correlate with expanded tissue distributions 
and potential for lymphocyte decline. Further work analyzing correlates of FFV infected cats with 
hematologic indices are warranted to investigate this limited observation in one animal. 
Necropsy and histologic analysis of experimentally infected cats yielded minimal to 
moderate changes in the lymphoid compartment, CNS, large intestine, lung, and thyroid. FFV-
associated lung lesions have previously been noted in another experimental FFV infection 
study, including mixed cellular infiltrates and eosinophilic fluid within alveolar walls [59], similar 
to findings reported here. The consistent changes in tissue histology and in renal indices 
particularly warrant further investigation. Alterations in CNS histopathology of FFV-infected cats 
suggest viral replication or associated inflammation as is seen in other retroviral infections [184-
186]. FFV has previously been isolated from the CNS of cats, and may therefore indicate that 
FFV is capable of productive CNS infection and subtle neurologic alterations [187]. Future 
studies should be conducted to identify potential target cells of infection in the CNS and assess 
for development of neuropathogenic effects. These findings suggest a potential role for FFV in 
the development of mild acute inflammation in a variety of parenchymal organs and brain. The 
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pathogenic mechanisms and overall consequence of these lesions are undetermined, especially 
considering the low number of cats studied and that some of the histopathological changes 
were found in the negative control cat to a lesser extent, but suggest some microscopic 
alterations can occur during acute FFV infection.  
FFV has previously been detected in animals suffering from renal and urinary syndromes [9, 
59, 78, 83, 84, 124]. BUN concentrations remained normal during FFV-infection but were 
statistically elevated in FFV-infected compared to naïve groups on days 15, 21, and 28 p.i., 
which coincided with the days when animals were first FFV PCR and ELISA positive [57]. 
Borderline proteinuria (increased UPC ratio to 0.2 [119]) was also seen in cat FFV3 on days 122 
and 142 p.i., which coincided with the timing of the highest viral load measured in the study 
period. These mild increases in renal parameters could be considered a transient systemic 
alteration due to infection. Mildly increased UPC could also develop due to non-infectious 
reasons including fever, hypertension, exercise, and others [188-190]. The cats in our study, 
however, remained clinically normal and no changes were made in their management that could 
account for increased periods of activity during that time. Interestingly, a recent report on 
chronically zoonotically SFV-infected people also noted increased BUN compared to un-infected 
controls, in addition to other hematological alterations [49].  
Ultrastructural kidney changes (glomerular podocyte foot process effacement, myelin 
figures, vacuolization, and wrinkled glomerular capillary walls) are non-specific and reversible 
changes. If enough podocytes are irreversibly injured, then the patient can develop segmental 
to global glomerulosclerosis, a disease process in humans and small animals that can cause 
proteinuria, usually with UPC > 2. Although a cut off for the number of irreversibly injured 
podocytes has not been established in cats, a model of glomerulosclerosis in rats estimated that 
>40% of the podocytes have to die and detach in order for glomerulosclerosis to develop [191]. 
Notably, glomerulosclerosis was not identified in any of the cats in the present study. Tubular 
atrophy noted on histopathology is an irreversible lesion and often seen in cats with clinical 
 72 
evidence of CKD [114, 115]. Electron-dense structures identified in proximal tubular epithelial 
cells in the kidney could represent viral structures at immature stages of assembly before 
forming the spherical shapes of FFV virions reported in the literature [12, 34, 192]. Similar 
structures have been found in the central nervous system in both cats and humans. Cook and 
others described similar tubular structures as “paramyxovirus nucleocapsid-like” in the 
cytoplasm of oligodendrocytes taken from a demyelinating lesions in the optic nerve of three 
clinically healthy adult cats [193]. These inclusion-body like structures were of 16-17 nm in 
diameter and fused into penta- to septa-laminar shapes and 900 nm in length. The authors 
suggested a possible viral etiology. Wilcox and others (1984) reported similar structures in optic 
nerves and brains of 24 clinically healthy cats from which FFV was isolated [187]. While also 
finding 10-18 nm wide and 500 nm long structures they also reported structures in much smaller 
shapes, appearing as “short, disorganized fragments,” located next to where budding virions 
were observed, in addition to intranuclearly. These structures were, however, found in the 
cytoplasm of cells that did not display CPE and thus these lesions were not attributed to FFV 
but perhaps a morbillivirus [187].  
A higher FFV prevalence in Australia versus the USA may be attributable to the lifestyle of 
cats in Australia, which are commonly allowed outside [194, 195], where contact with other 
infected cats would lead to greater chance of exposure and transmission of virus compared to 
cats in the US which are more typically housed indoors. All of the USA samples were evaluated 
by ELISA, while Australian samples consisted of serological samples assayed by ELISA but 
also whole blood samples analyzed by PCR. PCR is not as sensitive as ELISA for detection and 
can yield false negatives [56, 57, 62, 80, 168] therefore, it is possible that the FFV prevalence is 
even higher in Australia. 
We found that in male cats with CKD, there was a significantly higher risk of FFV infection 
compared to CKD-negative males, especially in the USA. This further supports some role of 
FFV infection in development of CKD, but additional studies should be conducted to verify this 
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observation. Male sex has not been found to be an overall risk factor for CKD, however males 
can be overrepresented in certain age groups affected by CKD [196].  
The association of FFV with male sex, particularly in the USA, is also notable. One reason 
for this could be the increased testosterone-associated territorial aggression in males that leads 
to a higher incidence of infection of male cats as is seen with FIV, another retroviral infection of 
cats [62, 197, 198]. A recent study of feral cats in the US found an association between FFV 
infection and male sex [81]. However, our epidemiological results were obtained from desexed 
animals. An epidemiological study of FFV in Australia did not find an association between sex 
and FFV infection in desexed domestic cats, but did see higher incidences of FFV in female 
feral cats [62]. Thus it appears that the association between male sex and FFV is not due to 
desexing and ensuing behavioral patterns due to hormonal influence. Estradiol has been shown 
to be associated with decreased apoptosis of female cat lymphocytes [199]. Studies evaluating 
the effect of sex and hormones in cat response to infection are rare. Sex differences in innate 
and adaptive immune system response, genetic and hormonal mediators are differentially 
expressed in male and female mammals in general and could account for sex-based differences 
in response to infection with males being more susceptible to infection [200, 201]. Why this 
association was significant in the USA and not Australia is currently unknown. It is possible that 
there were false negatives in this cohort, as some of the samples tested in the AU cohort were 
whole blood and assayed by qPCR which is not as sensitive as the GST capture ELISA [56, 62, 
80, 168]. Also since specific gravity was not calculated in US cats, it is possible that the CKD 
negative cohort was actually positive. Experiments to elucidate the reason for increased FFV 
susceptibility in males and due to geographical location are warranted. 
 
Conclusions 
Collectively, our findings reinforce and expand on the current established notion that FFV is 
widely prevalent and apathogenic over an acute time period, corroborating decades long 
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assumptions that FFV is well adapted to the domestic cat host. However, our detailed analysis 
of hematological and histopathological changes indicates sub-clinical alterations that could 
contribute to metabolic or degenerative diseases over time, supporting work conducted by 
earlier researchers [9, 11, 12, 58, 59, 78, 83-87, 124-126]. The negative correlation between 
lymphocytes and viral load in one cat with higher viral load suggests that a differential 
susceptibility and potential pathogenicity may exist in some individuals. Further, multiple lines of 
evidence outlined above hint that FFV may play a role in renal disease that has yet to be fully 
elucidated.  
Since FFV is widely prevalent in both domestic and feral cat populations, practitioners and 
researchers should be aware of the potential for FFV to be associated with lymphoid depletion 
and worsening of CKD symptoms, especially in males. Until more information is determined 
about correlates of disease that are dependent upon FFV infection, it might be prudent for 
clinicians to screen cats acting as blood donors for FFV prior to using potentially infectious 
blood for transfusions to immunocompromised individuals as one relatively easily attained 
precaution.   
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The viral family Retroviridae consists of clinically significant viruses that cause specific 
disease syndromes in domestic cats (Felis catus). Retroviridae is composed of two subfamilies: 
the Orthoretrovirinae and Spumaretrovirinae. Feline immunodeficiency virus (FIV), a lentivirus 
from the Orthoretrovirinae, and feline foamy virus (FFV), a spumavirus, both establish lifelong 
infections with differing clinical outcomes in the feline host and are frequently found co-infecting 
the same animal [62, 63, 71]. While FFV is generally considered apathogenic [58, 141], it has 
been linked to other retroviral infections and potentiation of those infections has been 
documented [88, 142]. 
FIV infects and replicates in CD4+ T lymphocytes and in some cats, leads to an 
immunodeficient state predisposing the host to secondary bacterial infections and neoplasia 
(typically lymphoma or leukemia) [63, 131, 134-139]. Prevalence of FIV in healthy cats is 2% 
and in sick or at-risk cats up to 30% [63, 136, 138, 140]. Many FIV-infected cats live an 
asymptomatic life following infection [138], however, about 18% of cats infected with FIV will 
develop disease and require euthanasia or die within 2 years post-infection (p.i.) [136]. Virus is 
typically transmitted in the saliva via biting during antagonistic encounters [63, 127, 139]. Risk 
factors for FIV infection include sex (male), aging, and outdoor access [62, 63, 136, 138, 140].  
FIV clinical disease typically progresses through three distinct phases: an initial acute 
phase, a longer asymptomatic phase, and in some cats, a final terminal clinical stage that may 
warrant euthanasia in client-owned cats [135, 136]. The initial acute phase can last from days to 
months and is characterized by a detectable plasma viremia that peaks around 2 weeks p.i., 
transient lymphadenomegaly, fever, enteritis, stomatitis, respiratory tract disease, ocular 
problems, and dermatitis, while appetite, body weight, and social behaviors tend to remain 
normal [63, 131, 135-137, 139, 202]. The following asymptomatic phase is marked by 
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alterations in various leukocyte subset populations including peripheral white blood cells (WBC), 
CD4+, CD8+, and CD21+ lymphocytes, and lasts on average about 8 years [131, 135, 140, 
202, 203]. During this latent phase, FIV plasma RNA can become undetectable and remain at 
low levels for the remainder of the animal’s life [131, 135]. The terminal stage of FIV clinical 
disease, when it occurs, is characterized by fever, anorexia and weight loss, marked 
panleukocytopenia leading to feline acquired immunodeficiency disease syndrome (FAIDS), 
non-regenerative anemia, secondary infections, neurologic disorders, and immune-mediated 
disease due to hypergammaglobulinemia (such as glomerulopathy and polyarthritis) [63, 136, 
138, 140]. A hallmark of FIV infection is an inversion of the CD4+:CD8+ ratio due to decreasing 
CD4+ cells [131, 136, 137, 202, 203]. Cats in terminal FAIDS become non-responsive to 
symptomatic therapy and require humane euthanasia [63, 135]. In natural FIV infection, not all 
of these phases are apparent, and some cats that have progressed to FAIDS can still return to 
an asymptomatic stage following proper treatment [136]. 
In contrast to FIV infection and the associated immunosuppressive disease seen in some 
cats, FFV has not been linked to a specific disease process. Transmission of FFV is thought to 
occur through salivary shedding and ongoing intimate contact between cats such as grooming 
[58, 62, 139]. Prevalence of FFV varies by geographical location, population sampled, and 
assay used but can range between 8-80% [62, 71-80]. FFV experimental infections in domestic 
cats have been infrequent, and while some have not documented pathology [55, 56], one report 
found evidence of microscopic renal and pulmonary pathology [59]. In our laboratory, we have 
also found mild pathology and alterations in hematological parameters that could potentially 
lead to disease in chronic infection (Chapter 2). Additionally, others have isolated FFV from sick 
cats suffering from polyarthritis [85, 86], urinary syndromes [82-84], other retroviral infections 
including FeLV [88, 89], feline infectious peritonitis [78, 90], feline herpesvirus and feline 
calicivirus [9], and neoplasia [11, 12, 78, 87]. Recently, a group studying humans zoonotically 
infected with simian foamy virus (SFV) found hematological alterations indicative of anemia, 
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azotemia, and others [49]. Thus, infection is not obviously associated with clinical disease, 
however clinical implications of FFV are as of yet indistinct. 
Epidemiological studies have documented significantly higher rates of FFV/FIV co-infection 
versus single FIV infection, with up to 90% of FIV-infected cats showing FFV positivity [71]. A 
potentiating role of FFV in FIV disease, either by directly affecting host immune response or 
through direct interactions between viruses, has been suggested [62, 63, 71]. Only one study, 
conducted over two decades ago, has reported outcomes of experimental FIV/FFV co-infection 
[141]. While the study found no association between co-infection and worsened FIV disease, 
the authors evaluated a very limited number of hematologic indices and did not assess relevant 
parameters such as viral kinetics and immune activation during single versus co-infection. The 
authors suggested that FFV could potentially affect later stages of FIV infection that were not 
monitored in this study [141]. 
Increased pathology in macaques co-infected with simian foamy virus (SFV) and simian 
immunodeficiency virus (SIV) has been reported [142]. In that study, naturally SFV-infected 
macaques were experimentally infected with SIV. Co-infected animals showed a higher SIV 
viremia, more pronounced decreases in CD4+ T lymphocyte population numbers, and higher 
morbidity and mortality rates than singly SIV-infected macaques [142]. A second study identified 
active replication of SFV concurrently with CD4+ T lymphocyte depletion in the jejunum of SIV-
infected macaques, suggesting that co-infection might accelerate immune depletion [67]. An in 
vitro study also found that SFV-infected cells displayed increased permissiveness to HIV [204]. 
SFV has also been found to infect CD4+ cells [61].  
Based on evidence showing that FFV and FIV are frequently co-isolated, and reports of 
worsened pathology in co-infected macaques, we hypothesized that FFV infection potentiates 
FIV infection and disease progression. In order to determine if there is an association between 
these viruses, we conducted a serosurvey of naturally FIV-infected cats to measure FFV 
prevalence. The cats were part of a previous study comparing clinical outcomes in two groups 
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of FIV-infected cats housed differently: one group consisted of 1-2 cat households in Chicago, 
IL and the second of a large multi-cat household in Memphis, TN [205]. Cats in the multi-cat 
household had increased FIV-related pathology and mortality compared to the singly-housed 
group. We theorized that a reason for the increased pathology and disease was due to higher 
rates of FFV/FIV co-infection in the multicat group. We additionally conducted an in vitro 
FFV/FIV co-infection study to assess potentiated infection as determined by more rapid 
development of cytopathic effects (CPE) and/or higher viral titers in the supernatant. Findings 
described below show that FFV and FIV natural infections are associated and that these viruses 
enhance each other’s in vitro replication based on order of infection. 
 
Methods 
Naturally FIV-infected domestic cat samples used in the FFV serosurvey 
Plasma samples from naturally FIV-infected, desexed cats used in our FFV serosurvey were 
obtained opportunistically from Dr. Carolyn Guptill (Purdue University, West Lafayette, IN); 
blood collection and FIV testing methods are described [205]. Plasma samples from FIV-
infected cats were separated into two groups based on geographical origin and housing method 
(Table 1). Group 1 consisted of 39 plasma samples from cats that were adopted from a shelter 
in Chicago, IL and lived in 1-2 cat households. Group 2 consisted of 23 plasma samples from 
cats that were housed together in a large multi-cat household in Memphis, TN with unrestricted 
access to each other. Plasma samples were obtained from FIV-negative control cats that were 
age-, sex-, and location-matched, and lived in households of 3 cats or less (32 cats in Group 1 
and 47 cats in Group 2) [205]. A total of 141 samples were assayed. The authors found that 
animals in Group 1 did not develop significant morbidity or mortality during the study period, 
while 63% of cats in Group 2 suffered from weight loss, neoplasia, and death. Sex, FIV plasma 
viral load, FIV strain, white blood cell (WBC) count, lymphocyte numbers, and CD4+:CD8+ ratio 
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data was obtained for each cat if available. The authors did not find significant differences in FIV 
plasma load, CD4+:CD8+ ratio, or FIV strains between the two groups [205]. 
 
Table 1. Comparison of the two naturally FIV-infected groups used in our serosurvey. Expanded 
group descriptions and results are published [205]. 
 Chicago (Group 1) Memphis (Group 2) 
Source Large metro area shelter FIV+ cat rescue 
Living condition 1-2 cat households Large multicat household 
Morbidity Relatively healthy Anorexia, weight loss, and lymphoma 
Mortality rate 5.9% 63% 
 
 
FFV GST-capture ELISA for specific antibody detection 
A GST-capture enzyme-linked immunosorbent assay (ELISA) was performed on plasma 
samples from naturally FIV-infected cats to detect anti FFV Gag antibodies as described 
previously [57, 80, 172]. 96-well plates were coated with a glutathione-casein carbonate buffer 
overnight at 4°C then blocked with casein-blocking buffer (CBB, 0.2% w/v casein in PBS and 
Tween20, Sigma Aldrich, St Louis, MO) for 1 hr at 37°C. Plates were then incubated with 0.25 
µg/µl recombinant GST-Gag antigen or GST control for 1 hr. Cat sera (diluted 1:50 in CBB) was 
incubated for 1 hr, followed by a 1 hr incubation with anti-cat-IgG Protein A horseradish 
peroxidase conjugate (1:50,000 diluted in CBB). TMB substrate was incubated on the plates for 
5-8 min, then the reaction was stopped with sulfuric acid. Absorbance (measured as optical 
density, OD, at 450 nm) was immediately read. Samples were tested in duplicate, and the mean 
of ODs used as read-out. A cut-off value was determined from FFV-negative cat sera OD with 
the formula of 2 x (mean OD + 3 standard deviations). Samples that resulted in ODs closely 
above the cut-off were re-assayed with an additional pre-adsorption step of sera with 2 µg/µl 





Viruses and cells used for in vitro FFV/FIV co-infection assays 
FFV plasmid pcf-7 [57, 91] was used for in vitro infections. 3 µg of FFV plasmid was 
transfected into human embryonic kidney (HEK) 293T cells (seeded at 1.5 x 106 cells/well in a 
6-well plate) using Lipofectamine 2000 (Thermo Fisher, Waltham, MA). Virus-containing 
supernatant was cleared of cells by low-speed centrifugation, and this cell-free viral stock was 
used to infect Crandell feline kidney (CrFK) cells for virus production [9, 74, 79]. Cell-free 
supernatant of FIV strain C36, a well-characterized immunopathogenic strain, was used for 
infection studies [128, 132, 206]. GFox cells were used for the FFV/FIV co-infection and FIV 
titration assays; these cells are genetically modified CrFK cells, which are inherently permissive 
for FFV infection [34, 74, 79], that express the CD134+ receptor, thus rendering them 
susceptible to FIV infection as well [128, 133]. FeFAB cells were used for FFV titration; these 
are genetically modified CrFK reporter cells that express the β-galactosidase (β-gal) gene in the 
presence of FFV Tas protein produced early during FFV infection [169]. 
 
FFV and FIV in vitro co-infection titrations  
FFV and FIV viral stocks were titrated on FeFAB and GFox cells, respectively. For FFV 
titration, light emission from FFV-infected FeFAB cells was determined using a luminometer. 
FeFAB cells were seeded at a density of 1 x 104 cells/well on black-walled and clear bottomed 
96-well plates and incubated for 3-6 h in a humidified chamber at 37°C and 5% CO2. 25 µl of 
FFV-containing cell-free supernatant was added to all initial wells and a 1:5 serial dilution in 
triplicates was conducted down the row of the plate. The plates were incubated for 3 days and 
visual assessment of CPE (syncytia formation, vacuolization, and cell death) was conducted 
daily [9-12]. The GalactoStar System (Applied Biosystems, Foster City, CA), a 
chemiluminescent reporter assay that causes light emission in the presence of β-gal protein 
(Fig. 1), was used to detect FFV-infected wells [207]. FeFAB cells were washed with 100 µl/well 
1X PBS then incubated with Lysis Solution (10 µl/well) for 10 min to lyse cells and release β-gal. 
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Galacton-Star Substrate (100 µl/well, diluted 1:50 in Reaction Buffer Diluent and equilibrated to 
room temperature) was added and plates were covered in foil and incubated for 1 h. The 
Galacton-Star substrate is deglycosylated by β-gal, producing an unstable intermediate that 
emits light (Fig. 1) [207]. After the 1 h incubation, light emission was measured with an LD 400 
luminometer (Beckman Coulter, Brea, CA) for 0.1-1 sec/well (1-2 min/plate). Uninfected FeFAB 
cells were used as negative controls and the average of their read-out x 2 was used as the cut-
off for positivity. For a positive control, E. coli-derived β-gal (Sigma-Aldrich) was used to 
generate a standard curve by serial 1:10 dilutions in Galacto-Star Lysis Buffer containing 0.1% 
BSA. 10 μl of each dilution was added per well, in triplicate, from 1:10 to 1:108 and incubated 
with Galacton-Star Substrate concurrently with samples as described above. The AD LD 
Analysis Software (Beckman Coulter) was used to calculate the relative light unit (RLU) 
emission readout. The number of positive wells was used to determine TCID50/ml through the 




Figure 1. FeFAB cell β-gal production and diagram of GalactoStar chemiluminescence assay. β-gal 
is produced by FeFAB cells in the presence of FFV Tas. Tas binding to the FFV LTR leads to expression 
of the β-gal gene. β-gal deglycosylates the Galacton-Star substrate, leading to a detectable 
chemiluminescence. 
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FIV titer was determined on serial dilutions of supernatant using an FIV p26 capsid capture 
ELISA to detect presence of virus as described [209, 210]. GFox cells were seeded at 2 x 104 
cells/well and allowed to attach for 3-6 h in a 37°C humidified incubator. 20 μl of FIV C36-
containing supernatant was added to the first well dilution and 1:10 serial dilutions conducted 
down the row. Plates were incubated for 7 days after which supernatant was collected for 
titration by the p26 capture ELISA [209-211]. Briefly, 96-well plates were coated with 500 
ng/well FIV p26 monoclonal antibody (donated by Dr. Greg Dean, Colorado State University, 
Fort Collins, CO) diluted in carbonate buffer overnight at 4°C. Plates were then blocked with 
TEN buffer and 2% BSA for 2 h. Afterwards, 100 μl of supernatant from the GFox viral dilution 
plates were added and incubated for 2 h. Anti-FIV antibody containing sera from chronically 
FIV-infected cat 2104 (100 μl/well, diluted 1:200 in ELISA diluent) was added and incubated for 
1 h. Goat anti-cat IgG horseradish peroxidase (MP Biomedicals, Santa Ana, CA) was diluted 
1:5000 in ELISA diluent and 5% mouse serum and incubated for 1 h. TMB (100 μl/well) was 
used for the substrate reaction with an incubation of 10 min, after which sulfuric acid was used 
to stop the reaction. Absorbance (OD450) was measured and the average of negative 
supernatant controls subtracted from positive wells. Wells were scored as positive or negative 
based on a cutoff value of the average of the negative control wells x 2. TCID50/ml was 
calculated as described above [208]. FIV C36-containing supernatant (100 μl/well, diluted 1:10 
in ELISA diluent) was used as positive control. 
 
FFV/FIV in vitro co-infections 
FFV/FIV in vitro co-infection studies were carried out in 6-well plates. GFox cells were 
seeded at a density of 105 cells in 5 ml media per well and submitted to one of the following 
treatments per well after 6 h of incubation to allow attachment: 1) sham infection using GFox 
media, 2) single FFV infection, 3) single FIV infection, 4) FFV then FIV infection (FFV à FIV), 5) 
FIV then FFV infection (FIV à FFV), and 6) simultaneous co-infection (FFV + FIV). An MOI of 
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0.01 was used for all inoculations. All treatment conditions were conducted in triplicate. For the 
staggered co-infection assays, the second virus was added 24 h post-initial inoculation (day 1 
for the second virus is thus technically day 0 for that second virus). Cells were observed daily, 
and CPE were recorded. Both FFV- and FIV-infected GFox cells display CPE of vacuolization, 
syncytia formation, and cytomegaly; FFV additionally causes lysis of GFox cells at a varying 
rate based on amount of infecting virus [9]. 1 ml supernatant was collected on days 1, 2, 3, 5, 7, 
and 10 p.i. and frozen in -20°C to conduct viral measurement experiments over time (see 
below). 1 ml of fresh media was added to each well following supernatant collection. At the end 
of the 10-day timeline, GFox cells were collected and frozen in -80°C by trypsinization and 
washing with 1X PBS through two rounds of centrifugation to pellet cells and remove 
supernatant. A second co-infection experiment with a 100-fold increase of FFV and same 
amount of FIV was conducted to evaluate the effect of increased FFV load. All conditions 
remained the same with the exception of a shorter 7-day timeline due to lytic effects from the 
increased FFV inoculum. Collections took place on days 1, 2, 3, 5, and 7 post initial inoculation 
and cells were similarly washed and pelleted at the conclusion of the study period. The timeline 
for the second virus added was adjusted as in the first round of co-infections. 
 
Viral measurements over time 
As noted previously, the second virus added on the staggered co-infections had an adjusted 
timeline. The second virus was added one day after the initial virus and this day was marked as 
“day 0” for the second virus. Upcoming days for the second virus were added to the nearest day 
of single infection and timeline adjusted to match the single infection for comparison of single 
versus co-infection viral titer measurements over time. FFV was measured over time by the 
GalactoStar assay (Fig. 1) by adding 25 µl of each infection treatment per well in a 96-well plate 
containing FeFAB cells as described above. The RLU readout from the luminometer was used 
to calculate the amount of β-gal produced (ng) as a proxy of viral load in the supernatant sample 
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based on a β-gal dilution standard curve. For FIV, the average of the triplicate well ODs was 
used as read-out for each treatment condition through the p26 ELISA described previously. 
One hundred and forty microliters of supernatant per treatment well was submitted to viral 
RNA purification using the QIAamp Viral RNA Mini Kit following manufacturer protocol 
(QIAGEN, Hilden, Germany). cDNA was reverse transcribed from extracted RNA using 
Superscript II (Invitrogen, Carlsbad, CA), random hexamer primers (Invitrogen), and RNAse Out 
(Invitrogen). FIV-gag was detected through real-time PCR on a C1000 Touch Thermal Cycler 
(Bio-Rad, Hercules, CA) using 704F and 756R primers (10 µM each) and 727P probe (10 µM) 
[212] under conditions modified from previous reports [128, 213, 214]. Briefly, each 25 µl 
reaction consisted of TaqMan 2x Universal PCR master mix (Applied Biosystems, Foster City, 
CA) (12.5 µl), water (5.3 µl), forward and reverse primers (1 µl each), and probe (0.2 µl), and 5 
µl of DNA template, with the following cycling conditions: 2 min at 55°C, 8:30 min at 95°C, and 
45 cycles of 15 s at 95°C and 1 min at 60°C. Virus was quantified based on a cDNA dilution 
standard curve of a known FIV-C36 positive supernatant. For FFV, cDNA was quantified over 
time based on a FFV plasmid standard curve as described previously in Chapter 2. 
 
Statistical analyses 
Student’s t tests were used to determine statistically significant (P< 0.05) differences in FIV 
plasma viral load and CD4+:CD8+ ratio between FIV-infected and co-infected animals. FIV-
positive animals that did not have a detectable viral load (n=7) were omitted from analyses; one 
additional animal was omitted due to lack of FIV viral load data. A general linear model was 
used with each cat as a random effect to account for the individual heterogeneity in the viral 
loads, using the statistical program R, version 3.4.2 [177].  
Chi-square tests were performed to assess the independence of three pairs of categorical 
variables: 1) sex and FFV infection, 2) sex and FIV infection, and 3) FFV/FIV co-infection. For 
each pair of variables, cats were stratified by location (Chicago or Memphis), sex (male or 
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female), FFV status (+ or -), and FIV status (+ or -). If a Chi-square test produced a P-value less 
than a significance level of 0.05, risk ratios and 95% confidence intervals (95% CI) were 
calculated as an additional post-hoc test. Risk ratios (RRs) describe the probability of a health 
outcome occurring in an exposed group to the probability of the event occurring in a 
comparison, non-exposed group. A RR > 1 suggests an increased risk of that outcome in the 
exposed group, and a RR < 1 suggests a reduced risk in the exposed group. Chi-square tests 
and RRs were calculated using the R program and the ‘epitools’ package [180]. One cat was 
omitted from sex-related analyses due to lack of sex data. 
A two-way ANOVA was conducted on the co-infection experiments to determine statistically 
significant differences between treatment groups over time. All treatments groups were 
compared to each other on specified collection dates. For FIV, the p26 antigen absorbance 
(OD450) was used as the read-out and for the FFV GalactoStar assay, β-gal (ng) was used as 
read-out. P-values were included graphically as asterisks in the following manner: (*) = P-value 
< 0.05, (**) = P-value < 0.01, (***) = P-value < 0.001, (****) = P-value < 0.0001. Prism 7 
(GraphPad, La Jolla, CA) was used for analyses and graphical output. 
 
Results 
FFV and FIV natural infections are associated and co-infection is common 
We tested FFV and FIV prevalence on serum from cats in singly (n=71, Group 1/Chicago) or 
group housed (n=70, Group 2/Memphis) settings. Overall FFV prevalence (76%) was higher 
than FIV prevalence (44%) in both groups of cats (Fig. 2). Overall rates of co-infection and 
single FFV infection were the same (38%) and more common than single FIV infection (6%). In 
the Group 1/Chicago cohort, co-infection (48%) was more common than either single FFV 
(38%) or FIV infection (7%). In the Group 2/Memphis cohort, single FFV infection (39%) was 
more common than co-infection (27%) and single FIV infection (6%). FIV plasma viral load, 
WBC count, lymphocyte count, and CD4+:CD8+ ratio were not significantly different between 
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co-infected and singly FIV infected groups (data not shown). In both the Chicago and Memphis 
groups, nearly all animals that died were co-infected (Fig. 3). Males had higher rates of FFV 
infection than females in all groups (FFV “Overall” bars, Fig. 4).  
  
 
Figure 2. FFV is more prevalent than FIV, and co-infection is common. FFV overall prevalence (blue 
bar) was much higher than FIV overall prevalence (red bar) in both groups tested. Cats were more likely 
to be co-infected (black bars) in the Chicago group, whereas in the Memphis group, single FFV infection 
(blue checkered bar) was more common than single FIV (red checkered bar) and co-infection. Single FIV 
infection was the least common in both groups. There was a significant association (*) between FFV and 
FIV infection in the Memphis cohort (X2=4.413 P-value=0.036) and Overall (X2=5.573, P-value=0.018). 
 
Five chi-squared tests had statistically significant associations. When the Chicago and 
Memphis cohorts were combined, a significant association was found between sex and FFV 
infection (X2=7.331, P-value=0.007) (Fig. 4). FFV and FIV co-infection was also more common 
than single FIV infection (X2=5.573, P-value=0.018) (Fig. 2). Male cats had a RR of 1.36 for FFV 
infection (95% CI: 1.07, 1.73); female cats had a RR of 0.74 (95% CI: 0.58, 0.94). FFV+ cats 
had a RR of 2.04 for FIV infection (95% CI: 1.09, 3.85), whereas FFV- cats had a RR of 0.49 




Figure 3. Most cats that died were co-infected. Overall mortality per group is shown by the green bar. 
Across both groups, most or all animals that died were co-infected (black bars) versus singly FIV infected 





Figure 4. Males are at increased risk of FFV/FIV co-infection. FFV infection was much higher in males 
than females in all groups tested. A Chi square analysis showed that there is a significant association (*) 
between the male sex and FFV infection (X2=7.331, P-value=0.007) and that in males, there is also an 
association between FFV and FIV infection (X2=4.495 P-value=0.034). In FIV+ cats, males were also at 
an increased risk of FFV infection (X2=4.289, P-value=0.038). 
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Amongst all male cats from Chicago and Memphis, there was a significant association 
between FFV infection and FIV infection (X2=4.495 P-value=0.034) (Fig. 4); male FFV+ cats had 
a RR of 2.69 for FIV infection (95% CI: 0.96, 7.56), whereas male FFV- cats had a RR of 0.37 
(95% CI: 0.13, 1.04). There was also a significant association between sex and FFV infection 
status amongst all FIV+ cats from Chicago and Memphis (X2=4.289, P-value=0.038) (Fig. 4). 
Male FIV+ cats had a RR of 1.36 for FFV infection (95% CI: 0.97, 1.91), whereas female FIV+ 
cats had a RR of 0.74 (95% CI: 0.52, 1.03). Finally, there was a significant association between 
FFV and FIV infection in the Memphis cohort (X2=4.413 P-value=0.036) (Fig. 2). Memphis FFV+ 
cats had an RR of 3.17 for FIV infection (95% CI: 1.04, 9.61), whereas Memphis FFV- cats had 
a RR of 0.32 (95% CI: 0.1, 0.96).  
 
In vitro FFV and FIV infection is enhanced or suppressed relative to order of viral infection  
TCID50/ml for FFV stocks was calculated as 1.76 x 10
7; FIV stock TCID50/ml was calculated 
to be 2.15 x 104. An MOI of 0.01 was used in initial infection studies. FIV-only inoculated cells 
began displaying CPE of multinucleation and syncytia development 2 days p.i. (Fig. 5A) while 
FFV-only infected cells began showing CPE at 8 days p.i. (Fig. 5B). The size and number of 
cells affected by CPE in the FIV-only wells progressed over time, but cell death was not 
remarkable. Cells co-infected with both FFV and FIV (both simultaneous and staggered) 
showed CPE similar in organization and timeline as singly FIV-infected cells (not pictured).  
A second round of co-infections was conducted using FIV MOI of 0.01 and FFV MOI of 1. 
These cells (Fig. 6) experienced faster and more striking CPE development than the first round 
of co-infections (Fig. 5). All virus-inoculated wells began showing syncytial cells on day 2 p.i. 
(Fig. 6A), with increased number and size of syncytia in the simultaneously co-infected (FFV + 
FIV) wells (Fig. 6B). On day 3 p.i., FFV + FIV cells began developing larger syncytia than the 
FFV- and FIV-only infected cells. 
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Figure 5. Both FIV and FFV infected cells developed CPE (MOI of 0.01 for both viruses). FIV-only 
infected cells started showing CPE 2 d p.i. (A) while FFV-only infected cells displayed CPE 8 d p.i. (B). 
FFV/FIV co-infected cells (both simultaneous and staggered) developed CPE at a similar rate and 
severity as FIV-only infected cells throughout the infection (not pictured). 
 
 
          
A                B                    C 
 
      
D          E 
 
Figure 6. Expansive syncytia developed in all FFV-containing wells, particularly during 
simultaneous co-infection. All FFV-containing wells developed large syncytia by day 6 p.i. A FFV-only 
cells developed large syncytia by day 4 that grew in size by day 6, with more expansive syncytia present 
in simultaneous co-infection (FFV + FIV) (B). C Cells in FFV à FIV developed syncytia to a lesser degree 
than FFV + FIV. D FIV-only infected cells had scattered CPE that was not expansive as noted in FFV-
infected wells. E CPE in FIV à FFV was more prevalent than FIV-only but less than other co-infected 
conditions.  
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FFV-only inoculated cells showed numerous syncytia grouped in clusters, compared to more 
scattered CPE noted in FIV-only wells. By day 5, syncytia in FFV + FIV co-infected cells were 
becoming large enough to occupy the whole microscopic field of view. On day 6, syncytia in 
FFV-only containing wells were similar in proportion to syncytia in the FFV + FIV co-infected 
wells, but fewer in number. By day 7, there was marked cell death in all FFV-infected cells. FFV 
+ FIV co-infected wells were most severely affected, demonstrating large and numerous 
syncytia (Fig. 6C). In contrast, FIV-only wells demonstrated moderately sized syncytia scattered 
between normal looking cells (Fig. 6D). FFV-only and FFV + FIV co-infected cells had very large 
and expansive, almost ameboid shaped cells that were not present in FIV-only infected cells. 
The FFV à FIV inoculated syncytia (Fig. 6C) were similar to the other FFV-infected cells, while 
the FIV à FFV inoculated syncytia (Fig. 6E) were phenotypically similar to FIV-only infected 
cells. 
FIV reactivity on the first round of co-infections (Fig 7A) was detected on day 1 p.i. for all 
FIV-containing wells and was highest on day 7 during simultaneous co-infection (FIV + FFV, red 
line, Fig. 7A). Full reactivity data and statistical analyses for both first and second rounds of co-
infection are shown in Appendix File 9 and Appendix File 10, respectively. FIV-only reactivity 
(black line) was typically intermediate between FIV + FFV (highest) and FIV à FFV infection 
(lowest, green line). Interestingly, FFV à FIV (blue line) resulted in an increase in FIV reactivity 
on day 2 and an earlier peak in reactivity on day 3 compared to all other FIV conditions. On day 
3, FFV à FIV reactivity was significantly higher than FIV-only, FIV + FFV, and FIV à FFV 
infections (blue ****, p < 0.0001 for the three conditions). After day 3, FIV-only reactivity was 
similar to other conditions until the end of the study. FIV growth during FIV + FFV infection was 
significantly higher than FIV à FFV infection on day 5 (red **, p = 0.0023) and day 7 (red ****, p 
< 0.0001), and significantly higher than FIV à FFV on day 7 (red ****, p < 0.0001). FIV-only 
infection had higher FIV reactivity than FIV à FFV infection on day 7 (black **, p = 0.0041). FIV 
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reactivity trended lowest in the FIV à FFV infection compared to all other conditions, but this 
finding was not always significant. 
The second round of co-infections (FIV inoculated at an MOI of 0.01 and FFV at an MOI of 
1, Fig 7B) demonstrated a similar trend as the first round of co-infections (Fig. 7A). FIV reactivity 
was higher at an earlier timepoint for the FFV à FIV condition (blue line, Fig. 7B). Day 2 FIV 
reactivity in this condition was significantly higher than FFV + FIV (blue *, p = 0.0167), FIV à 
FFV (blue **, p = 0.0032), and FIV-only (blue **, p = 0.0022). On day 3, FFV à FIV reactivity 
was again significantly higher than the three other conditions (blue ****, p < 0.0001). 
 
 
A          B 
 
Figure 7. FIV infection is accelerated following initial FFV infection. A MOI of 0.01 for both viruses. 
FIV reactivity determined by p26 ELISA shows that a secondary FIV infection is significantly accelerated 
by an already established FFV infection (FFV à FIV, blue line) on day 3 when compared to FIV-only 
infection (black line) and other co-infection conditions (blue ****, p < 0.0001 in all comparisons). 
Conversely, initial FIV infection was inhibited by a secondary FFV infection (green line) compared to 
simultaneous co-infection on day 5 (red **, p = 0.0023) and day 7 (red ****, p < 0.0001), and to FIV-only 
infection on day 7 (black **, p = 0.0041). B FIV MOI 0.01 and FFV MOI 1. The FFV à FIV infection 
showed a similar trend as the initial round of co-infections. Day 2 FIV reactivity in this condition was 
significantly higher than FFV + FIV (blue *, p = 0.0167), FIV à FFV (blue **, p = 0.0032), and FIV only 
(blue **, p = 0.0022). On day 3, FFV à FIV reactivity was again significantly higher than the three other 
conditions (blue ****, p < 0.0001).  
 
FFV β-gal (ng) results are summarized in Fig. 8. Full β-gal results and statistical analyses for 
first and second rounds of infection are shown in Appendix File 11 and Appendix File 12, 
respectively. Similarly to FIV, it appears that a secondary FFV infection is enhanced by an initial 
FIV infection (FIVà FFV, green line) compared to other FFV infection conditions. For the first 
 92 
round of co-infections (Fig. 8A) (MOI of 0.01 for both viruses), β -gal concentration was 
significantly higher on day 7 in the FIV à FFV condition compared to FFV-only infection (black 
line) (green *, p = 0.0139), FFV + FIV (red line) (green *, p = 0.0384), and FFV à FIV (blue line) 
(green **, p = 0.0018). Also similarly to FIV, initial FFV infection appears somewhat inhibited by 
a secondary FIV infection. 
 
 
A           B 
 
Figure 8. FFV infection is accelerated following initial FIV infection. A FFV and FIV MOI 0.01. FIV à 
FFV (green line) β-gal concentration was significantly higher than FFV-only infection (green *, p = 
0.0139), FFV + FIV (red line) (green *, 0.0384), and FFV à FIV (blue line) (green **, p = 0.0018). 
Similarly to FIV, FFV was partially inhibited by a secondary FIV infection (FFV à FIV, blue line) when 
comparing to other conditions. B FIV MOI 0.01 and FFV MOI 1. On day 2, β-gal was significantly higher in 
the FIV à FFV than FIV-only (green **, p = 0.0015), FFV + FIV (green **, p = 0.0011), and FFV à FIV 
(green **, p = 0.0012). On day 5, the FIV à FFV β-gal amount was again significantly higher than FFV-
only (green **, p = 0.0043), and FFV + FIV and FFV à FIV (both green ****, p < 0.0001). 
 
In the second round of co-infections (Fig. 8B) a higher FFV MOI of 1 was applied (Fig. 8B). 
The same trend of increased β-gal concentration in FIV à FFV was noted. On day 2, β-gal was 
significantly higher in the FIV à FFV condition than FIV-only (green **, p = 0.0015), FFV + FIV 
(green **, p = 0.0011), and FFV à FIV (green **, p = 0.0012). The FIV à FFV β-gal amount 
was again significantly higher than FFV-only (green **, p = 0.0043), and FFV + FIV and FFV à 
FIV (both green ****, p < 0.0001). 
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Preliminary FFV qPCR results for days 1 and 2 post-infection show positivity starting at day 
1 p.i. but do not show a specific trend or evidence of potentiation during co-infection versus 
single infection (data not shown).    
 
Discussion 
This work was conducted to determine associations between FFV and FIV infection. In our 
initial studies, we evaluated two groups of FIV-infected cats with different clinical outcomes to 
determine whether FFV infection impacted FIV clinical disease. FIV-infected cats living in 
multicat household (Group 2/Memphis) exhibited severe weight loss, stomatitis, dermatitis, 
neoplasia (lymphoma most commonly), and death, whereas FIV-infected cats in 1-2 cat 
households (Group 1/Chicago) remained healthy, with only one death reported [205].  
We hypothesized that the cats in Group 2/Memphis that suffered increased mortality would 
have a higher prevalence of FFV, and that there would be evidence of worsened disease due to 
FFV/FIV co-infection. While we did not find statistically significant differences in FFV infection 
rates between the two populations, we found a significant association between FIV and FFV 
infection overall, as previously reported [62, 63, 71]. In one of these reports, FFV was highly 
prevalent in sick cats infected with either FIV, FeLV, both FIV and FeLV, and in cats negative for 
both FIV and FeLV. The authors of this study found that, especially in the case of FIV, it was 
more common than not to be co-infected with FFV, which suggested a role for FFV in 
potentiating effects on the initial FFV infection [71]. In our study, it was more common in the 
Group 1/Chicago cohort to have FFV/FIV co-infection versus single infection of either FFV or 
FIV, while in Group 2/Memphis, single FFV infection was more common than co-infection. Thus, 
the cohort with higher morbidity and mortality had lower overall FFV infection rates but equal co-
infection rates compared to the cohort with mostly healthy animals. This suggests that the 
higher morbidity and mortality in the multicat household may not have been primarily due to 
concomitant FFV infection. FIV viral loads, CD4+:CD8+ ratios, and white blood cell populations 
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in the co-infected versus singly FIV-infected animals were similar, also suggesting that FFV may 
not lead to increased FIV viral burden and subsequent worsened clinical symptoms. The 
authors of this study suggested housing modality and management as reasons for increased 
morbidity and mortality [205].  
Perhaps most significantly, cats most likely to die were co-infected with FFV and FIV, 
suggesting a comorbidity that was not detectable by comparison of blood and viral parameters 
measured. Mortality rates were higher in the multicat group and 100% of those animals were co-
infected, compared to 88% in the 1-2 cat households. One of the limitations in our study is that 
we did not have access to all the samples used in previous studies, and thus may not have a 
larger sample size of clinically affected and euthanized animals that could have contributed to a 
significant difference in parameters influencing worsened disease. In a previous report of 
experimental FFV/FIV co-infection, FFV infection was not found to potentiate FIV disease [141].  
Considering the highly-varied duration of acute, clinical, and terminal stages of FIV infection, 
it is not yet possible to make assumptions regarding the effect of FFV co-infection on 
progression to or severity of later stages of FIV infection. Perhaps FFV may play a role in the 
more clinically severe terminal stage of disease (the third and final stage of disease 
progression) when animals succumb to clinical symptoms related to FAIDS as the authors 
theorized [141]. High FFV prevalence rates of FIV-positive cats with terminal illness supports an 
added risk of co-infection. Additionally, the reports on worsened SIV-related disease and 
mortality, and the expanded SFV tissue tropism in areas of increased CD4+ depletion during co-
infection in NHP support this assumption [67, 142]. Co-infection studies assessing chronic FIV 
infection, and studies that sequentially evaluate co-infection, viral loads, and hematologic 
parameters are needed to further assess the potential association between these two viruses 
during later stages of FIV disease. 
Another possible reason for the association between these viruses is their shared salivary 
transmission [58, 62, 63, 149]. FIV transmission is thought to be via biting [62, 63] whereas both 
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biting and amicable grooming between cats have been suggested for FFV [58, 62, 63]. Thus, it 
is possible that based on the interactions between animals, both viruses could be transmitted 
concomitantly. Other reports have noted significant variation in the amount of salivary shedding 
of FFV, which could account for varied transmission rates between animals (Chapter 2 and [9, 
66]). This has also been reported for NHP infected with SFV [68, 69, 183].  
FFV and FIV infections were strongly correlated with male cats as reported by others [62, 
63, 138]. Increased risk in FFV has been documented in both domestic and feral cat populations 
(Chapter 2 and [62, 81]). A previous study found that feral cats were at increased risk compared 
to desexed pet cats, and the authors suggested this may be due to behavior related to intact 
male behavior, implying feral males roam more and are at increased risk of exposure [62]. 
However, our sampled population consisted of desexed animals, thus in our population, 
behavioral changes due to being intact did not contribute to the association. We have also found 
domestic neutered male pet cats to have an increased risk of FFV infection (Chapter 2) . It is 
possible that their behavior and time of desexing before study enrollment have influenced viral 
exposure or susceptibility. 
FFV/FIV in vitro co-infection assays were conducted to determine if viral kinetics and CPE 
development are altered during co-infection versus single infection with either virus. Increased 
permissiveness to HIV infection has been described in cells initially infected with SFV [204]. We 
thus theorized that part of the reason these viruses are associated is due to a co-factor effect 
during co-infection that potentiates one or both infections. Results from initial round co-
infections (MOI of 0.01 for both viruses) indicated that the timing and order of infections have 
different effects on both viruses. Our data indicates that the presence of an initial infection with 
either FFV or FIV accelerates infection of the second virus, causing an accelerated increase in 
replication compared to the other conditions. In the case of FIV, all infection conditions reach 
similar levels of viral replication. Thus it appears that FIV replication is accelerated if FFV 
infection is initiated first, however FIV replication during co-infection does not surpass replication 
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in the other single and dual infection conditions. In the case of a secondary FFV infection 
however, replication is not only accelerated but it also significantly surpasses all other single 
and dual conditions. In other words, secondary FIV infection is accelerated following initial FFV 
infection, and a secondary FFV infection is accelerated and boosted following initial FIV 
infection (Fig. 7 and 8). Increasing FFV MOI did not appear to cause a dose dependent 
enhancement or decrease of FIV (Fig. 7 and 8). FFV replication did reach higher levels in the 
second round of co-infections which is most likely attributed to the increased MOI (Fig. 8). 
Interestingly, during both FFV and FIV infections, exposure to a second virus appears to have 
an inhibitory effect on the initial virus at some of the timepoints, though not always significantly. 
This data shows that similarly to the findings in the PFV/HIV study, cells initially infected with 
one virus increased permissivity for the secondary virus. Reasons for this are numerous and 
could include: (1) change in cell surface receptors following initial viral infection, allowing 
enhanced binding and/or entry into the cell; (2) changes in cell metabolism/machinery changes 
following initial infection that enhance replication of a second viral infection. In the case of the 
PFV/HIV study, the authors found increased HIV permissivity in PFV-infected without enhanced 
HIV reverse transcription, nuclear import, or integration. They also found increased cell-to-cell 
HIV transmission from these co-infected cells. The authors determined this was mediated by a 
heparan-sulfate expression [204]. Heparan sulfate has also been found to be an attachment 
factor for PFV [23]. A similar mechanism could function in FIV/FFV co-infection perturbations.   
Conversely, initial infection by either virus dampened replication of a second viral infection. It 
is possible that following initial viral insult, a second virus usurps some of the host cell’s 
resources and machinery activated by the initial viral infection, resulting in enhanced, or ‘jump-
started’ infection. This effect was not always present or significant, thus it may not have a critical 
effect on initial viral infection. Follow-up experiments should be conducted with varying amounts 
of virus, altering the dose of FIV, employing the use of more relevant cell lines to retroviral 
infection such as PBMCs, longer culture durations, and with different viruses to determine if this 
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enhanced permissivity extends to other viral infections. The potential role of heparan sulfate in 
viral binding during co-infection should also be explored. 
Overall, our data support an association between FFV and FIV infection in the natural 
domestic host and in vitro models. Our in vitro studies show increased permissivity to a 
secondary infection of either retrovirus, and CPE findings demonstrate enhanced effects during 
co-infection, suggesting potentiated viral replication and pathologic effects. It is possible one of 
the reasons we did not see an association between increased FIV-related morbidity and FFV 
co-infection in naturally infected animals may be due to the timing and order of which virus 
infected the cats first (or simultaneously). Notably, almost all of the FIV-infected cats that died 
were co-infected with FIV and FFV, suggesting potentiation of FIV clinical effects—though 
associations with typical hematological indicators of pathology were not identified. Future 
studies should further interrogate whether the timing, order, and inoculum dose of infection 
impact on disease outcomes. Primary lymphoid cells should also be tested in co-infection 
experiments to validate preliminary experiments conducted in GFox cells. In vivo inoculation 
studies could be carried out in SPF cats to validate natural infections. 
 
Conclusions 
FFV and FIV infections are associated in the cat populations we sampled. Possible reasons 
for this may be related to sex, behavior, shared route of transmission, or synergistic interactions 
between the two viruses. In vitro studies showed increased permissivity to a secondary infection 
following either FIV or FFV infection, indicating approaches to study mechanisms for viral 
interaction that relate to potentiation of FIV disease by FFV infection. Future studies should be 
conducted to further understand in vitro dynamics and kinetics during co-infection, including in 
relevant cell lines, in addition to disease monitoring in chronically co-infected cats. Practitioners 
should be aware of the potential effects FFV can have on FIV-infected animals in relation to 






FFV is a sometimes highly prevalent retrovirus with a global distribution that has a unique 
molecular biology and causes an outwardly apathogenic infection during acute time periods. 
Due to this apathogenicity, researchers have used FVs to develop novel vaccine and gene 
therapy therapies with potential benefits to both animals and humans. Many questions still 
remain about infection in the host and about its molecular biology despite ancient origins and 
hundreds of thousands of years of co-evolution with their respective hosts. Therefore, 
investigating these viruses further could prove of much importance in filling these knowledge 
gaps in addition to clinical management of infected animals, and future therapies that could 
benefit both animals and humans.  
I inoculated SPF cats with two FFV strains and collected biological samples over a 6 month 
time period. One was the wild-type pCF-7 FFV and the second a novel chimeric vaccine vector 
with FIV vif replacing a truncated FFV bet. In Chapter 1, I investigated whether this in vitro 
replicative FFV-Vif chimera could infect immunocompetent cats, and compared findings to wild- 
type infection. I found that the FFV-Vif chimera was able to induce a specific immune response 
against FFV Gag and Bet proteins at antibody titers comparable to wild-type infection following 
boosting, and also against the inserted Vif. While able to elicit an immune response, the 
chimeric virus displayed an attenuated infection in vivo, as we were unable to detect virus 
through PCR in chimera-only inoculated animals. I furthermore found that cats can be 
superinfected with different strains of FFV, which adds more plausibility to the use of this virus in 
a population of pet cats which may already be infected by FFV. This chimeric vaccine construct 
could be used as a vector against lentiviral infection. However, more work would need to be 
performed to examine animals already infected with wild-type virus before being challenged with 
the vaccine candidate for further support of this vector.  
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In Chapter 2, I further characterized infection in terms of specific PBMC response to 
infection, viral tropism, and evidence of pathology, especially due to the reports in the literature 
of FFV being isolated from animals suffering from various morbidities. We found subclinical 
alterations in hematological and biochemical parameters and micropathology that could 
potentially lead to pathology over time, such as the ultrastructural kidney changes and 
histopathological changes in the lungs and brain, in addition to evidence of a potential 
susceptibility in unique cases, such as the cat with decreased lymphocytes and increased viral 
loads and expanded tissue tropism to non-lymphoid sites.  
Due to the renal changes we saw and the reports in the literature of renal pathology and 
FFV isolation from animals suffering from renal and urinary diseases, I further investigated the 
effect FFV could have on chronic kidney disease (CKD). After collecting samples from the USA 
and Australia, we did find an association of FFV and CKD in male cats, in addition to males in 
general also being at higher risk for FFV infection. More work should be conducted to determine 
the cause of this association, and more attention could be given to male cats suffering from 
CKD in relation to their FFV status.  
In addition to an association with CKD, I sought to determine if FFV was associated and 
could cause potentiation of FIV, a sometimes clinically important viruses in feline health 
management. The literature documents these two viruses being frequently co-isolated, and the 
reports in nonhuman primates show SFV and SIV potentiate each other in co-infected animals, 
leading to expanded tissue tropism, increased morbidity and mortality. Chapter 3 had two aims, 
first to investigate whether FFV was a factor in increased morbidity in a group of cats reported in 
another study, and to conduct in vitro co-infection experiments to determine if the frequent co-
isolation and association of these two viruses could be due to viral synergy during co-infection. I 
found that FFV and FIV are associated in these animals, and that again males were at 
increased risk of FFV infection in general. Others have suggested that the association between 
FFV and FIV could be due to a shared mode of transmission, or it could be due to desexing 
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status in males. In our laboratory we have seen increased risk in both feral and pets, and have 
also seen it in desexed animals, decreasing support for behavior related to increased 
aggressive encounters and spreading of virus.  
I conducted in vitro co-infection assays and these showed that FFV and FIV enhance each 
other’s replication. Regardless of which virus causes the initial infection, the secondary infecting 
virus’ replication is accelerated compared to single infection. This suggests that the reason for 
these viruses being associated could be not only due to potentially similar routes of 
transmission but also due to viral synergy based on the order of infecting viruses. 
Our data show that while FFV could make an attractive vector to develop vaccines and gene 
therapies, more studies should be conducted to understand the effect FFV has on other disease 
syndromes in cats, especially in certain population subsets such as males, and in chronic 
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Appendix File 1. Rescue of Vif-deficient FIV and Bet-deficient FFV by FIV Vif and FFV Bet. A Vif-
deficient FIV plasmid DNA was co-transfected with plasmids expressing FIV Vif or FFV Bet together with 
different feA3 restriction factors as given in the legend (left panel). Empty vector pcDNA3.1 served as 
control. Two days after transfection, cell-free supernatants were used to infect FIV reporter cells and luc 
activity induced by FIV infection was measured two days p.i. Titers are expressed as luc values of a 
representative experiment. B The Bet-deficient FFV genome pCF7-BBtr was co-transfected with plasmids 
expressing untagged and V5-tagged FFV Bet or two different amounts of FIV Vif expression plasmid 
together with the major FFV-restricting feA3Z2b-HA as shown below the bar diagram (right panel). Empty 
vector pcDNA3.1 served as control. Two days after transfection, cell-free supernatants were titrated in 
triplicate using FFV reporter cells as described in the “Methods” section and are expressed as focus-















Appendix File 2. Partial genome sequences from pCF7-Vif-4 and the stop mutations of the in vitro-
selected FFV-Vif variants. The Trp codon and the downstream G residue (TGGG) ~ 130 bp upstream of 
the vif coding sequence are in bold face letters and underlined. In pCF7-Vif W/*1 (in blue), the mutation is 
from TGG to TGA and for mutant W/*2 (in green) the mutation is from TGGG to TAGA, with both 
mutations resulting in a Trp (W) to Stop (*) mutation (W/*) as indicated. The bet nucleotide sequence is in 
black, the linker sequence in pink with recognition sites for NheI (in brown) and SacII (in light violet). 
The vif gene is marked in blue with the authentic Met start codon in bold. The BettrVif fusion protein is 
highlighted in yellow with the amino acids color-coded as described above for the genes. The Met residue 
14 amino acids upstream of the authentic vif start codon is highlighted in bold and underlining. The C-





Appendix File 3. Mutations in Tas generated during the analysis of the upstream ATG do not affect 
Tas-mediated LTR transactivation. The LTR promoter-based luc reporter construct pFeFV-LTR-luc [73] 
was cotransfected into HEK 293T cells together with a CMV-IE-driven FFV Tas expression construct, the 
empty control pcDNA3.1 and proviral genomes pCF-7, pCF7-Vif-4, pCF7-Vif W/*1, and pCF7-Vif W/*2, 
and their engineered M/T and M+ variants. Two days post transfection, luc activity induced by FFV Tas 
expression was measured in duplicates. Data from a representative experiment normalized to co-




Appendix File 4. Titers of pCF-7, pCF7-Vif-4 and engineered pCF7-Vif W/*1 and pCF7-Vif W/*2 
variants. Plasmid pCF-7, pCF7-Vif-4, pCF7-Vif W/*1, and pCF7-Vif W/*2 and their engineered M/T and 
M+ variants were transfected into HEK 293T cells and 2 days post-transfection, cell-free supernatants 
were inoculated on CrFK cells and serially passaged every (A) 60 and (B) 84 h p.i. FFV titers were 
determined in duplicate using FeFAB reporter cells and are shown as bar diagrams for the different 









Appendix File 5. Date FFV was first detected by PCR and ELISA in experimentally infected cats. 
Day of first detection of FFV genomic DNA by qPCR with indeterminate and clear positive results (two left 
columns) and nested PCR (nPCR, middle column) after experimental infection with either wild-type FFV 
(WT), FFV-Vif W/*1 chimera (CH), chimera then wild-type FFV (CH1WT and CH2WT), twice with FFV-Vif 
W/*1 chimera (CH3CH and CH4CH), or sham inoculation in naïve cats. In addition, first detection of FFV 
Gag and Bet, and FIV Vif antibodies by ELISA is displayed correspondingly (right columns). Hyphens (-) 





Appendix File 6. All cats infected with wild-type FFV and FFV-Vif W/*1 developed FFV Gag-specific 
immunoreactivity. A GST-capture ELISA was performed to evaluate antibody response to FFV infection. 
Anti-Gag reactivity (1:50 dilution) at the final time point for each animal is shown. All animals exposed to 
wild-type FFV (red bars) or FFV-Vif W/*1 (blue bars) seroconverted against Gag antigen and for many of 
these samples, reactivity is out of the linear range. Naïve animals (black bars) remained below the cutoff 
for detection (black dotted line). Black and blue striped bars denote chimeric animals re-inoculated with 
wild-type virus (CHxWT). Error bars represent standard deviation. POS = positive control, NEG = 
negative control, H2O = absolute negative (water) control. 
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Appendix File 7. Antibody marker combinations used for PBMC phenotype analysis by flow 
cytometry. 
Antibody-Marker Combination Panel Dilution Species specificity Source 
CD4-FITC A 1:200 Cat SouthernBiotech 
CD8-PE A 1:200 Cat SouthernBiotech 
CD25-PE/Cy7a A 1:20 Cat Dr. Gregg Deanc 
CD134-647 A 1:20 Cat AbD Serotec 
Fas-APC/Cy7b A, B 1:200 Cat R&D Systems 
CD56-APC B 1:20 Human BioLegend 
CD14-PE B 1:40 Human Caltag Medsystems 
CD21-PE/Cy7 B 1:20 Human BD Pharmingen 
MHCII-FITC B 1:20 Human BD Pharmingen 
a antibody conjugated to fluorophore with an Abcam conjugation kit (ab102903), b antibody conjugated to 





Appendix File 8. FFV prevalence and chi-squared analysis data for CKD studies. Seven cats were 
ommited from sex-specific analyses due to lack of sex data. 
 
Group
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 24 24% 29 30% 53 All 44% Sex vs. FFV 5.188 0.023
CKD- 19 19% 26 27% 45 CKD+FFV+ 45% (Sex | CKD+) vs. FFV 6.594 0.010
Total 43 44% 55 56% 98 CKD-FFV+ 42% (Sex | CKD-) vs. FFV 0.021 0.886
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 16 41% 8 21% 24 M FFV+ 59% Sex vs. CKD 0.677 0.411
CKD- 7 18% 8 21% 15 CKD+FFV+ 67% (Sex | FFV+) vs. CKD 2.181 0.140
Total 23 59% 16 41% 39 CKD-FFV+ 47% (Sex | FFV-) vs. CKD 0.003 0.956
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 8 14% 21 37% 29 F FFV+ 33% FFV vs. CKD 0.017 0.897
CKD- 11 19% 17 30% 28 CKD+FFV+ 28% (FFV | M) vs CKD 0.811 0.368
Total 19 33% 38 67% 57 CKD-FFV+ 39% (FFV | F) vs. CKD 0.430 0.512
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 59 47% 28 22% 87 All 67% Sex vs. FFV 0.000 1.000
CKD- 25 20% 13 10% 38 CKD+FFV+ 68% (Sex | CKD+) vs. FFV 0.142 0.707
Total 84 67% 41 33% 125 CKD-FFV+ 66% (Sex | CKD-) vs. FFV 0.468 0.494
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 27 48% 10 18% 37 M FFV+ 68% Sex vs. CKD 0.091 0.763
CKD- 11 20% 8 14% 19 M CKD+FFV+ 73% (Sex | FFV+) vs. CKD 0.002 0.967
Total 38 68% 18 32% 56 M CKD-FFV+ 58% (Sex | FFV-) vs. CKD 0.845 0.358
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 30 47% 15 23% 45 F FFV+ 69% FFV vs. CKD 0.039 0.844
CKD- 14 22% 5 8% 19 F CKD+FFV+ 67% (FFV | M) vs CKD 0.709 0.400
Total 44 69% 20 31% 64 F CKD-FFV+ 74% (FFV | F) vs. CKD 0.067 0.796
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 83 37% 57 26% 140 All 57% Sex vs. FFV 2.733 0.098
CKD- 44 20% 39 17% 83 CKD+FFV+ 59% (Sex | CKD+) vs. FFV 4.338 0.037
Total 127 57% 96 43% 223 CKD-FFV+ 53% (Sex | CKD-) vs. FFV 0.000 1.000
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 43 45% 18 19% 61 M FFV+ 64% Sex vs. CKD 0.101 0.750
CKD- 18 19% 16 17% 34 M CKD+FFV+ 70% (Sex | FFV+) vs. CKD 1.003 0.317
Total 61 64% 34 36% 95 M CKD-FFV+ 53% (Sex | FFV-) vs. CKD 0.408 0.523
Total Subgroup Prevalence Variables X
2
 Statistic P-Value
CKD+ 38 31% 36 30% 74 F FFV+ 52% FFV vs. CKD 0.727 0.394
CKD- 25 21% 22 18% 47 F CKD+FFV+ 51% (FFV | M) vs CKD 2.212 0.137



























Appendix File 9. FIV Absorbance (OD450) values for first (1-X) and second (2-X) round of FIV and 
FFV co-infections. Absorbance values were obtained through p26 ELISA. Cutoff values for positivity are 
shown on the right column. 
Day FIV FIV + FFV FIV à FFV FFV à FIV Cutoff 
1-1 0.36 0.33 0.34 0.28 0.31 0.20 0.39 0.36 0.35 0.35 0.35 0.34 
0.19 
1-2 0.29 0.30 0.31 0.30 0.32 0.31 0.25 0.32 0.27 0.38 0.40 0.45 
1-3 0.47 0.53 0.52 0.55 0.56 0.62 0.37 0.53 0.44 1.72 1.71 1.68 
1-5 1.65 1.66 1.78 1.88 1.84 1.68 1.38 1.59 1.68 1.82 1.61 1.66 
1-7 1.66 1.74 1.82 1.95 1.83 1.92 1.28 1.54 1.69 1.65 1.51 1.55 
Day FIV FIV + FFV FIV à FFV FFV à FIV Cutoff 
2-1 0.20 0.22 0.21 0.20 0.18 0.20 0.21 0.23 0.27 0.27 0.22 0.23 
0.15 
2-2 0.35 0.38 0.39 0.48 0.37 0.42 0.35 0.45 0.35 0.63 0.72 0.58 
2-3 0.82 0.99 0.89 1.10 0.95 1.03 0.83 1.03 0.95 1.80 1.65 1.64 






Appendix File 10. Significant differences in FIV absorbance (OD450) values for first (1-X) and 
second (2-X) round of FIV and FFV co-infections. Values and symbols attributed to significant 
differences in the co-infection studies (Fig. 7). Conditions in the left column are significantly higher than 
the second column. 
Day Condition significantly higher than Symbol P-value 
1-3 FFV à FIV 
FIV **** < 0.0001 
FIV + FFV **** < 0.0001 
FIV à FFV **** < 0.0001 
1-5 FIV + FFV FIV à FFV ** 0.0023 
1-7 
FIV + FFV 
FIV à FFV **** < 0.0001 
FFV à FIV **** < 0.0001 
FIV FIV à FFV ** 0.0041 
Day Condition significantly higher than Symbol P-value 
2-2 FFV à FIV 
FIV ** 0.0022 
FIV + FFV * 0.0167 
FIV à FFV ** 0.0032 
2-3 FFV à FIV 
FIV **** < 0.0001 
FIV + FFV **** < 0.0001 
FIV à FFV **** < 0.0001 
 
 120 
Appendix File 11. β-gal (ng) values for first (1-X) and second (2-X) FFV and FIV co-infections. β-gal 
amounts were obtained through a FFV Galacton-Star Luminescence assay standard curve. Cutoff values 
for positivity are shown on the far right column. Cutoff values for the adjusted timeline of staggered FIV à 
FFV infections that were different from the original date’s cutoff are the second reported. 
Day FFV FFV + FIV FFV à FIV FIV à FFV Cutoff 
1-1 0.05 0.05 0.05 0.06 0.05 0.05 0.05 0.06 0.05 0.04 0.05 0.08 0.09 
1-2 0.05 0.06 0.14 0.05 0.06 0.16 0.05 0.05 0.14 0.00 0.00 0.00 
0.09, 
0.15 
1-3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.79 0.42 0.00 0.15 
1-5 0.34 0.08 0.56 0.19 0.01 0.67 0.07 0.00 0.12 26.73 7.14 11.07 0.15 
1-7 20.33 2.94 6.87 22.69 1.12 17.07 2.77 0.00 7.67 88.68 24.30 2.10 
0.15, 
0.06 
Day FFV FFV + FIV FFV à FIV FIV à FFV Cutoff 
2-1 0.09 0.03 0.05 0.11 0.03 0.06 0.03 0.01 0.04 0.00 0.00 0.00 0.06 
2-2 0.05 0.01 0.01 0.01 0.01 0.12 0.11 0.04 0.00 0.04 0.02 0.00 0.06 
2-3 2.57 1.34 0.97 0.51 0.28 0.29 0.57 0.83 0.99 47.08 45.90 49.98 
0.06, 
0.19 







Appendix File 12. Significant differences in β-gal (ng) values for first (1-X) and second (2-X) FFV 
and FIV co-infections. Values and symbols attributed to significant differences in the co-infection studies 
(Fig. 8). Conditions in the left column are significantly higher than the second column. 
Day Condition significantly higher than Symbol P-value 
1-7 FIV à FFV 
FFV * 0.0139 
FFV + FIV * 0.0384 
FFV à FIV ** 0.0018 
Day Condition significantly higher than Symbol P-value 
2-3 FIV à FFV 
FFV ** 0.0015 
FFV + FIV ** 0.0011 
FFV à FIV ** 0.0012 
2-5 FIV à FFV 
FFV ** 0.0043 
FFV + FIV **** < 0.0001 
FFV à FIV **** < 0.0001 
 
 
